var title_f25_11_25776="FBA complicated by pneumonia";
var content_f25_11_25776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    73-year-old woman with recurrent right lower lobe pneumonia and bronchiectasis due to airway foreign bodies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bronchoscopy revealed a benign granulomatous tumor obstructing the right lower lobe bronchus. After resection of the \"tumor\" with a large forceps, two peanut fragments were found. The patient did not recall having eaten peanuts for 18 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25776=[""].join("\n");
var outline_f25_11_25776=null;
var title_f25_11_25777="Placement uterine manipulator";
var content_f25_11_25777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Laparoscopy: placement of uterine manipulator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 260px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEEAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAyPWikxnrSigAoopGz2oAXIyRkcUZFRxB85YY45yafznoMfWgBc0Zrn/ABT4x8P+FRGNe1W3tZ5ceTbZ3zzZOBsiXLvzxwDXNDx54i1Ik+Gvh5rk0QcoZtWli01c5wGCOTIVxznZn2oA9FzRXnEt18TrtvMePwh4ds8bWNxLNeyqf7wI8tPwOazbrTfGVxPGIfi/pVvIACYo9FtmB59GkJx260Aes0ZFed6XpvxDScBfGfhzUbZRgyS6M27OP7sc4HX3/wAKsXeo/EXTWldvD+ga3bhvkSy1B7Wcj12yoUz7bxQB3lFefQ/FXQ7S4S18V2upeFbqRtiDWLfy4ZDjJ2TqWiIHuwPtXeWtxDd28dxaTRzW8i7kkiYMrD1BHBoAlooGe9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRkUUUAFFFFABRRSf5zQAtGRjrRiigAopOM+9LQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVfUr610zT7i+1CeO3tLeNpZZZDhUUDJJNAC397a6dZzXeoXMNraQrukmnkCIg9WY8AfWvOT4k8SePC8XgWP+x/D5258R30JLzjqfssDD5hjb+8fC8tgHGaw7zUD4x+ya/4mtpG8PSMX0Tw5yH1DDDbc3SnjZ91lU5Ubl+8zKD6hZ2dxqmkmLxJbWhEqrutY8si45wSevPbp25oA4rwno3hnwnPMvhDTp/EfiCRj9r1N5lmnLHGTNctgL0HyLz329TXWQWOuakN2sX0enxHn7JppJbHo07DJ/wCAKn1NbttBDawJBbQxwwoMLHGoVVHoAOlZ15r1nBM8EAnvbpGCtDaRmUqemGI+VP8AgRFAECeEtBV1d9LtpnU5DXC+ac9c5fPPvVv+wdIAUDStPwvAH2dOP0pi32pys3l6QY0A4+0XKKSfom4frV25tlvrF7e7VgkybZFjkZTz1AYYP4jFAGLc6R4Wmk+zy2mkiVGzsUIjAj6YNWI/DOlwr/osU1rnqba5liz9drDNNGiw6dBHBo2laWlsi48pk2Z9shT+ZFV/LWyiLpb3OkuMZaEedAceqjOBjqxVT7igA1DTbm1s2jF5Pf2LgxyWl3ard5U/QqxGM53Fia4S48A6bBfxS+AbzU/C+pzHdcS6ThrKOUAACezduh5xhQB3I7+paTdm8ty7SWsu1tu+3fcp/wAD7c1BqVvYahMbdrhYdRVD5csLqs8WR95c5/Igg9wRQBwT+OfE3gwhfiRoaS6WoO7X9EV5oEHPM0GDJHgAZYblycCvRdH1Sx1nToNQ0m7gvLKdd0c0DhlYfUflXE3i+LdB1ea8klh1DTHcGR40ckoCo/eQjJVgufniODjJj9MFPC8ct5NrPwyv08NeImTz7jS2w9hfdgzovykEjHmx8jJBG7IAB7BRXFeAPHkHiSWfSdWtW0bxXZD/AEzSbhhvH/TSI9JIz2Zc9RnqCe1oAAMDFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeOeIbyPx/4kvlvBJL4H8OXKwvbKuRrOohhiEgj54kbC7TwznnIHHZ/FbxDdeHvCMp0jyzruozR6bpkbtt3XMzbFOSCPlBZ+eMIawvDGiW8Q03w5pbO2m6NC1ubgEgu+Sk8pAOA7uZEB6g+eR2JANvwdY3OoXU2t6wsTXLPsjMasFYrkbhu5KKSypxggGTrJx2VZ0l8sWoQabZQpJMFV5UDbVgi5AY4B64IVe+D0AJqXWbSW/wBLurW3untJZkKCeMfMmepHvjv2oAjGqQvrS6dD+9k8hp5HVgRGA+wA98kh/wDvhs9quxxpHuEaKgJLEKMZJOSfrmqunaVY6bu+wWscG5EjOwYyqDCj8Mn8zV2gCjf6pBZMwlivXKgH9xaSy9fQqpzUY1uwDqk0r25bp9pieEH8XAFTX817GY1sLOO4LfeaWfylX8QrE/lVacazMuFTTYwRgo5eUH15wvH4UAaoIIyOlFc0NL1a0R3057GKTGRChdIWOecqdwXPqoB65zTrTxBexz/ZtW0a6hmAJ3wYlRgO4AOT64UMQOuKANW50u1mmM6qYLo/8vEB2P8Aif4h7Nke1ZuoQtGijWrKLUrReDcpEDJH7snXHun5YyRfubZdSjgubW5ntpVyUkQYJB6qyMOR7EZGOMVH5+o2WDdxJeQZ+aS2UrIo9THzu/4Cc+gNAEUDy2VslxYTSalpxXITf5kqjnlHPL/Qkn0J4U5mp+HbfVHj1TRbhFdm83YSRG7YI3KRzFJnALL1wQytWpbQQyk6joM8WJWJljDfupm6HcB91xjBIGeMEHAxZ+ytDM13aKUeTmaAn5ZD6+zds9+/YgA4PxHp9h4jSK18TiWw1S0dTZazAFiubNycKSwztDHjIzG/Tg4Wr/h7xVqOkarF4c8feTFqMsnlafqsSeXa6mOwHJEc3rGTyeVyDgdTd2lnrtiGYENgqrlAHjJHKkEfgVIwR1BrktXsI4bCfQfE1gNS8NXCBNuwnyR2KEHdgEAgZ3pjKlgPkAPQaK8303xBdeCI7e18Vag2peGZiq2HiNiG8tG+4l4w4B5AE/3W43bTy3o4IYAggg8gigBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiquq38Gl6XeaheyCO1tIXnlc9FRFLMfyBoA8v8V3txqfxK+320TTaX4Ss5lR1faJdWnVEjgAPBIjkXB5AMuDyDjs9Chh8N+DPtKk3JSD7QzKDmY7flAGMjPAxjqe5Jzwnh60mk8C+F4bjL3WrltWv/ACJSku+7kVSwOMEILon/ALZrg8V6R4kJebRbQ2/nw3OoIJT/AM8xGjzK/wD33Eg/GgCfw7p8lhpw+1ssmoTnzruUHO+UgZwfQYCj0VQO1adFFACMwRSzkKoGSScACsrw9d3uoxS311GLe0mb/RIGUiQRgnEjk9C4wwXAKjAPOQJ/EFpLf6FqNnbiIzXFvJEglOEyykDdweOeeDUGt3NzY6XAllHuuZZYrZWVNwj3MFLkZHCjJ/CgCp4pvr2J4rewlNsmN89wAhfk7UijEhCl3OeTkAKeMstVtMsdJvdLj1D7Rqepxtx5k08rliDjPlqQnXrtUd6kh0l9X1OV9Xd59NsZFjtLWRGUSMqANLLkfvDknb/CMZ5bkP13xh4c8N3cOnajqEUF40Qljs4o2llMeSAwjQFsZBHTtQAQWkXnSJomp3Npcx43W07NKnPIzG5yAcH7pHQ1ck1S5sQTqtmVhBx9ptiZUAx1ZcBl/JgPWqek+KfDHio3FhYanY3swBWWzZsSgf7UTYYD3xUsv9paNloIjqOlov8AqgzNdJ6kMzHzR/s8NgcFjxQBdvLi5EUd3pwjvbcqGMSMAzr13I3Qn2OAfUUR6zZSQJMJGEbN5bFkI8puPlkBHyHkcNjrVKzls7m4nn0C9heaMBrizVxtJYZG9OsbkA84B9QcVCHTUZ3v9MRotShAhvLGf5DIn9xxyM9SrjI64JBNAGvcWChZ5LDy7S7lYO0yxA72AwN4/iH459CKmsWuXtY2vYo4rnHzpG5dQc9iQCR36CsDT7z7ErXFp50ukFtksDDMtg4xkbeuz1HO3IIyp+XduYY9QsiizSLHIAyywSlT6ghh+Hse+RQA+aNwS8BAkyMg9GHp7H3p2FuLcCaL5XX5o5ADj2PUGsgXV1o8qR6pL9osGO1L0qFaM9hKBxj0cAD1A6m7quorpkKTTQXElvnEjwxmQxj+8VHO31IBxQBx72t7o89zbWtql3Zyo32nS5W3JMh4Lx7uuckMD3wGB3eZWLpt9P4MtPt/hsT6z4ID4uNOQFrvR+OTEvV4h3j+8o5XK8D0m+tYdVs4nhnKsCJre5hbJVscMD0IIOCOhBIPWsr7IL+d5oSmneIbYBZJY0ysg7bl/wCWkbYOM8jnBUg0AbGkanZazpltqOlXUV3Y3CCSKaJtyuPY/wCcVcrxe9j1PwVrE+t+EtMmETlrjXvC6y7hIOM3dlwAWHO4DAcbQVVgK9R8K+I9K8V6Jb6toN5Hd2Mw+V0PKnurDqrDuDzQBr0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVw3xwu5rT4UeIxaxrJPd24sEVvW4dYP/ama7muC+Od5Hpvw2vL+4DGC0vdPuJNoydiXsDN+gNAEmr2V+/jvR7nT7xF0+OeGCa1GAFRILstjju0lvkf9Mx6V1WoSiPUdMV3VVkldFBP3m8tiAPfAb8jWDppil1OC1kUxT2uo3chSN8/Mcsu72McwbHuK2PEdtJLYx3FrH5l3ZSrcwqOrFchlHPVkLpz03Z7UAaF4sz2k6W0gjnZGEbkZCtjg4+tVfD94uo6Hp94kwnE8CSeaBgPlQc4q8jK6BkIKkZBHequl2f2C0+ziQyKJJHXIA2qzswQAdlBCj2AoAie6ePX4bR3/dT2zyRqEPDIyhst05Ei4Hsa0KyfEUWILW+UFn0+cXIGTjbtZH4yAfkd8Z4zg9qm1yCa80i4js3KzlQ8ZVtu4ghguewOMZ96AH6L9nOmQNaRNDE+ZPLY5ZWYksDyedxOeeua+U5vEMun+KvF9n4gy1vFrV9LOZrUPKkZePyWXDLLLGqAlgrKQhj2kj5T9G+HNWCagtklncixvmluIJhGSIJixea3mxnY4YswJ4PIByBnifjZ8PNR1a/tvEvhGCGTVUKQ39s2FN3AMgMrHpIoZsH0ORkogoA881PQvD2u2VhdaXpD3lzd3x8qVNT/AHE5kJcJDcuF+zyIzE+U6K+SQA3JOz4Y8f8Ai/wRr8+keIob3xP4fheNFu4Q097bK+FRnOxTJlxIhRgJAUbqFGeM8O+IdLhC6Zq876NrKwmG4WXTy29VLE297asWNygWRFU7Q4VSwcncF2TDFca7p3hcaDOviBHeKHS5Gj8m3TymIure6ZDvi2ogMcys2dqkjaQwB7naWOheMJbLxZ4a1eYzkKY7q0uWaJ1AGY5ISdvThgVDj1U1ahdb+6t7fVP+Jf4lhjws8K7VmAwWMWSd8ZPJRiSOM4ODXgkPh/4lfDbVLvW9A8Os9uyKbiy0+4S6t7rDHduiCpIHwRiRASNuCCGOPZvA3jXw38U9CkSEGO+gI+16fKxS4s5RxkEYPB6Ov6HIABp3P2u31BbjbDbauwSIsSVtdQUZITqSj8nGeRn+MVcs7tLd5fsscqPzJNprgeYhyNzoM4I5JO3IJ6HPBmgDWFitnrtyt5C37sXU6qPMGFwJAAFDFt2MADgdzzK+jRShop5ZZrU/MqSMd8TdikgIZePc+xHOQC6rW9/aEjy57aZSpBGVYHggg/iCDWaWOgRIu2SXSl+UEZZrUds9ynv1X3HKkmlXNs5uNNusXROZEmH7u444D46NjA3gZ4GQ2MVJDqskbBNUs5LIk7RLuEkRP+8OR9WC/wBKAJNOsUt7qa4s7lmsrkeaIBhkDnkuh7BuSR0JOeCTllu2nazLDeRHdc2bsgPKSQk43Iw6gHAyp4OFPYGp7HTYLCaRrMtFDJkm3X/VhicllH8JPOccEknGeadeWKzuJomMN2owkyjnHow/iX2P4YPNAExmhFysJZROVLKp6lc849e2fw9q8jvvD2s6Breo+JvBOnfZtYEm7VtDBItNXjycTQt0SYjJz/eyGByS/pvkNqVsI7+IwXsByssXOxsEb42I788H3BGOtd724uYp9Ma4Ww1oLmKQx7klxg70B+8v95c5GSMjhiAJ4M8V6V4w0ZdS0WZmjDmKaGVdk1vKPvRSIeVcdx+IyCDW7XlHiDwxqc+sS+JfBpj0LxzEgF3ZTHdZ6rGvQSYxu6/LIMMM4bHBXf8Ah38RLHxZLc6XewPo/imx+W+0e5OJYz/eQ/xpyCGHYjOMjIB3FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWD428TW3hHQJNWvYZp4UkjiKQ43Zdwo6kDqaAN6iuD8SfFDRvDl/rttqUF4P7JFt5jRqreaZ/uhAWHTknOOAcZ6VrXfjvwxZy2kdzrFtG10iSR5zja5wrMcYQE8AtjNAHTUVx+r/ABC0Gzi1FLPUrC6v7Bts9q1x5ZjxMkTbjg4wzgdOTxVufx34Yt9bXR5tatU1JpxbeQSciU9FJxgE9s9e1AHS0Vg6f4w8P6jrT6RZapbzagu8eUufmKffCtjDFe4BOO9b1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWH460htf8F69pCbRJfWM9uhZdwVmQhTj2JB/CtyigDxfQfG9/NB8P9QnuYF0O/wBMMk7Ftsn2yABZxJITjaIzM+3G7dARkdK9orxh9Jex1zxF4TeBpPLuD4o8P5YgSAt/pNqDtwuWaRSBuOy5zjpXpHg/U477S4EE0szKi7XkVgzptG1jnkllKsc8gkg8qQADfpkk0UbxJJIiPK22NWYAucE4HqcAn6A1m+IRcRW9ve2rTk2U32iSCI/6+PayshHfAYsB3ZFqXUbSPVrCNoZAsilZ7adQCUfHysPwJB9QSO9AGhWLokjWV5Po82QsCiS0Y/xwHjbnuUPynvgoT1ydVHdSqzAZP8Q6E+lVtU09b5I3SQwXcB3wTqMlGx3H8SnoV7j0OCABk9g6XhuLIxr5x/0mFx8swwBuz2YAde44PYjEg1mHwxHcWGsyS/YLCJXS/KM6pCc7RKQMqVCnLn5SBkkHIrb0q+mmX7PqESwajGoMiISUfployeq5P1HQ1FrGnPLPHf2SRteRoYnjk+7cQk5aNvyyCehz2ZsgFLxf4N0TxfbwjVrVGuIfmtryML50BP8AdYg8HupBVuhBFfOWp+GvFPwj8S6Vq935Oo6LpO42d9BCkEZQw7XgucKWRpNoVXLFA7An0Hvml2Z05RP4XnmhtE+a40K5TPlr1IhUkGJuuBkxnjAAO6uktr2w1iCa3BSXKbZ7WZMOoIwVeNuQCPUc0AecWGuSapG3ivwbeR3eiXPzXMKKRPaSgAsJYudxwckYBAIxkEOt3WfBek+M5LbxBpd5/YnjCBFZNV077+cDAkQ8TRkAcHII4DYznD8S/CzVfDmsy+KPhHfLp+qGNUn0e5YtZ3aKMKgBPyEDgDIA7FBnN3wF4sh8QSzppsEOi+NLMEaj4evv3YYnBZo+CyqxIbegI5BZSSDQB0fh7xZcf2mnhvxvawafr0qt5Dx5NpqSD7xgZv4hn5omO4Dnkc0us6Dq+k38eqeEZFmQSqZ9InkEcJi2kN5OANshIXG47B83AJzV+6i0TxvpdxpOtWG50w09jdDbNA38LqQcjvtkQ9c4OQccpFrGtfDSWK18W3NxrPhFmEcGvSfNcWXZUvAB8ynoJh3+8BkGgDvNA1y21qGbyUlt7q3YR3NpcLtlt3xnDD3HIYEgjkEio7t9QsJZHkQ6lp0hJZFQedCD2CjiRfbAYY/jzxX13w/p/iGGPULWVYdR8kfZNTtzllGdyHg4kTPO05ByfXNXdQ1YaXIh1GMpZFRuvV/1cbd946ov+1yBzkjuAVYtQg0y3in84SaJIMpc78rbj0Y/3P8AaP3ehwOm5G6yIrxsrIwyrKcgj1Bqj9iW1mmutPTDyZd4Q21JW9fZvcde+eMVtHjtlnkOnFrZVws9iwAEbdiF/hP0+U/rQBrugYqWz8pyOcc0q5wN2N2OcdKWs3xBPbW9kr3rXEcHmANPCSPI6/OxHRRjknjnnjNAGlgZBxyK87+LfwytfHVvb31hdyaP4qsBmw1WAlXTkny3KkEocnHdSSR1YN1LTyRWqJq7K8CjcuoQ4Cj0Zh/Ccck8r9AcVNbam0F0LLVdsU7ttt5ukdzxn5fRuvyE54JGR0APL9D8U+OfClmR4mtP+Eq0y1Aju7nT4RFqNmwGT5tvkrIvTDIeV+bnNeneF/Emj+KtJj1Lw9qFvf2b4+eJslTjO1l6q2CPlIBFS6jpgluk1Cy8uLU4kKJK27a6/wByQKRuXkkZ+6eR3B4DX/CFhqWrDUdNln8FeM2Y7L61CmO7PUiReEuAeuGw/HYCgD1GivKIfiLrng6ZLP4qaOLa1J2x+INLVpbJ+cDzVxuhPKjnIJzjAFeoWN5bX9nDd2FxDc2syh4poXDo6noVYcEe4oAnooooAKKKKACiiigAooooAKKKKACuf8e+GIfGHhe70ee4ktfNKOk8YDGN0YMpweCMgZHp6V0Fcj8V9cvvDfgPUdU0l40vYXgWNpE3qN88aHI78MaAMG/+F82q2Hic6tr3natrgtg11DZiOOEQMrIBFvOeV5y3PbFR+I/hXJrerTalPq9q1ze28UN8s1gZIpWjGA8aeYNnHYlx9aw7Pxf4ts/EUFvfataXlrD4mTQ5UFiIjMkkRfeSGO0rjAA/EmsfTvirr01/qxhvop7caVqN1FDcQIk1tLApKh0X7vT7rFjj0oGeh3nw4+0+EfEmh/2ps/tnVn1Tz/s+fK3TpLs27vm+5jdkdc47UX3w4+1f2n/xNNv23XIdZ/4987PL2fu/vc52/e4xnpXnninxf4jg8O61b6xd2Opx3Hhy01qJTaeUsTSTqhjwGO4d8k9cdK2rv4ga4PG9xptrqNrJNDr8enx6StsDJNasql5C2crtBJ3cAY5z0oA6Hwn8Lo/DfiO2v7fUIZ7O1mnlt4pbTM8fmhgV83fjHzn+AE9Ca9JrxLT/AIl6hf3Wk6RPcRDU5dRvrTUIPIKtHGiyGP2BIVT781yB+IWseGvAPhqHSdQEE8WjpdmO6iQx3H71gQrNlnbA5VcYHJPoAfTlFeE3/izxFpHiP4hy2+ptc3MFvaXNjpksTOFjdE3yxrn7sYZt20fMRk88VaHjzxC1mYtN1O01CB/EFlplprLWg8u4jmXMnyKQDsY4ypGf1oEe2UVX06O5hsYI7+4S5ulQCWZI/LWRu5C5O36ZNWKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4r4o6HfX2m2Ot+H4lk8R6DP8AbbJeAZ1xia33YJAkTK/7wQ8YzWJazx6ouk+IfCswax1AiazmcYjicth7eXAJXLGXBOcOzpkEx49QryDxC4+Gfii8vLuJ5Ph94klIv8E40u7f5TLxyIpc/N6NzkZAIB6rpl6moWaToCpOVeM9Y3HDKfcHIqhaY0e+Nmw2WFw5a2cnhJGJLRewJyV+pXjCiq2j2I0+7s1/tdbiaaJ8h9u66iXGxzjq6hkUuPvDqBxjcvLWG9tpLe6jWWGQYZW7/wCfWgCVlDKVIyDwaq2V5FcTXNurkz2zhJFYENyMqcehHcccH0ID7G2a0tlha4nuApOHmILAdhkAZx0yck9yTzUWoabDeSRzbpIbqIYjniOGX29CPYgigChrUtuZ4odTL2eZB9kvo2xtc8BdxGFYk4w3DZxz0qzpcuprM9vqsELbRmO6tzhJB6MhOVb25Hv2qfTnvSskeoxxCRDhZoT8ko7HaeVPqOR6E1coAq3+n218mLmPLAfLIpKunurDBU/Q1z2pWMcMMU2otJe2ca/utSjO25tVI+8XTG5P9odsbgRlq6s8jmqnlrp1lFDp1kvlIyRrBDtjVELAEgcABQS2B6YHOKAMez1DWLPUY7a/tUvtKkjLRatbuuQAu799HxjOOGTcCf4Vzis/xZ4R8PfELTrS+WYLew4lsNYsJAJ7duoKOOo55U5HtnBHT2unQ2c5e0Lwxt96FD+7J9Qv8J/3cZ75qC5sZbW3kOgx2NrPJMZ5VeHCTsR824rghicfNyeOhoA8qutX1zw3e29h8SkeS0T5dP8AFemR7WR88LKvJQsMDaQVYjHz549Q0uS4uLeK3vDBqVrLBj7bFt2TYADb06DcScBdwwDnHALINTtNSMmlaxapb3cqlHsrra6zrjJKHpIuM5xyO4HSuI1DwP4g8KXE2ofDbUd0JO5tCv5C1u3ciNzkpnrg9+jKMqQCSXwzrngC4nvvASjUdAkk8248NSttMOc72s3JwnJ3eU3yn5sFcgDq/C3ivQ/GNncpp8u+WIeVe6fdRGO4tyRgpLE3K9xyMHBwTWZ4Q8f22rsbHW7V9D1yMDzrG6YBh7jOMrno33T2LVc8X+BdI8TTxX0vn6frVuMW+q2Enk3UQ9N4+8vJ+VgV5PFACnSb7w6yyeGla60/AWTS57ggIB0aB2ztx0KH5TxgqQdzoNW0jXruO0ka503WkXekE6m3ukA6lc8SKO5Ush75rlx4i8a+CgY/F2lP4n0lThdY0SEC4VeOZ7XP1JaPIAHSupsNQ8LfEXQd9lcWesafvViFb5oXHI3Dh43HocNzQBsWkWoxyqLm7tpoVByVgKu3pk7sZ9SBz6CrBuoBdi2M0YuCu8RFhuK+oHcVj6lqOq6Vdq76c2o6UUG+W1ObiJ9xyTFj50wV+6S3B+U1YtrrSPElmklvLBeRA7gVOHjb9GRh07EdKAB7CbT2MujCMRk5ks24R/dD/A36HuAeadFc6frEMtjPGu8ACWzuFAdR2yvpkcMMjjg0EX+nR/ug+owKOFZgJwPQE4V/xwfUnrTRJpeuAxMA08POx1aKeHpyAcOvbkYzxigCOGy1PTgFsrtb22HSG8J81R6CUdf+BKT6tR/aNpdwrZ65araSzAA291ho3PXCt91ue3XjOBV6wgurZ2jluftFuB+7aQfvB7MRww9DgH1z1p+pxvLYypHbwXLED9zMcI/PIJwf5daAM59JmtInj06RZbVxteyuyXjZSMEKxyV47HcvsMk1wSeEZNM1Z7j4fXx8LarJukm0O8iMmnXWOCyxqQF52kvERgYyuSa6yMw2DbIp73RXzgR3Q821bk9GJKgHnCqyH1FdFp/2v7P/AMTA25myfmgztYdjg9D7ZP1oA80k+Ktx4Vm+zfFDQbjQlztj1WzDXdjN/wACVd6E9lZc+uK9B8PeINI8R2C3uhala6hat/y0t5A4Hsccg+x5p9ppUNtHcQeZNNZzDH2adhJGg5yFyM4OfukkDHAFeT+Pfgx4LuL9L/Tje+E9TkJ8vUdMYxwrIegdR8qfhsyTjOSBQB7RRXkvh7wn4102G2t9O8cahMiElrm/8nU4JuDwQVjlTnB4kcdq3VvviRpuftejeHNciBwHsbySzkI9dkiuv4b6AO9orhk+ILWsvla/4U8UaZIPvOlgb2H6h7cycfUCnr8VPBXSfXoLR8btl5HJbvj/AHZFU/pQB21FcPY/FrwDezeVD4t0hX/6bTiEfm+BmuytbmC8hWa0ninhbo8ThlP4igCaiiigAooooAKKKKACs/S9GsNKuNQnsIPKlv5/tNy29m8yTAXdyTjgDgYFTanqFnpVjNe6ndQWdnCN0k88gREHqWPArzaX4ux6ldwx+EtHl1CxkJH9q3sv2S0GCFLDKtIyqxVWYJhSy5IDA0Aep0Vynw98YL4tsb0XFhPper6fObe90+4zvhbAZWGQCUdSGViBnn0rq6ACiiigAooooAKKKKACiiigAooooAKKKKACiivmfRdX1KH4nvPe32oWemHxdfWZ1Br6V4WVcFLRoSdiglhhvc/3aAPpiivBdJ8deLda1q+0+W9tLO4lS+hbT/LAuLRkRzEyKPnY/KMknB3cdhU3gTxT4j1O18F6TYeJLWeW+sp5Lq6uLUzyRPEIv3bfOCXG45Ynv0oA90orxrRPGviXU/GEemLdwC6uLm+tp9NNp82mxxq3kzs/UgkL14bdhaz7L4keL7/wnr+q29kiy6PBBYzxm3LEXnmYuJMDkhEwdvQZz0BoA91orw3SvHfii9t9LtbXWNJnlvdYWyS+WJZwImhZsOqFV3Bl7EcYzior/wAS+KPDniL4hournU9Qsre1mtLCS3ba6siCSaNNx2qmWLBeCRyc0Ae71FdW8N3byW91DHNBIpV45FDKwPUEHgivC7b4i+IP7C3S63prWr6pb2z6yiJL9kgkRixkVfkDblCgnoG5AOK7P4ETtceEL+V7k3W7VrwiYjG8eYcHHbPXFAHJ6pbj4fXUHh3XrqSPwfcS50DWpMs2iz84tpnP/LI5wrE/dLKxK8r6doXiI3EtxYalEbfVLXiWIAkMDuKsh53IwUlW74IIDKyLP40bRJNAurHxMkc2nXkbRSQSAnzFxk9OmAM7sjbjORjNfPnhrXpPBssGm62moTeBDL5Gi+JJ4G3WQkAIt5WICyQdOR8uRlT8qlAD6ctp4rqBJrd1kicZVl6EVlalq17Y6xbwf2TPcabKqhryBt5jcsRtMYGcD5SW6YJ9OcC0u73SbvEyqPOYMJQd0E4P8RIyfT5sbhkbg4HmV19reRXDNGMxzp9+J+GX39x7jIoAs1Be3UdlbPPOJPKT7xSNnIHrhQTip6ihuIppJY43BeI4dehX0yPQ9j3oAqvIdQtEutIvYydpMbj95E+ezAdR9CCPzBisr+6BKavZraPkhZIpPMhYDvuwCpPoQPYmn3emZuPtOnzfY7okGRlQFJh6Ovf2III9cZBgjvL2BGj1qyRozx59rmSNs9dyEbl/8eHqRQBe1Wxi1PTriyuGmSKdCjNBK0Ui+6upBUjsQaTSbWWx0y2tbi8mvZYYwjXM4XzJcfxNtAGfoBUWmRRjMtldtLZuPliyGVDx909QOvBPGeMdKvllDBSwDHoM8mgBrxo7IzorMh3ISMlTgjI9DgkfiayrhtS050+yWq39gqhfLEpFwuB13OcSfiVPPfvsUUAc5qOl6B4304G6hW4MLMiSjdDc2knBIDDDxP8AdJHB6Z4rgJPDXjfwPPLceG71tb0vO5oNiCfHq0JKRyNgD5o3hYkklXNeoXeh6fcz3Fx9nEN5OoV7qA+XMcKVB3rg5AYgVkFfFGjK5VoPEVogJCtttrzr0yB5TnHtGM9SKAM/wl8RLDVxJBqSiwvoMLOrbgEb/bRwskXUf6xFB3DaW60/xN8OtD1++OsWMt3ouuOARqukTeRNIOPv4+WUHAHzA8cAitXU9K0XxM0aapp7rfQKTFI6tDcQZClvKlXBGNyglGxnjNcmugeMvB29/DVzB4hsCxdrS72W9znjkOAI3PXPEZPGWagCSLU/H/hOPy9b0uPxhp8ef9P0rbBehQOr2zEI7dv3bD6Vt+H/ABj4c8X+fbaRqfkaqqmOW2kXyL23I5IMUg3DB9iv1rK0b4r6JPqMWl67Hc6DqrqT9n1GPyTnOMc9c9mGUPQMTXSeJPCnhzxfaoNc0ux1FNv7uZlBdBnPySD5l/4CRQAwf8JLp0rs5tNatSVCrGv2adB3PJKOen9zv0qU3WmapFA+p2z2Vx5xgjS8XyZVkx0RgcN14KMQex4rm08HeJPD/nHwd4rle2yWj07Xo2vYk9FWbcJVUcYyz49KjufHWpaFFEvjvwlfW8SuN+o6Wv2+zTHPmELiVBnHWPr3oA760tzbRlPOmlXOV81txUYAxnGT0zkknnrVZLu+W4eObTmaMEBZYZkIYcckMVI78c/WuT0p/CHjG6l1PwhrsEeqcPLc6VcIJsdMSxkEMPaRDjqMHmtQad4rgdJF16xvERwxglsPKMi91Misdv12np0oA3dSv7SxjU3zlInyCxRig/3iBgde+KfZXVrcx5s7iKZBzmNw2M/SueGr+J7OWRtS8NQXFqHYK+lX4llCZ4LRypGOnUKzH0Bp63ug6jc26XVnJbXlwjTKLmzeGQBSckuQNp+XPXPQ0Aa91bX/AJry2V8Bn/ljPEGQfQrhh+JP0qOO61JG8u801ZFPHmW0ysDxzlX2kD6ZqbTreONRLa3k89s6/KrS+av1DHLH/vrFJOmopITbS28qE52TKVIHpuH+H50AV49G0q42Tx2CwOM4KIYHHr0we1UL6z0y03+Vrd1pk33NyXu8L9I5d6Z/4DWl9q1ZSd+m25GePLu88figqxZNO8kpns47ccFWEgYuec5wOO3fv2oA5yPUrvzT5WuLdx7sDydJkmwPRmjOM+/FWv7Svzwt9pqYG4/abaWBgP8AdZq27u/s7MqLu6t4C3IEsgXP0yadHLbXsLCN4biI8NtIdT9aAOb1LSLvWrUR6zpnhzV7dhkRzRkqRjtuDCvN5vgubPV/tvge81fwVfOd7mxuhc2LHrh43ZWOTjjBXGOPT0u+hjtBJMtpdaRKCT9rtAJIc+rov3hgcllGOcEHmuhsZ0ubSKaOaKdWX/WRH5WPfHJ75oA8t8KePtZ0PVbfQPiQLN5J5/sdnr9gc2tzOODDKMDypuOhAB5xjHPrNcL8TdEsLnT3ub+3SfTLox2WrW8jhUkt3cKJsn7skTFXD9QAw67Sq/Cm91COw1Pw3rs7XWp+HrkWRumPzXUBRXglb/aKMA3J+ZTyaAO5oork/FvjrTPD9z/Z0IfU9fkRmh0qzIaZsDOW7IuPmyeSAdoYjFAHVSOsaM8jKiKCzMxwAB1JNeba78UIp7tdN8EwQareynYt9cu0WnxsQ4QeaAfMLOmwbPlLEKXBIB5rWH1LxE803jG+tX06BBMdN09WltoV8wNFdNn/AI/YeAsgIUIQcKD8w0bC3jls4tFvRYxC3xbWROZEsp2X5bc/37OVQNme3ycMqbQDmtS0eTVr23vvEd9LrV4jyTxyXVuxS32BS6JZ7vLSaEgEx/O0sW8qxbpqQzW32dxhIDbAiUqPOXylCjcS2N6xK6ZJx5tpJnLEYF4ySwxB72SSPBJebO+aLySBuZiAHntzzk8zQZyrkYqnNC8RSVDbWstmJGHyFo7cpksgXuieazgDBa2uZAv3QSAX/A13dRfFs21xC0Sz6G8RHm7iGt7hcRSDruQXBAc53oyNnk16/XjHg6JoPi/pLtYw28R0O8tI2Eu+VDHPbn7PJ6+WCNr5O+NkPufZ+9ABRRRQAV5xqvxb0fTvFl7pL2V/JYadNDbajq6Kv2WzllICK5JzjJAJxhSeas/GvxhqvgTwS3iHSLS0vFtbmNbqK4LLmJ8oCpHRt7R9eMbu+K8c/ZQluPFvg7xboGq2iPo85kN9duztPdz3A2khzwNqIc9TllPHOQD6horj/hHf3t/8O9HOrMG1K1R7C6beXLS28jQsxJ6kmMnPvXYUAFFFFABRRRQAUUUUAFYcni3QY7dZ31O3ELXElqrZPMqAl06dQFP5VuV5nZfDG6tddtblfEJfTLXWJNYhsmsl3B5A25TIGyeWODj8D2ANfRfib4Y1Twxb679ta1tZpDCIp0/eiTk7Ni7snAz8ueK0U8deGHn0+BdcsTNqCRvaJ5nMwdyi7R3ywIx1GDnpXGp8JJF8NaLpZ15Xk0W4lksJms/lEUgO6OVRIN55+8Cv0rc8GeAF8Na7b6kt7BJ5WmHTvIgtPJTJuHnLj52wMvjHPTOeaAN2HxdoE1vY3Cata+RfRTTW8hfCyJEMyMCeyjqTUnhzxPo/iMTnRbwXPkhS+I2TAbO0jcBkHacEccVwGk/CS6sF0yCTxILmw0u2vrW0gl05DtS5Xadx3YfHfIwcYwOa6L4b+BpPBgv92qvdpc7NlvGjxwQbQRlEaRyCc8/NjgcCgDtqKKKACuW8ZX3iRbiz07wtZQia5z5moXQ3Q26gHJ2g5LDggHAPAGfmK5PiCDUfGOtXeiAXmn6PanZczo2wyEgHCkdSQeB0UHcwLFQveQRLDDHEhcqihQXcuxAGOWJJJ9ycmgDmNC8Gw2envBrupah4inkuxevJqUm9FlH3QkQwiIp+YKBwcHqAR0d/Z2uoWc1pf28N1aTKUlhmQOjqeoKngip6KAPH5/B/iP4c28kngNn17wwCzzeGb+Tc8Snk/ZZTkjH9xsg89WNTeHvGmh+MyIfDN8LPxBA7GXRdVLW9zE4B3hDyUbnkqHXruUkmvWq4X4ifC3wz46xPqdo1rq0eDDqdmfKuYyMYO4fexgYDZx2x1oA29M1mYhlv4XV0AZ12/vYenDoM5Gf40LKevAq5Mmn6pJE8Nwgu1QtDNCw8xFzgkdcjPUEEZ6ivHLqD4n/D9VW5gT4ieH4f9XIMxanAMdQRksfcbmPqtbXhnxZ4R8cTo2h6mkOuqdpsb5zaX0T9Cu4DLEDIOA/cZGTQB6Q9/Lp6n+1QPKHS6iU7Ov8AEOSp9+nuOlaUUiSxJJE6vG4DKynIIPQg1zcN5rOlRltWNvdW+PlbiKT0wT9zPfkqDntitm01O0uJFhjlCTFcrE42sR6qD1HuMigBLnTY5JTPbyPa3R6yxY+b2YHhvxGRk4Ipt1ai6iht7+D7RndmaL5PKOOGB3blJB6ryPamCHVYATHdW90BkhJ4/LJ44G9cgfXafpQ+qtAwS7sLxHJxmKIzIfcFMnH1APtQBoBTHCFiG4quFDuTnA4yxyfx5rPXV443Ed9BPaSkhRvQsjEnAw65U59Mg+oFWdO1C31GOR7V3ZY3Mb7o2QhgAcYYA9xWT4xuvEFpaQS+GrKG9dWJmiJXzGAU7Qm50XlsAktwOQCeKAOgopkLO8KNKnlyFQWTOdpxyM96o2ljdWt5I638s1rI7OYZ1DFCSThGGCFB6A5wOB2wAWr6zhvrdoLlS0ZIPyuUIIOQQwIIIPcGswadqNgM6ZftcRDpbX7Fxj0EuN4+rb6sTaRE129zbXF1aTScyeTJ8r+5Rsrnp82M8da0icDJ4AoA5TVrvStT0WaPxpofkWyOFkiv4FuIsnIDKy7l29eTggEZC5xXMad4HsWgGo/C7xfdaXEDtEUE639iSB90xuSRwQMBhtHQCu1vfE1nBJJ9laPUIbdWe7+xzLLLbAdGaMHcRw3TJ44B7c7rf9iPcW1/p/h3XptSuU3rLpMElnI6kcCWQtGpx12yHg9s0AMi8SeNtBRh4q8LJq0CAn7d4bk8wkbsDdbSlXBxydjP9K19H+IXhbVrwWUOrw2+o52myvla0uM+nlShWP4Cqmhf8JpcQvLLHa6bEyqkVvqTi6nTbkFnMJVctwcb2x6jJAm1rRp9Tt2s/Elvb6vbyEuCumxPFF8pXbtkdiTuIbOP4cGgC34j8C+GPEk4uNZ0Wznux0ulXy51+kqYcfgax5fAur2G9vC3jbXNPDEHyNQ26lCo9B5v7wfhJTbLwpo0EkUXhzVta8PTh/ktYrpxGSBnatvPuj24GSEUcd60Xh8bacim2utE1xQeUuUexkI/308xf/HBQBniX4l6Y7eZbeFtft1XC+VLNp8zH1IYSp+op0fj66tl8vxL4M8S6a+3LtDbLqEOO/zW5c/morRXxVf2keda8LazasG2l7RUvYz7r5TGTHuyLUiePfDO9kudXgsnX7wvla1x9fMC0Ac7B4k+G9/czGLVLXTbkhWlIll0yQg9Nx/dk/jXV6C2mTWUY8P6yLi0JBUx3YugeSTh2LHnOOvAAxitW2uLPU7RZbWa3vLV+jxssiN+IyDWRf8AgrwtqGft3hzRpyTnc9lGWz65xkH3oA1jDd/a4nW7X7OsZV4miyXfs27PH0xVDUIvEBggGnXelrKsQEpuLaRg8mOSArjaM9uax5Phx4eBlaxGq6a8gAJ07Vrq2UY77EkC5/Con8Bzgk2/jTxdAOOBeRSYx/10iagC1PB4kdhMdG8NS3bAI8r3UgwvOP8AliScZJ25H1Gc1Xu9O1xod9xoeg3ksZDI1tdyWsg45Kt5ZIPp8w7cioW8L+MoGJsfiBNIvZdQ0m3mx+MflHNR3Nv8T7Zf9D1DwdqBx0uLO5tefqskn8qANe1jlk2xW2papplzhf8ARb0JMAxTdtDNnzCADkrIwBB5q5o32Kyv7u2+1M2oXLmaRJV8ovgAFkTABHHJGT6k8VzcOpfEobhceGfDEjI2AyavKoYeoBgJ/PFc5498QeOrO3tl1LwN4ZvrSaTapk1EzJHIASoYPEvLYIXA5OF6soIB2nj+aLVNKuvDljsutWvUCi3Df6pcgmSQj7iAdz1OAAScVx9p410TQ/G3j3W9Tv4RZma1022itwZZbqWCEtL5arksVabYQBhdmSRzjyuy8TfEXxrrr+FdOTTPBunIDFeXelRBQrnzVjQvuyu6VDFlcENnqflPX+CPCfh/w68MWiaOGbcLiCS5PmT3EnlyboZMgDLRSXcOzbhWtyWwzAUAbuq+MfEniMzwW6P4Zs4WkE0OBNfyIhIcgodse0lCyLuk8tg6HkCqWkaLY6VbSw6XDCDLMsmLibe/myOzxRyXA5kickiC6++jfLkksla0qfZZlaxv2KQRxXNrd4WQS27fLBcls5fygxhlPVonDE52mpJYY2hzDauAu+MafjLeUObmxUocl4yPOiI57J8uaAK8N0I5Y3FyYLkSGSO6nQIY5d2wzOi4H3isVwnA3FZBt3AmZoWMUEsdoRZyeZaSaechoyCTLZbsDPIMkD8YI2gqsgouIvNkV5Ht7nc8S/aZlLxTCVdsF0QBjZMuYJh0PDDGOZNPuA0N0L9LlbZcQ37SP+9WJD8lxuBJ823kHlvJ94hUkJxsNADraVL11KX0bfaTBv1FflLTEAWV6qgYJfHkuOMlQhG0YNAmS0MTECyntxlC3zra+WSASck4hZyjEY3W0ykk7TixNbtDfmzvbaOe5DzQzW7DHnLIN0kagZwkyKZUHAEsbqSOizMiz3UM0E8DtP5f+kuCUnkZdltO47iVM28gODkIBjapoAztFFvD8UPB11EvlrdWuoWYVvnlgdBGzWb8dI9jlXOPlAX+6T7P3r5Y+LGst4Yl8F6nZXdxpMv297d76EFitttWOVJFKlfOiC+WWKFmVEIzyF62e4vFZlm+OWlQkfeDXFkSD/3yuKAPeqK8fj8I+KGWN3+J91IkioFKBAH3/cIIHfHGOtD+DdcmmCn4q6yhdBKqRLH90gkEfL0wpP4UAd/8QtCPiXwLr2jIoaW9s5YogW2jzCp2c9vmxXC/sueGz4e+EGmSTRlLnVGbUJARztfAj/Axqh/Go9J8H6prCSHT/it4jn8vG8rHEuM5x/APQ11HhzwJPpdxBPfeK/EWpvDgiOW68uI4YnlEABGNowePl9zQBD8KsQXfjewUbUtvEVwyjPaVI5j/AOPSNXe49q8rtbG11bX/AIn6bdvPbWwu7O8aaGSSNlJs4jnEbK/Hl5685I5waoz+AtBh8oXWr6nIkjMFU/bZAdrYIOZD3Hf8KAPYqK8hg8CeFlA33usShRtP7iduPTkGppfh54SbPmW2ryY6/wDEvLflmL+VAHrFFePT/D3wYEAfTNZcbu2khuT/ANsa2PBvgbwtpeuWep6Xpd5Bexl2jkn01ICm5GU5YRKRwSOvtQB6TRRRQAUUUUAFFFFABRRRQAVxXijV73UfEEHhrw/dPa3n+turlUyYEAU5GRgn5l47ll6gOB0+u6nFo+kXV/cAskCbggIBdjwqgnjJJAGeMmofDV//AGzotjqz2n2WS8gWUIx3MEPKgnAPQg4xxmgDQt4zDbxRGR5Sihd8hyzYHU47mpKKKACiiigAooooAK4rx98MPCnjtfM13TF+3KMJf258q4THT5x97HYNkD0rtaKAPG7XRvih4BaRNHvYfHeh/wAFpqU/kX0Y54EzZVh/vH6AVJbePvCNxcCy8TWmp+DNSmfm31WEwwSsOSUc5hIyfvfKTXrd3cQ2drNc3UqQ28KGSSRzhUUDJJPYAVlarc219JcaVcaRPqURAWZJLcGAg4OCZMK3GOBmgCpC2ow2yXWlXI1i0lAZCkqtuB7gsQCPff8AhVqz8QwttXUYJtOkIzm4UrHnOMbyAM/XGe2a5l/hTotlcvdeEbzU/C100nmt/ZVwVgkbGPnt33REe20VTvPEHi3wi0Vprsel+K1fbtGnE22oyJ0Zvsp3I4B6kOo9qAPTagvbj7LbNMYpZVXGViXc2PXHfFeURfEbTYdV/s7EngkMSE/4SG3eBJMAZMScRY7Z8wc5+U5zXWLpqHyLnxHbz6uqR5Fwkpmt2ySd5txhQeeMK+Bgbj1oA1dO8V6Pqj7dHuv7SwYwzWiGRU35wWYcD7pzzkd+1X7G4vrh43uLJbSBoyWSSUNMr7sAELlcbechj1xjioLZdL1dUvLCWKRkHlie2fDLj+Akdgf4Txntms+91ptPuZLa3vIdTuUyWtFUmZe4BMYO3jpuUZ9aALa6NdTSF9R1i9lBJ/dW5FvGAe3y/Px67s1QbwpbxSySS21vqsRbcIb5DM6gZxteQnLe7dfUUkniTUSFD6NLpinGZtRcbFyOCPK3g4PUMyfWpRfWss2661a78nzZGjkUCOB0ZMYEijBC54O7OR7UAXrHUdJhnSzjMFjcudq20iiF2OM4Ufxcc/Lmi48S6PAxX7fFK4bYUtwZmU+hCAkfjT00nS7uwgikiS+tFTEYuJDcKw9cuTuPucn3p+m6LY6ZM0lhE8IZAgiWZ/KRR0Cx52L/AMBAoAq/8JCHkKW2lavOeMEW3lg59DIVFZsia9LfG5061u7UMQXgvr6PyzzzgKkpH0BA+ldDNqljBci3uLqGGYkBUlbYXJ/u5+9+GauUAYElp4huHxNd6NHAwIZPsUkrAEY4YyAfmtUrPwpf2jOYfFGqRKU2LDGkXkx+hVXViPTAOOOlb+p2BvljAvLu1KEnNu4Xdn1yDS6bZvZRuj3tzdhjkG4Kkr7AgDj60Ac5D4d8Q20EEY8VXN4YpfMZ7mCNHkGQSrFABtwMDCjqa2by4eBZYb3T7i8tiSfMRVlBBOcFODxnHAPAHOat3mpWVlIqXlzFblgSDK20EfU8Un9pWr28s1tKt2IwGK2xEjYPTAFAHJX+k+B5bgzXWiW1veHkzx6e8My/9tEUMPzrKn8Dw6odugeONZsG2ieNLPUpZQqljhiskj5B2kf3cg8V3p1e3QfvYruPsN1tJz+QNVp9T0W4Aa6CEAq4M9swAKncp+ZeoPI9DzQB5+3w++IkUjfYvi1dpF1CT6NDKR/wIt/Srx0L4qQL+68aaDdHZj9/o5jyfX5X/wDre1dX9q8O3EUtpb6raxmeXzWFtfbHL5ycbWz25HTrUZ8LM0zTReItfQOxbat0rLz2AZTxQBzS2/xXhY4ufCt0DkfPLLF9CMQtz+dRLcfGJGbOn+B5EAO3/SrkMT2ydmD+Q/CuoudBntrcyyeLNZgSMZaWV7faB6nMWKylhsbqGN/+E21i7jDcSWs0W1sjpmOP+tAGFf678YreELb+DvDlzLtGXi1I7c9/lbaf1/E1y2u6h8ZNa0a5s9U8CoGcBkbT9XtYlikRw8cgDb33KyqeGHK5GK9VtbHw9Be29yb69vbqD5o/Ovp58HHXy9xXPJ525rqLadbmBZYw4Rum9Cpxnrg80AfFjx+N/AfiW81lfA2s2Ok3CPHdQLO90iw+c8qsJFyEeMGMI3AHl5wdzV654d8Q2niuK2nsor+wv76AX0tn5JjuEJw7SRRtw0bOonjddy7t6sQZsH3yvJvCHh/SdR13xt4XurFTpGjapDcaaqMY3snmhSZ/IkUho8SMxG0jAYjpxQBJp8qkeRDBbNO0kk1pGih4ZBIN80KHOGinTMqAnG7IODFgPSFWhlW2v3VV8l0vWXeyA8Wt02eXK7TDICcsFySMHNXUfBmr6GCvmXniLSjcmdJYyiajZDPmDGQEuAJRvB+SRSxxvBINLTtdtdRurmSG1E1zZzPFeWD2rxvG02DLCYpBuEVyArpkbfNXaWORQBt7I72B4FsLeWaPz1WychlkiYgXtjuxzzh1BADfu/4VJFKMm3v4bq2lS6nYxsssuP8ATUdRHC7MQOZUAt3z0kSFsAYDSw28seoLHb3kzPI8E9vdySP87qNtvM54JEiZt5c5OVQ4G7NWplgv40hgtwttdNKI7YSYZZGz9ssXKnCscF0Ib76k8BQWAGPFDeacj5uJo7eEOswTbLJYF9wIzyJrZwrd2BjHG6TFUFhza7LqFb2QebHJBFki4V13zRx4OCsyATxDgCRSu4DgWdOmuraaF47sXk6SLNbyNhVndgV54AUTqGBBwEnTodwFWrlLaJYFjmlNlJAXjdM7/sgcMpHB/eW0jAgHkITjJyKAPOfi74Xl8f2nhrQbbVbWPVrzUAWlkjIjuoxazOl2mOQSkWxwM/MFHAALS6T8GPiJpVlbWdj420mO1gRURJNMSUgAYxl0JI5PfocV1skMtt4v8ExTRQ/6PrMwIR+YGksbkny/WGQjzBg/KQydgF9foA8mi8IfEoRsreL9KDEBQ620/wAuMdFEoHOPwzU6+DviEfv+NrDjsLG45574uRXqVFAHmH/CGePSoH/Ce2q49NNmJP1zc+9W9I8I+N7G9jkl8ewz229DLE2ksxZFPKqzzttJHGcGvRKzfDV82p+HdLv3YM9zaxTMVGASyAn9TQB5rpek6nrHxC+Jc+iawdKla60y2W5FuJuYYBI64LAHPmgH6d81d/4Vv4ikleS5+IOsMXYufLV0GScnA8zaBzwoGAPpVn4PyyXl94+vniMUc3iW5iiyc7lhSOEt+JjNejUAebP8OtcYAf8ACwNeC9GHHI/E1Tn+Fmtyylv+Fi6+qEk7fJhJGfQla9VooA80tvhVgH7b4p1m6JOSWSAH/wBFmtjQfh7p2ja1b6pFfX89xAWIEywYO5SpyVjDdGPQ12dFABRRRQAUUUUAFFFFABRRRQBz/i3TNP8AEtq+gXl+YWlUSzW8UoEksGdrqV67GBZCffjBwa6CuK8N+H79fiL4l8R6xDGvmxxWWnESbysA+ZyP7oZhHlT0KEj7xrtaACiiigAooooAKKZNLHBDJNPIkcUalndyAqgDJJJ6Cqsckt6bK5tJlWxkjMjK0TB5AwG3rgr1JIIz06c5AG3Wr2NreLaS3AN2wDeRGpkkClgoYqoJC5PU8U9Zb177YLaOO0ViGkeTLONoIKqB0ySDkg/L0OeMXWda8M+AdJ8zULm30+FiXWMZea4bHJCjLyNjqeT3NeeXHj7xx4vv7ex8D6ANFsLiVY21XVk8ySNSm9nWFCVUqpX77cl1XAJ4APVb2HTbCNtR1aaERW0jXC3F66hbbK7SVZuEGCR+J9a4TXvjPoVrqFrpnh6z1LxHql3zbxWFuxjdd23zPMIwY8gjegYcH0OOR0z4bz+NbjUZNe1W71WNp3t5tSvgkvlxg4eCzTAjRsjDzBflOUTJBcezeHfDmleHYGj0mzjgLhVkl+9JLtGF3OeWwOACcAcDAoA5Cw0zx54nkM/iPVYfDWlsTs07RxvuXTjHmXLj5TnPCKpweoNdto+j2GjxPHp1ssW85kkJLySn1d2JZz7sSal1bU7DR7CS91a9trGzjxvnuZVjRcnAyzEDkkCuDbxf4g8Xr5XgDTGt9OcHOvatG0URBAw1vCRvlznhmCqCP4ulAHZ+KBo76FdxeJTaf2VKvlzLdkCNgeMHPcnp3z0ryLTNG0xGuovhK3iHR7hSdht5DJYNIc5MsU5ZFA4yF2ydcD177Sfh9p8ci3XiG6ufEOpFCrXGoHcgyMMEjHyoDk8D1x0xjrY0t7G0VI1itrWFMBVARI1A/IACgDyDUNL8bf2us/jLRbfX9PCKgk8M3Rs5kwDkyK7K8gJbosu3jO3nja0/xTo+gWcUIu7/AEKzX5BBq+jyRQwcnrMFVBk/xFyK7GLXWvNRtoNKsZryzkRZW1AMFtvLZdwKPz5hIIxtBHPJFbVAHNaH4nXV7U3Gniw1W3UlXn0i/juUUjsT8vPsM1oQW+n6hO9xLpgS543PPbBXOOnzY5/Os3XfAHhPXrmS51Xw9ps93Jw1z5ASY9v9YuGz754rJk+Gdso26f4p8YafEDlY4dYkkVfYebv4oA25Ljwtd30tst7pf2/zfLkSC5RJvMHG07SGzwBin3MWl6e6wvrMtkwHCSX2SevOJCaxZvCfimMKunfELU1RcAC8060nP4lY0J/E1LJp/wAQYUQweIvDd0V4Kz6NNHv+rLcHB+g/CgCx/aWmvA5k8YWc8POfNktin44A70/SbLS7vH2O90uaE8t/Z/7pmPb5o5P6VXjuviBAzibSvC96v8LR6lPbn6FTA/55rN1DUfE9xIv9p/Dazv0VwCYtUglOOzKJUTp74oA7i2sEt5AyTXLAdFkmZx+pqu2lMhlNpqF7blznG8SKpzk4Dg4rgzql/bOWb4Z+IYdxO4Wl9bFc+wWccY9hVW58ZRWRxefD34hrk4PkRG4XkH/nnO3v29PagD0b7PqyFRHqFq6Dr51oS7firgf+O0j/ANsRktHFps74AyXeHP6P3rzm38beF1cSapoPjbSIwcia+06+VCfTK7v14q9F8Vvh1cWbW8fiyO1SJiD5rzQvkHJXMgDHr0oA7XGvzEfNpdpg88SXGR+ceKmii1YSKZL2waPIyFs3UkZ5wfNPb2rz+28e/DBxJcrr9rPtILefLNIeAOQrZyMHqBT5PHvwvhDMl5p7g4U/ZrKSTOehGxD6jBHqKAPTJESRGSRVdGGCrDIIqpDplnbyK9rCLcqpQLCSi4/3R8uffFebH4g/DwS7YZ9XeVMJ5cWn6hkZ7YCe9Rnx94NUt9m0jxTdhfmbZpV6wBz33Ad6APSJNPuCjIL0zRnAEd1CsijB742k/iaSa21CWJopZdPljbHyvatj8RvOe1edt488JlA8+jeL7YKe+l3yYz3+UelTD4keBMYuLjW7Y/cxNYagn67MfrmgDt7HRpbbUI7kXnlRrkG3t0KROMYAKszAYPOV2++asXOqxfbFsbJluL0sA6J8wgXu0mPu8dAcEngdyOEi8beAb6VAranqTkcKdKv7kHnH3fLIzx6VoS+MdTFoq+GPAWuXShtqi5EOnxgZ64kbeBz/AHM0Adb4g1ix8P6Je6tq0629jZxNNNIeyj0HcnoAOSSAK4j4GaLd2PhjUNa1W1a01LxJqM+sy2z8tbrK2Y4ye+FAPIBBYggYp0vgjV/FmoQ3fxA1GJ9PglSaDQdOJFqrqcgzSEB5yDg4wqgjoc16LQAVgeK/COjeKYAmrWpMyoyR3ULtFPED1CyKQwGcHGcEgZBxW/RQB5TP4b1XRLxotZSXxB4YIJS4tVKX9qXAWXzETAljcgOTGAwf5guQGDoNUtLiJ5JtRjmsJyD/AGjE4ZRJH9y6XskiEATIQMbdxAUOK9UrndZ8JWN/evqNm0umauVYfbbTCs+Vx+8QgpLgAY3g47YyaAOUuIpLi7a0u0jF2GZfKDMgE7Dc8QO7KxTKokjYH5JFJySoUME7hYo5bgRztKJ7Sac7AtwT5Y3rwNsrExOn8MrccuhCeJn1TTI7ceINKjlt4F8qPU9LjcwFBhgs9uN0kOGUFZE8wRsqtkDcpbDMmpwPeeba3unyjMmowETWrsRs807CVCkfJMnAHDggAsADI18RjUfh/wCXbTqia/DHbkSEPCghuA9rIwJBMT5wD1TgZ+Yn2qvHbBm1b4n6BpLTh7rSGm1TVISNxR1h+z2/mtjmQiZiG43pGjEDgD2KgAooooAK8xvPFVp8M116212N47EzNd6KkMTbbkOoJtUwCBIJd2F4yrggYDY9OooA4j4NaLqei+ArNfEOf7bvpZtQvlIA2zTSNIwwBgY3AEeua7eiigAooooAKKKKACiiigAooooAKKKKACiiigDjvhVq99r3hqbUtRuDcfaLyeS3OwKFty2YlAAHRCo55znNdjXNfDwaMPDSDw1ava6Wk80MaOSc+VI0RIySduY+PbFdLQAUUUUAFFFFAGLrkL6jfWGnpJCbYSfaL6JmG54grbFxnPMmw56ERup64PJ/EDxrqcOrjwt4Ksxd+IZUDT3L4MWnI3AkZc/O3K4XoNyluCA3Z3OqCz1mG1vAIre5ULbzEHa0uTmMnoDjBAOM84zjFeeeKvBeu2fju68R+HJZb211SLyr2xN0bZreULGqzROmCQViVWTcM/KcnACgFnS/APh7w6JNZ8ZX66prMnnxzalqcqlpEkYARqMDau1QojXgb3UZDcxfE3x9qmj+GLu70HSjaRSDauqaorwQx5wDJsCl8jIwHCbiMDccAz6boeqLPLdLDPaXaf8ALS1s4jcsSdrKLi5kl3DjP3VyMHvWhZeG7ue8W5ksEiuUbKXmrXTX00ZzkGOPOxDkcEEY9D0oAr+HPH3hyy8H2UsOm6/pel28CxwR3OkXIxGowp3hCuCBnJb3OKpWXjTxV41iT/hCPD0mk6bJ/wAxrXk2jb/eht1O6TIOVYsq/Wutj8HaZJfQ32r+drN9Cd0U2olZBEc5ykYAjQ9OVUHjrWvqWqWemojXk4QuSscYBd5GxnaiLlmOOwBNAHKaH8OtPt76DVfEt3c+Jtei5W91LBSFuMmGEfu4hkZ+UZ9zXbEgEAkZPQVhpe6xqN0EtbD7Bp5DBrm6cCfO07WjiAI64++Qf9mtOxsY7OEIHmnKu7iS4kMjjexYgMeQBnAHYADtQARyzXNvFJChtyxBZZ0+YDcMjaD1IzznjIOD0rOg8NWCaouo3LXN7eoxaOS6nZxFn+4n3V+oGa26KACiiigAooooAKKKKACiorqR4baSSKJpnVSVjUgFj6c1x1hP4v1+8trkC10PSEkSTy5YmknuEBBKkHaUBHHIBHcHpQB0ep65Y6ezRyy+Zchd32eH55APUj+Fc8bmwuSOarnWJdR8PyXugxGa4O0Rq6ZUkkZwdyq4AJ+ZW28HBOKsXug6Ze3Mc13aRzbHMgjfmMycfOU+6zDAwxBI7Vp0Acpo+g6vIxm8Q6tJKHPz2UJVonAyBvJUZyMEhFQZyDu6nVtvDulW77xZRSOCxQyjf5YJJ2oDwi89FwK1qKAAAAAAYAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5zU/BPh3UtQe+uNMjS9kz5k9tI9u8uRj5zGVL8f3s10dFAGH4S8J6D4Q082XhrS7bT7djlxEvzSHnl3OWYjJxknA4rcoooAKKKKACiig9RQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcf8L7PUrHQ76HU1ZIv7SuTZq+8SCDzCF3KwGDkMRjIKlSDzXYV5zrPiTVNH+Kem2lzcR/2JeMto0OPuNKhNu+ccEyQXKHkZDJwTjHo1ABRRRQAUUUUAMmjWaF4n3bXUqdrFTg+hHI+oqldz39tOPIshd2u0D93KFlB+jYBHTuDWhRQBzn/CRX6P5c3hbWhJ/wBMzbuh+jeb/PFP/tnWJH/ceGbtYwp5uLqBGLdgArNwfXI+ldBRQBzU1nr+spi7vf7DtyMGOwZZZ2+srptUf7q554YEVt6dYwafbiG2D443PI5d3IAG5mYkscAckk8VaooAKKKKACiiigAooooAKKyvEWv6f4fs1uNSm2722RRLzJM+M7UXuf8AJqDTpr7XdEuBf2dxpJnBWLbMRKEI4fjBQ89DzxzjpQA3XfFNhpUotkEt9qLZ2WdovmSEj1x938f1xUWvx+JNUsbBNBuINE84k3kt1Es1xAmOBEoJjL57sWUejVc8P+HrDQYStlGWmYDzJ5MGSTgDkgADoOAAPQVr0AYPhbwrp3htbh7Nru4vboJ9qvby4aee4K5wWZjxjceFAAzwBW9RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGT4gjkt7K71PTtNiv8AV7e2kFvE7+X5p4YR7sHGWVcEjg+nNJ4U1+08S6JBqVjvVJCUeKQYeJ1OGRh6g/mMEcEVr1xs1/D4L1JbaWwKaHetNdSajHtC2shK5EqgAlTknzOcAYbAG6gDsqKRWDKGUgqRkEHINLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWdfavbW139ijYTak0TzJaocsVUdTjO1ScDJ7kCgDRrjJda1PxJdz2XhoJb2MR8u41KTnB/uxAdWx78Z5wertH0vXtXvbPVvE1y9gIG82DS7STAQ4x+9cH5z7Dj3wSD10MMcESxQRpHEowqIoAA9gKAKGnaPDa2lpFcySahNakmK5uwryqT6HAxxx64HJJ5rSoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACq2oWMGoW/k3KkqGDqQcFSO4P6EdCCQcgkVZooA5b+3Lfw9qZ0m+tEsNJihj+x3SgLEFAClWAwEAOORwARnb8u7qAQwBBBB5BFRXVrBdqi3MSSBGDruGcH1H4Ej6Ejoa5vU/EEXhrULDTv7Hmi0fYYxcW65WIjbsVY1BJU5YcfMCo+Ug7gAdVRVTTdSstUg8/TrqG5izgtE4bafQ+h9jzVugAooooAKKKKACiioYru2muJoIbiGSeHHmxq4LR5zjcOozg9fSgCaqupajaaZb+ffTLFGTtXgkseuFUcseDwATxXM6rr/iCe9l0/RfDtxHIAR9rvHRYl9GG0sCO/XcOPkPIrRt9Ae+0aK08WTx6xIJfNb915UR4ICFAcMoBPDZB7jpgAh0PxI/iG6uY9Nsp47FEIXUJCu0v2Cr/F69eMYODxUvhXwnpvhwSy2yNNqFxzc3sxLSzEnJyT2z2/PJ5reijSKNY4kVI0G1VUYAHoBTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqO4giuYXhuIklicYZHUMpHuDUlFAGDqOgldPWDRJBYyKVJdWYO4UYUF8k8dPmDjHbpUNg3iKz0+4k1FrW7khjYRxCMh5X42kyJkY6g4iB9vXpKKAOf03xPHeagNPk07UYLzYXYNAfLAA6+Z05PA78jIFYUvxLtracRX3hfxhbernR5JUH/AAKPcPyrvaKAMjxBqOo2mkC50LR31a7cjZbGdbbgjOWZ/uj2wTz0rCabx7qCbIbXQtE3DmSd3vWTI/hVSgY57kj6Gu0ooA5HxD4Tvte14XF34gvINISIImn2i+WGf5tzSNk785GAVwNvetXRPDGk6MqfY7RTKjF1llO91JUKdpP3AQMYXA9q2aKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25777=[""].join("\n");
var outline_f25_11_25777=null;
var title_f25_11_25778="Patient information: Marfan syndrome (The Basics)";
var content_f25_11_25778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87047\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/40/26244\">",
"         Pneumothorax (collapsed lung)",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"          Transthoracic echocardiogram (echo)",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/59/21439\">",
"           Scoliosis",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30307\">",
"         Patient information: Aortic dissection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/30/40418\">",
"         Patient information: Pneumothorax (collapsed lung) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/20/18754\">",
"         Patient information: Scoliosis (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Marfan syndrome (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H260299302\">",
"      <span class=\"h1\">",
"       What is Marfan syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Marfan syndrome is a condition that involves the body&rsquo;s connective tissues. The connective tissues make up and support the skin, bones, blood vessels, and other organs. People with Marfan syndrome have a problem with their connective tissues. Because of this, they can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have certain body features (listed below)",
"       </li>",
"       <li>",
"        Have medical problems that can affect the heart, blood vessels, eyes, joints, and other parts of the body",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Marfan syndrome is a condition people are born with. It is caused by an abnormal gene. Usually, people get the abnormal gene from their mother or father.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260299317\">",
"      <span class=\"h1\">",
"       What are the body features of Marfan syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with Marfan syndrome sometimes have certain body features that include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A tall, thin body with long arms and long, thin fingers",
"       </li>",
"       <li>",
"        A &ldquo;pushed out&rdquo; or &ldquo;caved in&rdquo; look to their chest",
"       </li>",
"       <li>",
"        Joints that are very loose and stretch more than usual",
"       </li>",
"       <li>",
"        A long head and eyes that look &ldquo;sunken in&rdquo;",
"       </li>",
"       <li>",
"        Flat feet",
"       </li>",
"       <li>",
"        A curved spine, called scoliosis (",
"        <a class=\"graphic graphic_picture graphicRef56860 \" href=\"UTD.htm?20/59/21439\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with these body features do not always have Marfan syndrome. These body features can also happen in people who do not have Marfan syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260299355\">",
"      <span class=\"h1\">",
"       What medical problems does Marfan syndrome cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Marfan syndrome can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Problems with the aorta, which is the big artery that carries blood from the heart to the body &ndash; These problems usually involve the first part of the aorta, called the aortic root . The walls of the aorta get weak and the aorta can widen. A widened aorta is called an aneurysm. The inner wall of the aorta can sometimes tear, which is called an aortic dissection. When this happens, the aorta might not supply enough blood to the body&rsquo;s organs and the wall of the aorta might burst open. This causes lots of internal bleeding and is an emergency.",
"       </li>",
"       <li>",
"        Heart valve problems",
"       </li>",
"       <li>",
"        Eye problems",
"       </li>",
"       <li>",
"        A lung problem called a pneumothorax &ndash; This is when air leaks out of the lung and collects in the space between the lung and chest wall (",
"        <a class=\"graphic graphic_figure graphicRef64892 \" href=\"UTD.htm?25/40/26244\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260299399\">",
"      <span class=\"h1\">",
"       Is there a test for Marfan syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for Marfan syndrome, your doctor or nurse will:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Do an exam &ndash; He or she will look at your body features and look in your eyes with a special light.",
"       </li>",
"       <li>",
"        Ask whether your family members have Marfan syndrome",
"       </li>",
"       <li>",
"        Do a test called an echocardiogram (also called an &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create pictures of your heart as it beats (",
"        <a class=\"graphic graphic_figure graphicRef77971 \" href=\"UTD.htm?33/35/34354\">",
"         figure 2",
"        </a>",
"        ). It can show how wide your aorta is.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      He or she might also order a blood test to check for an abnormal gene. In some cases, this test helps tell whether you have Marfan syndrome.",
"     </p>",
"     <p>",
"      Your doctor or nurse will check for Marfan syndrome if you have body features of the condition. He or she might also check for Marfan syndrome if you have a closely-related family member with the condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260299437\">",
"      <span class=\"h1\">",
"       How is Marfan syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your symptoms and condition and can involve:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Regular exams and tests to monitor your condition",
"       </li>",
"       <li>",
"        Medicines called &ldquo;beta blockers,&rdquo; which lower the blood pressure and reduce the amount of work the heart has to do",
"       </li>",
"       <li>",
"        Avoiding contact sports and exercise that involves intense activity &ndash; If your child has Marfan syndrome, let your child&rsquo;s school or caregiver know which activities and sports your child should avoid.",
"       </li>",
"       <li>",
"        Surgery to fix your aorta before a serious problem happens",
"       </li>",
"       <li>",
"        Emergency surgery to fix your aorta if an aortic dissection happens",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other treatment depends on the problems you have. For example, people with eye problems need to be treated by an eye doctor, called an ophthalmologist. People with scoliosis might need to wear a back brace or have surgery to fix their spine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260299452\">",
"      <span class=\"h1\">",
"       Should my family members be tested for Marfan syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have Marfan syndrome, your family members should be tested for the condition.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260299467\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse before you start trying. If you or your partner has Marfan syndrome, you might pass on the gene that causes it to your child. You might want to talk with a genetic counselor, a person who specializes in genetic conditions.",
"     </p>",
"     <p>",
"      Your doctor will also talk with you about possible problems women with Marfan syndrome can have during pregnancy and delivery. Pregnancy increases the chance of having an aortic dissection. Because of this, your doctor might recommend that you have surgery to fix your aorta before you try to get pregnant. He or she will also make sure that your medicines are safe to take during pregnancy.",
"     </p>",
"     <p>",
"      During your pregnancy and delivery, you will be closely monitored by a team of specialists who have experience caring for pregnant women with Marfan syndrome.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H260299482\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/38/30307?source=see_link\">",
"       Patient information: Aortic dissection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/30/40418?source=see_link\">",
"       Patient information: Pneumothorax (collapsed lung) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/20/18754?source=see_link\">",
"       Patient information: Scoliosis (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/11/25778?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87047 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25778=[""].join("\n");
var outline_f25_11_25778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299302\">",
"      What is Marfan syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299317\">",
"      What are the body features of Marfan syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299355\">",
"      What medical problems does Marfan syndrome cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299399\">",
"      Is there a test for Marfan syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299437\">",
"      How is Marfan syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299452\">",
"      Should my family members be tested for Marfan syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299467\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H260299482\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87047\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/40/26244\">",
"      Pneumothorax (collapsed lung)",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/35/34354\">",
"       Transthoracic echocardiogram (echo)",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/59/21439\">",
"        Scoliosis",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/38/30307?source=related_link\">",
"      Patient information: Aortic dissection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/30/40418?source=related_link\">",
"      Patient information: Pneumothorax (collapsed lung) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/20/18754?source=related_link\">",
"      Patient information: Scoliosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_11_25779="Fistulotomy photograph";
var content_f25_11_25779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intra-operative fistulotomy of an anal fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This intra-operative photograph shows the fistula tract between the primary internal opening and the secondary external opening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bradley J Champagne, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25779=[""].join("\n");
var outline_f25_11_25779=null;
var title_f25_11_25780="Rimantadine: Patient drug information";
var content_f25_11_25780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rimantadine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     see \"Rimantadine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=see_link\">",
"     see \"Rimantadine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flumadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flumadine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat influenza A.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rimantadine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11276 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25780=[""].join("\n");
var outline_f25_11_25780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216937\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216938\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015697\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015696\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015701\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015702\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015704\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015699\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015700\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015705\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015706\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=related_link\">",
"      Rimantadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=related_link\">",
"      Rimantadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_11_25781="ACE inhibitor-induced angioedema";
var content_f25_11_25781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    ACE inhibitor-induced angioedema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Grant NN, Deeb ZE, Chia SH. Clinical experience with angiotensin-converting enzyme inhibitor-induced angioedema. Otolaryngol Head Neck Surg 2007; 137:931. Copyright &copy; 2007. Reprinted by permission of SAGE Publications.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25781=[""].join("\n");
var outline_f25_11_25781=null;
var title_f25_11_25782="EEG normal awake adult";
var content_f25_11_25782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62111&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Electroencephalogram of normal awake adult",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prominent 8-12 Hz (alpha) activity is present in recordings from the posteriorly placed electrodes in this alert adult subject.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahram Khoshbin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25782=[""].join("\n");
var outline_f25_11_25782=null;
var title_f25_11_25783="Candida KOH low power";
var content_f25_11_25783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candida albicans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Potassium hydroxide preparation of candida infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25783=[""].join("\n");
var outline_f25_11_25783=null;
var title_f25_11_25784="Dry eyes";
var content_f25_11_25784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dry eyes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/11/25784/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25784/contributors\">",
"     Roni M Shtein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/11/25784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25784/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/11/25784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25784/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/11/25784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry eye disease is a multifactorial disease of the tears and ocular surface that can result in ocular discomfort and visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/1\">",
"     1",
"    </a>",
"    ]. Dry eye is also known as keratoconjunctivitis sicca, dry eye syndrome, and dysfunctional tear syndrome.",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment options for dry eye will be reviewed here. Various conditions associated with dry eye are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"     \"Allergic conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of dry eye disease is unknown due to the difficulty in defining the disease and the lack of a single diagnostic test to confirm its presence. However, the prevalence of dry eye increases with age and has been estimated at 5 to 30 percent of the population age 50 years and over [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This prevalence is expected to increase as the population in developed countries continues to age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for dry eye disease include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Female gender",
"     </li>",
"     <li>",
"      Hormonal changes (primarily due to decreased androgens)",
"     </li>",
"     <li>",
"      Systemic diseases (eg, diabetes mellitus, Parkinson disease)",
"     </li>",
"     <li>",
"      Contact lens wear",
"     </li>",
"     <li>",
"      Systemic medications (antihistamines, anticholinergics, estrogens,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      , selective serotonin receptor antagonists,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , nicotinic acid)",
"     </li>",
"     <li>",
"      Ocular medications (especially those containing preservatives)",
"     </li>",
"     <li>",
"      Nutritional deficiencies (eg, vitamin A deficiency)",
"     </li>",
"     <li>",
"      Decreased corneal sensation",
"     </li>",
"     <li>",
"      Ophthalmic surgery (especially corneal refractive surgery)",
"     </li>",
"     <li>",
"      Low humidity environments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sj&ouml;gren's syndrome (SS) is a chronic inflammatory disorder characterized by diminished lacrimal and salivary gland function. Risk factors specific for Sj&ouml;gren's Syndrome include a genetic predisposition, low androgen status, nutritional deficiencies, and exposure to environmental agents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/8\">",
"     8",
"    </a>",
"    ]. Dry eye related to Sj&ouml;gren's syndrome is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry eye disease can have a significant impact on visual acuity, daily activities, social and physical functioning, and workplace productivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Utility assessment is a formal method for quantifying the relative impact on patients by a variety of disease states. Previous studies evaluating the impact of dry eyes on quality of life show that patients with moderate to severe dry eye report utility scores similar to patients with moderate to severe angina or patients receiving dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, patients with dry eye incur direct medical costs through frequent visits to health care professionals, as well as pharmacologic and non-pharmacologic therapies. Indirect costs include decreased productivity and time lost from work [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/12\">",
"     12",
"    </a>",
"    ]. A cost analysis study estimates an overall annual cost of $55.4 billion to the United States from a societal perspective [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dry eye has a complex and multifactorial etiology. The tear film of the eye consists of aqueous, mucous, and lipid components (",
"    <a class=\"graphic graphic_figure graphicRef64230 \" href=\"UTD.htm?17/4/17479\">",
"     figure 1",
"    </a>",
"    ). A healthy tear film relies on a synergistic interaction of the lacrimal glands, eyelids, and ocular surface, which together comprise the lacrimal functional unit [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/14\">",
"     14",
"    </a>",
"    ]. Dysfunction of any component in the lacrimal functional unit can lead to dry eye disease.",
"   </p>",
"   <p>",
"    Dry eye is classified into two general groups: decreased tear production and increased evaporative loss. In both groups, tear film hyperosmolarity and subsequent ocular surface inflammation lead to the variety of symptoms and signs associated with dry eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Decreased tear production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired lacrimal tear production can be caused by any form of lacrimal gland destruction or dysfunction. The reduced volume of aqueous fluid leads to hyperosmolarity of the tear film and subsequently the ocular surface, which incites inflammation of the ocular surface cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/15\">",
"     15",
"    </a>",
"    ]. Deficiency of aqueous tear production can further be subclassified into Sj&ouml;gren and non-Sj&ouml;gren syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Sj&ouml;gren syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sj&ouml;gren syndrome is a systemic autoimmune exocrinopathy in which there is inflammatory infiltration of the lacrimal glands leading to cell death and tear hyposecretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Non-Sj&ouml;gren syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Sj&ouml;gren syndrome, aqueous tear-deficient dry eye involves lacrimal dysfunction without associated systemic findings. The most common form is age-related dry eye in which it is believed that there is lacrimal ductal obstruction over time, leading to decreased lacrimal gland function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/16\">",
"     16",
"    </a>",
"    ]. Lacrimal gland obstruction can also be due to conjunctival scarring conditions such as trachoma, mucous membrane pemphigoid, and ocular burns [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=see_link\">",
"     \"Epidemiology, diagnosis, and management of trachoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-Sj&ouml;gren syndrome, aqueous tear-deficient dry eye can also be caused by lacrimal gland infiltration. Infiltrative etiologies include sarcoidosis, lymphoma, graft versus host disease, and episcleritis. In addition, contact lens use is associated with reduced corneal sensitivity and subsequently reduced reflex sensory tear secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/17\">",
"     17",
"    </a>",
"    ]. Diabetes mellitus is also associated with non-Sj&ouml;gren aqueous deficient dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29128?source=see_link\">",
"     \"Complications of contact lenses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=see_link\">",
"     \"Episcleritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Increased evaporative loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive water loss from the ocular surface without any lacrimal dysfunction leads to tear film instability and a similar cycle of tear hyperosmolarity and lacrimal functional unit inflammation that is seen with decreased tear production. Increased tear evaporation is most commonly caused by meibomian gland dysfunction, also known as posterior blepharitis, in which the accessory lacrimal glands responsible for the lipid component of the tear film are dysfunctional [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/1\">",
"     1",
"    </a>",
"    ]. The amphiphilic nature of the lipid layer allows even spreading of the tear film to form a membrane and provides a barrier to minimize evaporation of tears [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/19\">",
"     19",
"    </a>",
"    ]. Abnormalities of the lipid layer are associated with a higher rate of tear film evaporation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Structural abnormalities of eyelid position or decreased blink function also increase evaporation of the tear film by increasing the area or the time of tear film exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. Lastly, topical medicated or preserved eye drop use, chronic contact lens wear, and ocular allergy syndromes can cause ocular surface irritation and increased tear film evaporation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/1,21\">",
"     1,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms in dry eye disease result from activation of sensory nerves of the ocular surface, either due to tear hyperosmolarity, the presence of inflammatory mediators, or hypersensitivity of the sensory nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/22\">",
"     22",
"    </a>",
"    ]. Most patients will present with symptoms of chronic eye irritation. However, there is considerable variability in patient-reported symptoms and clinically measurable signs over time, as well as a recognized lack of correlation between these symptoms and signs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/21,23-25\">",
"     21,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A good patient history may elicit many of the complaints below, as well as inciting or exacerbating causes (including medications, windy conditions, cold weather, low humidity environment, time of day).",
"   </p>",
"   <p>",
"    Common eye complaints include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dryness",
"     </li>",
"     <li>",
"      Red eyes",
"     </li>",
"     <li>",
"      General irritation",
"     </li>",
"     <li>",
"      Gritty sensation",
"     </li>",
"     <li>",
"      Burning sensation",
"     </li>",
"     <li>",
"      Foreign body sensation",
"     </li>",
"     <li>",
"      Excessive tearing",
"     </li>",
"     <li>",
"      Light sensitivity",
"     </li>",
"     <li>",
"      Blurred vision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The blurred vision associated with dry eyes tends to be quite variable. Since the tear film is the first layer encountered by light rays as they enter the eye, an irregular tear film can degrade the quality of the image that is received by the retina. The visual impairment associated with dry eyes is usually temporary and often improves with treatment of the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Rarely, in severe dry eye conditions, permanent damage to visual acuity can occur from corneal scarring.",
"   </p>",
"   <p>",
"    If ocular complaints are accompanied by mouth dryness and other systemic complaints, an evaluation for Sj&ouml;gren's syndrome should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single definitive diagnostic test to identify or measure the severity of dry eye. A variety of symptom questionnaires and diagnostic tests described in this section are often used in an attempt to standardize the identification and classification of dry eye disease. However, there is currently no 'gold standard' or general consensus of the criterion for diagnosis of dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Primary care evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the known lack of correlation between patient-reported symptoms, clinically measurable signs, and available diagnostic testing, dry eye is diagnosed primarily on the basis of patient symptoms and supporting findings on the physical examination. The diagnosis can often be made at the office of the primary care clinician. The physical examination may also give clues to other associated conditions.",
"   </p>",
"   <p>",
"    Dry eye disease can vary considerably in its intensity over time and under different environmental conditions (",
"    <a class=\"graphic graphic_picture graphicRef62824 \" href=\"UTD.htm?17/19/17714\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75685 \" href=\"UTD.htm?29/25/30096\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75497 \" href=\"UTD.htm?15/11/15541\">",
"     picture 3",
"    </a>",
"    ). A complete clinical examination by the primary care clinician should include observation for the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conjunctival injection, usually symmetric in both eyes (",
"      <a class=\"graphic graphic_picture graphicRef72833 \" href=\"UTD.htm?14/27/14771\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Excessive tearing, which can paradoxically be a sign of dry eye",
"     </li>",
"     <li>",
"      Blepharitis, often visible as erythematous or irritated eyelid edges (",
"      <a class=\"graphic graphic_picture graphicRef64540 \" href=\"UTD.htm?28/6/28771\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61924 \" href=\"UTD.htm?25/60/26562\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Malposition of the eyelids (inward or outward turning, also called entropion and ectropion, respectively) (",
"      <a class=\"graphic graphic_picture graphicRef63579 \" href=\"UTD.htm?41/61/42964\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef72737 \" href=\"UTD.htm?19/16/19714\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reduced blink rate",
"     </li>",
"     <li>",
"      Visual impairment, with visual acuity assessed in each eye separately. This should include evaluation as to whether acuity improves with increased blink rate or use of lubricating eye drops.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ophthalmology evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmologist will perform a thorough slit lamp evaluation along with other testing to assess the status of the patient's lacrimal functional unit to determine the severity of dry eye disease and possible etiologies. The following may be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extent and pattern of conjunctival injection",
"     </li>",
"     <li>",
"      Eyelid health &mdash; Any eyelid or punctal malpositions are noted, as they can lead to dry eye, and often can be surgically repaired. Careful evaluation for meibomian gland dysfunction (posterior blepharitis) is performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link&amp;anchor=H10#H10\">",
"       \"Blepharitis\", section on 'External examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ocular surface staining &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       Fluorescein",
"      </a>",
"      is used to stain for areas of discontinuity in the epithelial surface of the cornea. Lissamine green and Rose Bengal are used to stain areas of devitalized epithelium in the cornea and conjunctiva.",
"     </li>",
"     <li>",
"      Tear break-up time &mdash; Measured with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      stain in the eye to determine tear film stability. The patient is instructed not to blink and the tear film is observed through the slit lamp. If the smooth, stained green tear film layer begins to develop blue gaps in less than 10 seconds, the patient's tear film is considered abnormal.",
"     </li>",
"     <li>",
"      Schirmer's test &mdash; Assessed by quantifying the number of tears produced by each eye. Small strips of filter paper are placed in the lower eyelids of each eye, either with or without prior instillation of anesthetic eye drops. Results are measured in millimeters of tears collected over a five minute time period. This test is often used in the clinical setting, but has been shown to provide extremely variable results [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Corneal sensation &mdash; Objectively measured by the ophthalmologist with a variety of techniques to provide information about ocular surface and possibly systemic associations of dry eye.",
"     </li>",
"     <li>",
"      Tear hyperosmolarity &mdash; Tear osmolarity testing is a potentially useful measure and is commercially available for use in the clinical setting [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Further investigation is needed to determine how best to use for guiding patient care.",
"     </li>",
"     <li>",
"      Questionnaires &mdash; Due to the variability of findings on clinical evaluation of dry eye, some clinicians base their assessment of dry eye on the results of validated questionnaires [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/2\">",
"       2",
"      </a>",
"      ]. Some of the more widely-available questionnaires that are used specifically for the evaluation of dry eye symptoms include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ocular Surface Disease Index (OSDI) &mdash; 12-item questionnaire validated in patients with dry eye disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Impact of Dry Eye on Everyday Life (IDEEL) &mdash; 57 questions in three modules validated in patients with dry eye disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Salisbury Eye Evaluation Questionnaire (SEE) &mdash; six-item questionnaire used in self-reported, population-based prevalence surveys to determine visual impairment among older adult subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions that can cause similar symptoms to dry eyes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blepharitis &mdash; Posterior blepharitis often coexists with dry eye and may require several specific treatments, including warm compresses and patient education on eyelid hygiene. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"       \"Blepharitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ocular allergies &mdash; Allergic conjunctivitis can also coexist with dry eye. Symptoms of itching will often be the primary complaint. The allergen should be promptly identified and avoided. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=see_link\">",
"       \"Allergic conjunctivitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Viral Conjunctivitis &mdash; Dry eye can be confused with \"pink eye.\" A careful patient history to elicit course of symptoms, any recent illnesses or sick contacts, and presence of lymphadenopathy can help to distinguish the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"       \"Conjunctivitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other microbial infections &mdash; Some ocular infections can begin with an indolent course of symptoms similar to dry eye. Referral to an ophthalmologist should be considered for any patients at high risk for ocular infections (eg, contact lens wearer, history of diabetes mellitus), particularly those with signs of an infectious process on physical examination (eg, unilateral conjunctival injection, purulent drainage).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current treatment for dry eye disease is aimed at increasing or supplementing tear production, slowing tear evaporation, and reducing tear resorption. The patient should discontinue unnecessary systemic or ocular medications that can contribute to dryness. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The first line of treatment in patients complaining of dry eye includes tear supplementation and environmental coping strategies. Although several therapies discussed below have been studied in randomized trials, these studies have been limited by small sample size, lack of placebo control, and non-standardized clinical endpoints. Clinical trials of dry eye are also limited by the lack of clear diagnostic criteria for the condition. Thus, assessment of treatment efficacy is difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Artificial tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    generally include cellulose to maintain viscosity, a spreading agent such as polyethylene glycol or polyvinyl alcohol to prevent evaporation, and a preservative to prevent contamination. Available without a prescription, \"artificial tears\" come in liquid, gel, and ointment forms. Preservative-free forms of these supplements are often recommended as some individuals with dry eye will have inflammatory reactions to the preservatives [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/34\">",
"     34",
"    </a>",
"    ]. However, these are often expensive, single-use formulations.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    are considered first-line treatment for dry eye and have been shown to improve irritative symptoms in patients with dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/6,35\">",
"     6,35",
"    </a>",
"    ]. Artificial tears can also improve visual acuity in patients with dry eye symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    have shown some efficacy in randomized trials, but these trials are mostly limited due to sample size, lack of an adequate control group, and non-standardized outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. As laser-assisted in situ kertomileusis (LASIK) is a refractive procedure that causes dry eyes, in part due to decreased postoperative corneal sensation, LASIK serves as a model for assessing treatment of dry eye. Artificial tears given to postoperative LASIK patients appear to improve dry eye symptoms compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/41\">",
"     41",
"    </a>",
"    ]. Issues related to dry eye and LASIK are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=see_link\">",
"     \"Laser refractive surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reasonable starting dose for artificial tear administration is one drop in each eye, four times per day. Patients often begin to notice improvement within a few days of initiating treatment, but may take up to three to four weeks to note a significant change in their symptoms. If individuals remain symptomatic, the frequency of artificial tear use can be increased to the level of symptoms, even as frequently as every hour. If used more often than four to six times per day, it is recommended that a preservative free formulation be used to minimize the potential for toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/42\">",
"     42",
"    </a>",
"    ]. Higher viscosity artificial tear gels and ointments are also commercially available and can be used if patients feel that the eye drops are not providing enough symptomatic relief. Patients should be warned that the gels, and especially ointments, can blur vision temporarily and are often best used at bedtime.",
"   </p>",
"   <p>",
"    Unless there is a specific inciting factor that can be eliminated, dry eyes are most often a chronic condition and require chronic treatment. Patients should be advised that they will need to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    for relief of dry eye symptoms indefinitely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Environmental strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental coping strategies address the importance of environmental causes that could be contributing to or even causing dry eye symptoms. One important strategy includes frequent blinking, especially during visually attentive tasks such as reading or computer use. The patient should also be urged to minimize exposure to air conditioning or heating. Humidifiers are useful in the bedroom, office, or any space where the patient spends a significant amount of time.",
"   </p>",
"   <p>",
"    Swim goggles or other \"moisture chambers\" are recommended to protect the humidity of the local environment around the eyes. Moisture chambers can be purchased and fitted to current glasses in select optical shops by trained opticians (",
"    <a class=\"graphic graphic_picture graphicRef75764 \" href=\"UTD.htm?17/40/18048\">",
"     picture 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef52738 \" href=\"UTD.htm?21/4/21570\">",
"     picture 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Topical cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is an immunosuppressive agent that has been found to be relatively safe, well-tolerated, and to improve signs and symptoms of dry eyes significantly in some populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two six-month trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (0.05% or 0.01% one drop twice daily) versus vehicle in a combined 877 patients with moderate to severe dry eye disease, those randomly assigned to either dose of cyclosporine had significantly greater improvements in corneal staining, Schirmer values, and blurred vision compared to those receiving vehicle [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/44\">",
"       44",
"      </a>",
"      ]. All patients were allowed to use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      as frequently as needed.",
"     </li>",
"     <li>",
"      In a prospective cohort study of 158 patients with persistent dry eye symptoms despite",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      , patients in all three severity groups (mild, moderate, severe) receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      showed improvement in symptoms, Schirmer scores, and mean tear breakup times compared to baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the available evidence, we have not seen such a degree of beneficial results in our practice. There appears to be a subset of patients who do respond favorably to this treatment, but there are no good predictive models available to guide clinical decision-making at this time.",
"   </p>",
"   <p>",
"    A 0.05% emulsion of cyclosporin (Restasis&reg;) is available for treatment of dry eye disease. It may take up to six weeks or longer to achieve noticeable improvement of dryness. In some patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can result in long term resolution of dry eye symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/46\">",
"     46",
"    </a>",
"    ]. Serum cyclosporine concentrations have been undetectable or negligible with topical use, and no systemic toxicity has been reported. Cyclosporine can cause an occasional, temporary burning sensation in the eye. Another important limiting factor of cyclosporine use is high cost [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As patients may have other concurrent problems such as infection leading to eye irritation, they should have a complete ophthalmological examination prior to receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although several other treatments are available for dry eye, they are not in common use and should only be used as an adjunctive treatment by eye specialists.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sodium hyaluronate &mdash; In a placebo-controlled trial of topical sodium hyaluronate solution versus vehicle control in 444 subjects with dry eye, those randomly assigned to sodium hyaluronate had improved symptoms and ocular staining scores compared to the control group [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Topical glucocorticoids &mdash; Low-dose topical glucocorticoid eye drops can help to relieve symptoms and signs of dry eye [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/48\">",
"       48",
"      </a>",
"      ] and are useful on a short-term basis. As these drops can have significant side effects with continued use, including cataracts and glaucoma, glucocorticoid eye drops should be used with caution.",
"     </li>",
"     <li>",
"      Autologous serum tears &mdash; The serum of a patient's blood can be formulated into eye drops that have been shown to improve dry eye symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tear stimulation &mdash; Systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      (a cholinergic agonist) has been found to improve dry eye symptoms in patients with Sj&ouml;gren syndrome, but is associated with systemic side effects in a significant portion of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/50\">",
"       50",
"      </a>",
"      ]. Other tear stimulation agents, including those for topical use, are being explored as potential treatments for dry eye [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Omega-3 and omega-6 fatty acids &mdash; Oral omega-3 and omega-6 fatty acids may improve symptoms of dry eye [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/52-54\">",
"       52-54",
"      </a>",
"      ]. Animal studies have found that the topical use of omega-3 and omega-6 fatty acids may also be beneficial for the treatment of dry eyes [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral antioxidants &mdash; Small randomized trials have shown some efficacy of oral antioxidants in the treatment of dry eye [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. As an example, in a blinded, placebo-controlled cross-over trial of 24 dry eye patients, those randomly assigned an antioxidant combination compared to placebo had improved tear break up times, Schirmer scores, and clinical symptoms, including burning, itching, and redness [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin A &mdash; Systemic vitamin A deficiency is associated with severe ocular surface dryness with keratinization of the conjunctiva (Bitot spots) and night blindness. In dry eye patients without known deficiency, topical vitamin A eye drops can improve dry eye symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Punctal occlusion &mdash; Either temporary or permanent occlusion of the openings of the tear drainage system can be performed to delay tear clearance and improve dry eye symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Scleral contact lenses &mdash; In patients with severe dry eye, large diameter contact lenses can be used to help retain a tear reservoir over the ocular surface [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/60\">",
"       60",
"      </a>",
"      ]. These types of contact lenses require a specialized fitting by an experienced contact lens practitioner.",
"     </li>",
"     <li>",
"      Acupuncture &mdash; Small studies have shown some improvement in dry eye signs and symptoms following acupuncture therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. Acupuncture is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=see_link\">",
"       \"Acupuncture\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgery &mdash; Eyelid abnormalities should be surgically corrected to realign and maintain normal lid architecture. Surgery can also be performed on structurally normal eyelids to reduce the ocular surface area and thus reduce tear evaporation.",
"     </li>",
"     <li>",
"      Investigational &mdash; In a phase II randomized trial, twice daily topical use of an integrin antagonist (SAR 1118, a small molecule that decreases inflammation by blocking lymphocyte-endothelial adhesion) led to improvement in symptoms and signs of dry eye disease, compared to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25784/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     REFERRAL TO OPHTHALMOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest referral to an ophthalmologist if the etiology of the patient's symptoms is not clear or if a patient does not get adequate relief from tear supplementation and environmental strategies. The ophthalmologist can reevaluate the patient and provide the other treatment options described above. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/46/30433?source=see_link\">",
"       \"Patient information: Dry eye (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dry eye disease is a multifactorial disease of the tears and ocular surface that can result in ocular discomfort and visual impairment. Dry eye is generally due to decreased tear production",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      excessive evaporative loss. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients present with symptoms of chronic eye irritation, such as eye dryness, red eyes, and burning. However, there is considerable variability in patient-reported symptoms over time. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no single definitive diagnostic test to identify or classify the severity of dry eye disease. The diagnosis is based primarily on patient symptoms and supportive findings of dry eye from examination. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Primary care evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      for the initial treatment of all patients with dry eye disease (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). When appropriate, environmental strategies should be undertaken, including discussing the importance of frequent blinking and minimizing exposure to air conditioning or heating. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other treatment options include topical cyclosporin, other topical medications, oral medications, scleral contact lenses, punctal occlusion, and surgery. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/1\">",
"      The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/2\">",
"      The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/3\">",
"      Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000; 118:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/4\">",
"      Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications : recognition and management. Drugs 2007; 67:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/5\">",
"      Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/6\">",
"      Gilbard JP. The diagnosis and management of dry eyes. Otolaryngol Clin North Am 2005; 38:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/7\">",
"      Latkany R. Dry eyes: etiology and management. Curr Opin Ophthalmol 2008; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/8\">",
"      Moutsopoulos HM, Manoussakis MN. Immunopathogenesis of Sjogren's syndrome: \"facts and fancy\". Autoimmunity 1989; 5:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/9\">",
"      Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008; 14:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/10\">",
"      Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003; 110:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/11\">",
"      Buchholz P, Steeds CS, Stern LS, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf 2006; 4:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/12\">",
"      Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea 2004; 23:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/13\">",
"      Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 2011; 30:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/14\">",
"      Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998; 17:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/15\">",
"      Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45:4302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/16\">",
"      Damato BE, Allan D, Murray SB, Lee WR. Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease. Br J Ophthalmol 1984; 68:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/17\">",
"      Gilbard JP, Gray KL, Rossi SR. A proposed mechanism for increased tear-film osmolarity in contact lens wearers. Am J Ophthalmol 1986; 102:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/18\">",
"      Kaiserman I, Kaiserman N, Nakar S, Vinker S. Dry eye in diabetic patients. Am J Ophthalmol 2005; 139:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/19\">",
"      Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998; 17:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/20\">",
"      Bron AJ, Tiffany JM, Gouveia SM, et al. Functional aspects of the tear film lipid layer. Exp Eye Res 2004; 78:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/21\">",
"      Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995; 21:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/22\">",
"      Belmonte C, Acosta MC, Gallar J. Neural basis of sensation in intact and injured corneas. Exp Eye Res 2004; 78:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/23\">",
"      Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea 2004; 23:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/24\">",
"      Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004; 23:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/25\">",
"      Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003; 44:4753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/26\">",
"      Mont&eacute;s-Mic&oacute; R. Role of the tear film in the optical quality of the human eye. J Cataract Refract Surg 2007; 33:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/27\">",
"      Liu Z, Pflugfelder SC. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 1999; 106:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/28\">",
"      Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/29\">",
"      Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/30\">",
"      Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010; 51:6125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/31\">",
"      Hesse L. Intravitreal injection of tissue plasminogen activator: four considerations. Arch Ophthalmol 2001; 119:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/32\">",
"      Rajagopalan K, Abetz L, Mertzanis P, et al. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health 2005; 8:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/33\">",
"      Rubin GS, West SK, Mu&ntilde;oz B, et al. A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project. Invest Ophthalmol Vis Sci 1997; 38:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/34\">",
"      Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can J Ophthalmol 1988; 23:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/35\">",
"      Drugs for some common eye disorders. Treat Guidel Med Lett 2010; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/36\">",
"      Nilforoushan MR, Latkany RA, Speaker MG. Effect of artificial tears on visual acuity. Am J Ophthalmol 2005; 140:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/37\">",
"      Willen CM, McGwin G, Liu B, et al. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye Contact Lens 2008; 34:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/38\">",
"      Huang FC, Tseng SH, Shih MH, Chen FK. Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes. Ophthalmology 2002; 109:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/39\">",
"      Bron AJ, Mangat H, Quinlan M, et al. Polyacrylic acid gel in patients with dry eyes: a randomised comparison with polyvinyl alcohol. Eur J Ophthalmol 1998; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/40\">",
"      Brodwall J, Alme G, Gedde-Dahl S, et al. A comparative study of polyacrylic acid (Viscotears) liquid gel versus polyvinylalcohol in the treatment of dry eyes. Acta Ophthalmol Scand 1997; 75:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/41\">",
"      Lenton LM, Albietz JM. Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg 1999; 15:S227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/42\">",
"      Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/43\">",
"      Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008; 126:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/44\">",
"      Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/45\">",
"      Baiza-Dur&aacute;n L, Medrano-Palafox J, Hern&aacute;ndez-Quintela E, et al. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol 2010; 94:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/46\">",
"      Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/47\">",
"      Vogel R, Crockett RS, Oden N, et al. Demonstration of efficacy in the treatment of dry eye disease with 0.18% sodium hyaluronate ophthalmic solution (vismed, rejena). Am J Ophthalmol 2010; 149:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/48\">",
"      Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/49\">",
"      Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004; 88:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/50\">",
"      Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sj&ouml;gren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/51\">",
"      Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004; 23:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/52\">",
"      Miljanovi�� B, Trivedi KA, Dana MR, et al. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. Am J Clin Nutr 2005; 82:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/53\">",
"      Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye 2008; 31:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/54\">",
"      Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011; 30:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/55\">",
"      Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 2008; 126:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/56\">",
"      Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol 2009; 19:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/57\">",
"      Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr 2001; 55:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/58\">",
"      Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009; 147:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/59\">",
"      Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010; :CD006775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/60\">",
"      Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007; 26:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/61\">",
"      Tseng KL, Liu HJ, Tso KY, et al. A clinical study of acupuncture and SSP (silver spike point) electro-therapy for dry eye syndrome. Am J Chin Med 2006; 34:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/62\">",
"      Gr&ouml;nlund MA, Stenevi U, Lundeberg T. Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study. Acta Ophthalmol Scand 2004; 82:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25784/abstract/63\">",
"      Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012; 153:1050.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6894 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25784=[""].join("\n");
var outline_f25_11_25784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Decreased tear production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Sj&ouml;gren syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Non-Sj&ouml;gren syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Increased evaporative loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Primary care evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ophthalmology evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Artificial tears",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Environmental strategies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Topical cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      REFERRAL TO OPHTHALMOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6894\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6894|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/4/17479\" title=\"figure 1\">",
"      Precorneal tear film",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6894|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/19/17714\" title=\"picture 1\">",
"      Severe dry eye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/25/30096\" title=\"picture 2\">",
"      Severe dry eye 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/11/15541\" title=\"picture 3\">",
"      Punct epithelial erosions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/27/14771\" title=\"picture 4\">",
"      Dry eye conjunctival vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/6/28771\" title=\"picture 5\">",
"      Anterior blepharitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/60/26562\" title=\"picture 6\">",
"      Posterior blepharitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/61/42964\" title=\"picture 7\">",
"      Entropion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/16/19714\" title=\"picture 8\">",
"      Ectropion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/40/18048\" title=\"picture 9\">",
"      Moisture chambers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/4/21570\" title=\"picture 10\">",
"      Moisture chambers use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28457?source=related_link\">",
"      Acupuncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34856?source=related_link\">",
"      Allergic conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29128?source=related_link\">",
"      Complications of contact lenses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8409?source=related_link\">",
"      Epidemiology, diagnosis, and management of trachoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/29/42457?source=related_link\">",
"      Laser refractive surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/46/30433?source=related_link\">",
"      Patient information: Dry eye (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_11_25785="Valproate: Drug information";
var content_f25_11_25785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Valproate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/35/11831?source=see_link\">",
"    see \"Valproate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"    see \"Valproate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Depacon&reg;;",
"     </li>",
"     <li>",
"      Depakene&reg;;",
"     </li>",
"     <li>",
"      Depakote&reg;;",
"     </li>",
"     <li>",
"      Depakote&reg; ER;",
"     </li>",
"     <li>",
"      Depakote&reg; Sprinkle;",
"     </li>",
"     <li>",
"      Stavzor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Divalproex&reg;;",
"     </li>",
"     <li>",
"      Apo-Valproic&reg;;",
"     </li>",
"     <li>",
"      Depakene&reg;;",
"     </li>",
"     <li>",
"      Dom-Divalproex;",
"     </li>",
"     <li>",
"      Epival&reg;;",
"     </li>",
"     <li>",
"      Mylan-Divalproex;",
"     </li>",
"     <li>",
"      Mylan-Valproic;",
"     </li>",
"     <li>",
"      Novo-Divalproex;",
"     </li>",
"     <li>",
"      Nu-Divalproex;",
"     </li>",
"     <li>",
"      PHL-Divalproex;",
"     </li>",
"     <li>",
"      PHL-Valproic Acid;",
"     </li>",
"     <li>",
"      PHL-Valproic Acid E.C.;",
"     </li>",
"     <li>",
"      PMS-Divalproex;",
"     </li>",
"     <li>",
"      PMS-Valproic Acid;",
"     </li>",
"     <li>",
"      PMS-Valproic Acid E.C.;",
"     </li>",
"     <li>",
"      ratio-Valproic;",
"     </li>",
"     <li>",
"      ratio-Valproic ECC;",
"     </li>",
"     <li>",
"      Rhoxal-valproic;",
"     </li>",
"     <li>",
"      Sandoz-Valproic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous;",
"     </li>",
"     <li>",
"      Antimanic Agent;",
"     </li>",
"     <li>",
"      Histone Deacetylase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seizures:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Administer doses &gt;250 mg/day in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Simple and complex absence seizure: Initial: 15 mg/kg/day; increase by 5-10 mg/kg/day at weekly intervals until therapeutic levels are achieved; maximum: 60 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Complex partial seizure: Initial: 10-15 mg/kg/day; increase by 5-10 mg/kg/day at weekly intervals until therapeutic levels are achieved; maximum: 60 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Regular release and delayed release formulations are usually given in 2-4 divided doses per day; extended release formulation (Depakote&reg; ER) is usually given once daily. Depakote&reg; ER is not recommended for use in children &lt;10 years of age.  In patients previously maintained on regular release valproic acid therapy (Depakene&reg;) who convert to delayed release valproate tablets or capsules (Depakote&reg;,  Stavzor&trade;), the same daily dose and frequency as the regular release should be used; once therapy is stabilized, the frequency of Depakote&reg; or Stavzor&trade; may be adjusted to 2-3 times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Conversion to Depakote&reg; ER from a stable dose of Depakote&reg;:",
"     </i>",
"     May require an increase in the total daily dose between 8% and 20% to maintain similar serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Conversion to monotherapy from adjunctive therapy:",
"     </i>",
"     The concomitant antiepileptic drug (AED) can be decreased by ~25% every 2 weeks; dosage reduction of the concomitant AED may begin when valproate therapy is initiated or 1-2 weeks following valproate initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Total daily I.V. dose should be equivalent to the total daily dose of the oral valproate product; administer dose as a 60-minute infusion (&le;20 mg/minute) with the same frequency as oral products; switch patient to oral products as soon as possible. Alternatively, rapid infusions of 1.5-6 mg/kg/minute  have been used in clinical trials to quickly achieve therapeutic concentrations, and were generally well tolerated (Ramsay, 2003; Wheless, 2004; Venkataraman, 1999). One study reported undiluted valproic acid administered at &le;10 mg/kg/minute (dose of &le;30 mg/kg) was well tolerated (Limdi, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus, refractory (unlabeled use):",
"     </b>",
"     I.V.: Loading dose: 15-20 mg/kg administered at 20 mg/minute; maintenance dose: I.V. infusion: 1-5 mg/kg/hour (Gaitanis, 2003). Alternatively, median loading doses of 25-30 mg/kg (maximum dose: 45 mg/kg) administered at &le;6 mg/kg/minute have also been reported (Limdi, 2005; Misra, 2006; Sinha, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Mania:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Depakote&reg; tablet, Stavzor&trade;:",
"     </i>",
"     Initial: 750 mg/day in divided doses; dose should be adjusted as rapidly as possible to desired clinical effect; maximum recommended dosage: 60 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Depakote&reg; ER:",
"     </i>",
"     Initial: 25 mg/kg/day given once daily; dose should be adjusted as rapidly as possible to desired clinical effect; maximum recommended dose: 60 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Depakote&reg; tablet, Stavzor&trade;:",
"     </i>",
"     250 mg twice daily; adjust dose based on patient response, up to 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Depakote&reg; ER:",
"     </i>",
"     500 mg once daily for 7 days, then increase to 1000 mg once daily; adjust dose based on patient response; usual dosage range 500-1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Diabetic neuropathy (unlabeled use):",
"     </b>",
"     Oral: 500-1200 mg/day (Bril, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F233045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"      see \"Valproate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seizures:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Administer doses &gt;250 mg daily in divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Simple and complex absence seizures:",
"     </i>",
"     Refer to adult dosing. Larger maintenance doses may be required in younger children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Complex partial seizures:",
"     </i>",
"     Children &ge;10 years: Refer to adult dosing. Larger maintenance doses may be required in younger children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Depakote&reg; ER is not recommended for use in children &lt;10 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Conversion to Depakote&reg; ER from a stable dose of Depakote&reg;:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Conversion to monotherapy from adjunctive therapy:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Rectal (unlabeled route): Dilute syrup 1:1 with water for use as a retention enema; acute and maintenance dose: 6-15 mg/kg/dose (Graves, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Migraine prophylaxis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years (Stavzor&trade;): Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;16 years (Depakote&reg; tablet): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V.: Lower initial doses are recommended due to decreased elimination and increased incidences of somnolence in the elderly; no specific dosage recommendations are provided by the manufacturer. Upward titration should be done slowly and with close monitoring for adverse events (eg, sedation, dehydration, decreased nutritional intake). Safety and efficacy for use in patients &gt;65 years have not been studied for migraine prophylaxis.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F233027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Mild-to-severe impairment: No dosage adjustment necessary; however, due to decreased protein binding in renal impairment, monitoring only total valproate concentrations may be misleading.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: Not recommended for use in hepatic disease; clearance is decreased with liver impairment. Hepatic disease is also associated with decreased albumin concentrations and 2- to 2.6-fold increase in the unbound fraction. Free concentrations of valproate may be elevated while total concentrations appear normal, therefore, monitoring only total valproate concentrations may be misleading.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: Use is contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 250 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakene&reg;: 250 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stavzor&trade;: 125 mg, 250 mg, 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sprinkle, oral: 125 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; Sprinkle: 125 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as valproate sodium [preservative free]: 100 mg/mL (5 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depacon&reg;: 100 mg/mL (5 mL) [contains edetate disodium; strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as valproate sodium: 250 mg/5 mL (5 mL, 473 mL, 480 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as valproate sodium: 250 mg/5 mL (5 mL, 10 mL, 473 mL, 480 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakene&reg;: 250 mg/5 mL (473 mL) [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, oral: 125 mg [strength expressed as valproic acid], 250 mg [strength expressed as valproic acid], 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg;: 125 mg, 250 mg, 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 250 mg [strength expressed as valproic acid], 500 mg [strength expressed as valproic acid]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; ER: 250 mg, 500 mg [strength expressed as valproic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes delayed release capsule",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F16335927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Stavzor&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM342867.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F232995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Oral valproate products may cause GI upset; taking with food or slowly increasing the dose may decrease GI upset should it occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; ER: Swallow whole; do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakote&reg; Sprinkle capsules may be swallowed whole or capsule opened and sprinkled on small amount (1 teaspoonful) of soft food (eg, pudding, applesauce) to be used immediately (do not store or chew).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depakene&reg; capsule, Stavzor&trade;: Swallow whole; do not chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Following dilution to final concentration, manufacturer&rsquo;s labeling recommends administering over 60 minutes at a rate &le;20 mg/minute. Alternatively, more rapid infusion rates of 1.5-6 mg/kg/minute have been used in clinical trials to quickly achieve therapeutic concentrations, and were generally well tolerated (Ramsay, 2003; Wheless, 2004). One study reported undiluted valproic acid administered at &le;10 mg/kg/minute (dose of &le;30 mg/kg) was well tolerated (Limdi, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral, I.V.: Monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures; monotherapy and adjunctive therapy of simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional indications: Depakote&reg;, Depakote&reg; ER, Stavzor&trade;: Mania associated with bipolar disorder; migraine prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F233064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refractory status epilepticus, diabetic neuropathy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depakene&reg; may be confused with Depakote&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depakote&reg; may be confused with Depakene&reg;, Depakote&reg; ER, Senokot&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Depakote&reg; ER may be confused with divalproex enteric coated",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valproate sodium may be confused with vecuronium",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (&le;31%), somnolence (&le;30%), dizziness (12% to 25%), insomnia (&gt;1% to 15%), nervousness (&gt;1% to 11%), pain (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (&gt;1% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (15% to 48%), vomiting (7% to 27%), diarrhea (7% to 23%), abdominal pain (7% to 23%), dyspepsia (7% to 23%), anorexia (&gt;1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Thrombocytopenia (1% to 24%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (&le;57%), weakness (6% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia (&gt;1% to 16%), amblyopia/blurred vision (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (&le;20%), flu-like syndrome (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (&gt;1% to 8%), chest pain (&gt;1% to &lt;5%), edema (&gt;1% to &lt;5%), facial edema (&gt;1% to &lt;5%), hypertension (&gt;1% to &lt;5%), hypotension (&gt;1% to &lt;5%), orthostatic hypotension (&gt;1% to &lt;5%), palpitation (&gt;1% to &lt;5%), tachycardia (&gt;1% to &lt;5%), vasodilation (&gt;1% to &lt;5%), arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Ataxia (&gt;1% to 8%), amnesia (&gt;1% to 7%), emotional lability (&gt;1% to 6%), fever (&gt;1% to 6%), abnormal thinking (&le;6%), depression (&gt;1% to 5%), abnormal dreams (&gt;1% to &lt;5%), agitation (&gt;1% to &lt;5%), anxiety (&gt;1% to &lt;5%), catatonia (&gt;1% to &lt;5%), chills (&gt;1% to &lt;5%), confusion (&gt;1% to &lt;5%), coordination abnormal (&gt;1% to &lt;5%), hallucination (&gt;1% to &lt;5%), malaise (&gt;1% to &lt;5%), personality disorder (&gt;1% to &lt;5%), speech disorder (&gt;1% to &lt;5%), tardive dyskinesia (&gt;1% to &lt;5%), vertigo (&gt;1% to &lt;5%), euphoria (1%), hypoesthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&gt;1% to 6%), bruising (&gt;1% to 5%), discoid lupus erythematosus (&gt;1% to &lt;5%), dry skin (&gt;1% to &lt;5%), furunculosis (&gt;1% to &lt;5%), petechia (&gt;1% to &lt;5%), pruritus (&gt;1% to &lt;5), seborrhea (&gt;1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea (&gt;1% to &lt;5%), dysmenorrhea (&gt;1% to &lt;5%), metrorrhagia (&gt;1% to &lt;5%), hypoproteinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (4% to 9%), weight loss (6%), appetite increased (&le;6%), constipation (&gt;1% to 5%), xerostomia (&gt;1% to 5%), eructation (&gt;1% to &lt;5%), fecal incontinence (&gt;1% to &lt;5%), flatulence (&gt;1% to &lt;5%), gastroenteritis (&gt;1% to &lt;5%), glossitis (&gt;1% to &lt;5%), hematemesis (&gt;1% to &lt;5%), pancreatitis (&gt;1% to &lt;5%), periodontal abscess (&gt;1% to &lt;5%), stomatitis (&gt;1% to &lt;5%), taste perversion (&gt;1% to &lt;5%), dysphagia, gum hemorrhage, mouth ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cystitis (&gt;1% to 5%), dysuria (&gt;1% to 5%), urinary frequency (&gt;1% to &lt;5%), urinary incontinence (&gt;1% to &lt;5%), vaginal hemorrhage (&gt;1% to 5%), vaginitis (&gt;1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (&gt;1% to &lt;5%), AST increased (&gt;1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (3%), injection site reaction (2%), injection site inflammation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (&le;8%), abnormal gait (&gt;1% to &lt;5%), arthralgia (&gt;1% to &lt;5%), arthrosis (&gt;1% to &lt;5%), dysarthria (&gt;1% to &lt;5%), hypertonia (&gt;1% to &lt;5%), hypokinesia (&gt;1% to &lt;5%), leg cramps (&gt;1% to &lt;5%), myalgia (&gt;1% to &lt;5%), myasthenia (&gt;1% to &lt;5%), neck pain (&gt;1% to &lt;5%), neck rigidity (&gt;1% to &lt;5%), paresthesia (&gt;1% to &lt;5%), reflex increased (&gt;1% to &lt;5%), twitching (&gt;1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus (1% to 8%), dry eyes (&gt;1% to 5%), eye pain (&gt;1% to 5%), abnormal vision (&gt;1% to &lt;5%), conjunctivitis (&gt;1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (1% to 7%), ear pain (&gt;1% to 5%), deafness (&gt;1% to &lt;5%), otitis media (&gt;1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (2% to 8%), bronchitis (5%), rhinitis (&gt;1% to 5%), dyspnea (1% to 5%), cough (&gt;1% to &lt;5%), epistaxis (&gt;1% to &lt;5%), pneumonia (&gt;1% to &lt;5%), sinusitis (&gt;1% to &lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (1%), hiccups",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important and/or life-threatening): Aggression, agranulocytosis, allergic reaction, anaphylaxis, anemia, aplastic anemia, asterixis, behavioral deterioration, bilirubin increased, bleeding time altered, bone marrow suppression, bone pain, bradycardia, breast enlargement, cutaneous vasculitis, carnitine decreased, cerebral atrophy (reversible), coma (rare), dementia, encephalopathy (rare), enuresis, eosinophilia, erythema multiforme, Fanconi-like syndrome (rare, in children), galactorrhea, hematoma formation, hemorrhage, hepatic failure, hepatotoxicity, hostility, hyperactivity, hyperammonemia, hyperammonemic encephalopathy (in patients with UCD), hyperglycinemia, hypersensitivity reactions (severe, with multiorgan dysfunction), hypofibrinogenemia, hyponatremia, hypothermia, inappropriate ADH secretion, intermittent porphyria, LDH increased, leukopenia, lupus, lymphocytosis, macrocytosis, menstrual irregularities, pancytopenia parkinsonism, parotid gland swelling, photosensitivity, platelet aggregation inhibited, polycystic ovary disease (rare), psychosis, seeing \"spots before the eyes,\" Stevens-Johnson syndrome, suicidal behavior/ideation, thyroid function tests abnormal, toxic epidermal necrolysis (rare), urinary tract infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F232998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to valproic acid, divalproex, derivatives, or any component of the formulation; hepatic disease or significant impairment; urea cycle disorders",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F232979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic failure:",
"     <b>",
"      [U.S. Boxed Warning]: Hepatic failure resulting in fatalities has occurred in patients; children &lt;2 years of age are at considerable risk.",
"     </b>",
"     Other risk factors include organic brain disease, mental retardation with severe seizure disorders, congenital metabolic disorders, and patients on multiple anticonvulsants. Hepatotoxicity has usually been reported within 6 months of therapy initiation. Monitor patients closely for appearance of malaise, weakness, facial edema, anorexia, jaundice, and vomiting; discontinue immediately with signs/symptom of significant or suspected impairment. Liver function tests should be performed at baseline and at regular intervals after initiation of therapy, especially within the first 6 months. Hepatic dysfunction may progress despite discontinuing treatment. Should only be used as monotherapy and with extreme caution in children &lt;2 years of age and/or patients at high risk for hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperammonemia/encephalopathy: Hyperammonemia and/or encephalopathy, sometimes fatal, has been reported following the initiation of valproate therapy and may be present with normal transaminase levels. Ammonia levels should be measured in patients who develop unexplained lethargy and vomiting, or changes in mental status or in patients who present with hypothermia. Discontinue therapy if ammonia levels are increased and evaluate for possible urea cycle disorder (UCD). Contraindicated in patients with UCD. Evaluation  of UCD should be considered for the following patients prior to the start of therapy: History of unexplained encephalopathy or coma; encephalopathy associated with protein load; pregnancy or postpartum encephalopathy; unexplained mental retardation; history of elevated plasma ammonia or glutamine; history of cyclical vomiting and lethargy; episodic extreme irritability, ataxia; low BUN or protein avoidance; family history of UCD or unexplained infant deaths (particularly male); or signs or symptoms of UCD (hyperammonemia, encephalopathy, respiratory alkalosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypothermia: Hypothermia (unintentional drop in core body temperature to &lt;35&deg;C/95&deg;F) has been reported with valproate therapy; hypothermia may or may not be associated with hyperammonemia; may also occur with concomitant topiramate therapy following topiramate initiation or dosage increase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal multiorgan hypersensitivity reactions have rarely been reported with some antiepileptic drugs including valproate therapy in adults and children; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis:",
"     <b>",
"      [U.S. Boxed Warning]: Cases of life-threatening pancreatitis, occurring at the start of therapy or following years of use, have been reported in adults and children.",
"     </b>",
"     Some cases have been hemorrhagic with rapid progression of initial symptoms to death. Promptly evaluate symptoms of abdominal pain, nausea, vomiting, and/or anorexia; should generally be discontinued if pancreatitis is diagnosed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: May cause severe thrombocytopenia (may be dose-related), inhibition of platelet aggregation, and bleeding. In some cases, platelet counts may be normalized with continued treatment, however, reduce dose or discontinue drug if patient develops evidence of hemorrhage, bruising, or a disorder of hemostasis/coagulation. Evaluate platelet counts prior to initiating therapy and periodically thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute head trauma: Not recommended for post-traumatic seizure prophylaxis in patients with acute head trauma; study results for this indication suggested increased mortality with I.V. valproate use compared to I.V. phenytoin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Contraindicated with significant impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbapenem antibiotics: Concomitant use may reduce valproic acid levels to subtherapeutic levels; monitor levels frequently and consider alternate therapy if levels drop significantly or lack of seizure control occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topiramate: Concomitant use with topiramate has been associated with hyperammonemia and hypothermia with or without encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution as elderly patients may be more sensitive to sedating effects and dehydration; in some elderly patients with somnolence, concomitant decreases in nutritional intake and weight loss were observed. Reduce initial dosages in elderly and closely monitor fluid status, nutritional intake, somnolence, and other adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children &lt;2 years of age are at increased risk for fatal hepatotoxicity; if valproate therapy is used in this age group, use with extreme caution and only as monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: May cause teratogenic effects such as neural tube defects (eg, spina bifida).",
"     </b>",
"     Use in women of childbearing potential requires that benefits of use in mother be weighed against the potential risk to fetus, especially when used for conditions not associated with permanent injury or risk of death (eg, migraine).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal: Medication residue in stool has been reported (rarely) with oral Depakote&reg; (divalproex sodium) formulations; some reports have occurred in patients with shortened GI transit times (eg, diarrhea) or anatomic GI disorders (eg, ileostomy, colostomy).  In patients reporting medication residue in stool, it is recommended to monitor valproate level and clinical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Viral replication:",
"     <i>",
"      In vitro",
"     </i>",
"     studies have suggested valproate stimulates the replication of HIV and CMV viruses under experimental conditions. The clinical consequence of this is unknown, but should be considered when monitoring affected patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For valproic acid:",
"     <b>",
"      Substrate",
"     </b>",
"     (minor) of CYP2A6, 2B6, 2C9, 2C19, 2E1;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), 2C19 (weak), 2D6 (weak), 3A4 (weak);",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15578418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: Valproic Acid may decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Valproic Acid. Valproic Acid may decrease the serum concentration of CarBAMazepine. Carbamazepine-Epoxide concentrations might increase, offsetting the decreases in the parent compound.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbapenems: May decrease the serum concentration of Valproic Acid. Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ChlorproMAZINE: May increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Valproic Acid. Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Valproic Acid may increase the serum concentration of Ethosuximide. Ethosuximide may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May increase the serum concentration of Valproic Acid. Management: In patients receiving valproic acid, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily and reduce valproic acid dose by 20%. Monitor for increased valproate concentrations/effects and decreased felbamate concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Fosphenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: May increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Valproic Acid may enhance the adverse/toxic effect of LamoTRIgine. Valproic Acid may increase the serum concentration of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LORazepam: Valproic Acid may decrease the metabolism of LORazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Valproic Acid may decrease the serum concentration of OXcarbazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: Valproic Acid may increase the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May increase the metabolism of Valproic Acid. A hepatotoxic metabolite of valproic acid may result. Valproic Acid may decrease the serum concentration of Phenytoin. Continued therapy usually yields a normalization (or slight increase) of serum phenytoin concentrations.  Free phenytoin concentrations, however, tend to remain relatively stable (possibly increased with continued therapy).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Valproic Acid may decrease the metabolism of Primidone. More specifically, the metabolism of phenobarbital, primidone's primary active metabolite, would be decreased. Primidone may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Valproic Acid may enhance the adverse/toxic effect of RisperiDONE. Generalized edema has developed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: Valproic Acid may increase the serum concentration of Rufinamide.  Management: Initiate rufinamide at a dose less than 10 mg/kg/day (children) or 400 mg/day (adults) in patients receiving valproic acid. In patients receiving rufinamide, initiate valproic acid at a low dose and titrate based on clinical response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temozolomide: Valproic Acid may enhance the adverse/toxic effect of Temozolomide. Valproic Acid may increase the serum concentration of Temozolomide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May enhance the adverse/toxic effect of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Valproic Acid may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vorinostat: Valproic Acid may enhance the thrombocytopenic effect of Vorinostat. This may increase the risk of gastrointestinal bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Valproic Acid may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F233015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may delay but does not affect the extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: May cause teratogenic effects such as neural tube defects (eg, spina bifida).",
"     </b>",
"     Teratogenic effects have been reported in animals and humans. Valproic acid crosses the placenta. Neural tube, cardiac, facial (characteristic pattern of dysmorphic facial features), skeletal, multiple other defects reported. Epilepsy itself, number of medications, genetic factors, or a combination of these probably influence the teratogenicity of anticonvulsant therapy. Information from the North American Antiepileptic Drug Pregnancy Registry notes a fourfold increase in congenital malformations with exposure to valproic acid monotherapy during the 1st trimester of pregnancy when compared to monotherapy with other antiepileptic drugs (AED). The risk of neural tube defects is ~1% to 2% (general population risk estimated to be 0.14% to 0.2%). The effect of folic acid supplementation to decrease this risk is unknown, however, folic acid supplementation is recommended for all women contemplating pregnancy. An information sheet describing the teratogenic potential is available from the manufacturer.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Nonteratogenic effects have also been reported. Afibrinogenemia leading to fatal hemorrhage and hepatotoxicity have been noted in case reports of infants following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to valproic acid. Developmental delay, autism and/or autism spectrum disorder have also been reported. In a prospective cohort study conducted in the U.S. and the United Kingdom, a lower Differential Ability Scale ([D.A.S.]; a battery of tests which measure cognitive development in children) score was observed in children 3 years of age with prenatal exposure to valproate compared to children with prenatal exposure to other antiepileptics (lamotrigine, carbamazepine, or phenytoin). Use in women of childbearing potential requires that benefits of use in mother be weighed against the potential risk to fetus, especially when used for conditions not associated with permanent injury or risk of death (eg, migraine).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to valproic acid during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP considers &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F233003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast milk concentrations of valproic acid have been reported as 1% to 10% of maternal concentration. The weight-adjusted dose to the infant has been calculated to be ~4%.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Stavzor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $153.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $301.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $555.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, sprinkles",
"     </b>",
"     (Depakote Sprinkles Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $137.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, sprinkles",
"     </b>",
"     (Divalproex Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $89.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Depakene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $404.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Valproic Acid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $82.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Depacon Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (5 mL): $25.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Valproate Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (5 mL): $8.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Depakene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (480 mL): $413.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Depakote ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $257.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $453.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Divalproex Sodium ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $167.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $295.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Depakote Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $144.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $283.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $522.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Divalproex Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mg (100): $89.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $176.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $324.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F232989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver enzymes (at baseline and frequently during therapy especially during the first 6 months), CBC with platelets (baseline and periodic intervals), PT/PTT (especially prior to surgery), serum ammonia (with symptoms of lethargy, mental status change), serum valproate levels; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F232992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, trough concentrations should be used to assess adequacy of therapy; peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity). Within 2-4 days of initiation or dose adjustment, trough concentrations should be drawn just before the next dose (extended-release preparations) or before the morning dose (for immediate-release preparations). Patients with epilepsy should not delay taking their dose for &gt;2-3 hours. Additional patient-specific factors must be taken into consideration when interpreting drug levels, including indication, age, clinical response, pregnancy status, adherence, comorbidities, adverse effects, and concomitant medications (Patsalos, 2008; Reed, 2006).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epilepsy: 50-100 mcg/mL (SI: 350-700 micromole/L); although seizure control may improve at levels &gt;100 mcg/mL (SI: 700 micromole/L), toxicity may occur at levels of 100-150 mcg/mL (SI: 700-1040 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mania: 50-125 mcg/mL (SI: 350-875 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: Some laboratories may report &gt;200 mcg/mL (SI: &gt;1390   micromole/L) as a toxic threshold, although clinical toxicity can occur at lower concentrations. Probability of thrombocytopenia increases with total valproate levels &ge;110 mcg/mL in females or &ge;135 mcg/mL in males.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epilepsy: Although seizure control may improve at levels &gt;100 mcg/mL (SI: 700 micromole/L), toxicity may occur at levels of 100-150 mcg/mL (SI: 700-1050 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mania: Clinical response seen with trough levels between 50-125 mcg/mL (SI: 350-875 micromole/L); risk of toxicity increases at levels &gt;125 mcg/mL (SI: 875 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Absenor (SE);",
"     </li>",
"     <li>",
"      Aleptiz (PH);",
"     </li>",
"     <li>",
"      Apilepsin (HR);",
"     </li>",
"     <li>",
"      Convulex (AT, BE, BG, CH, CZ, DE, EE, GB, HN, HU, IE, LU, PL, RU, SG, TR, TW);",
"     </li>",
"     <li>",
"      Delepsine (DK);",
"     </li>",
"     <li>",
"      Depacon (KP, PH);",
"     </li>",
"     <li>",
"      Depakene (AR, CN, CO, ID, JP, PE, PH, PY, UY);",
"     </li>",
"     <li>",
"      Depakin (IT, PK, RU, TR);",
"     </li>",
"     <li>",
"      Depakine (AE, AT, BE, BG, BH, CH, CY, EE, EG, ES, FR, GR, HN, HU, IQ, IR, JO, KW, LB, LU, LY, OM, PL, PT, QA, RU, SA, SY, TH, VE, YE);",
"     </li>",
"     <li>",
"      Depakine Chrono (KP, LU, TH, TW);",
"     </li>",
"     <li>",
"      Depakote (BZ, SR);",
"     </li>",
"     <li>",
"      Deprakine (DK, FI, NO);",
"     </li>",
"     <li>",
"      Desorate (TH);",
"     </li>",
"     <li>",
"      Epilim (AU, BF, BJ, CI, ET, GB, GH, GM, GN, HK, IE, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, NZ, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Epilim Chrono 500 (BB, BM, BS, GY, HK, JM, MY, NL, PR, TT);",
"     </li>",
"     <li>",
"      Episenta (GB);",
"     </li>",
"     <li>",
"      Epival (AE, BH, CR, CY, DO, EG, GT, IQ, IR, JO, KW, LB, LY, MX, NI, OM, PA, PH, QA, SA, SV, SY, YE);",
"     </li>",
"     <li>",
"      Ergenyl (SE);",
"     </li>",
"     <li>",
"      Everiden (HU);",
"     </li>",
"     <li>",
"      Lepavent (TW);",
"     </li>",
"     <li>",
"      Leptilan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Neuractin (CO);",
"     </li>",
"     <li>",
"      Oltril (TH);",
"     </li>",
"     <li>",
"      Orfiril (CZ, DE, FI, HU);",
"     </li>",
"     <li>",
"      Orfiril Retard (SG);",
"     </li>",
"     <li>",
"      Petilin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Valcote (CO, EC);",
"     </li>",
"     <li>",
"      Valeptol SR (KP);",
"     </li>",
"     <li>",
"      Valpakine (BR, EC);",
"     </li>",
"     <li>",
"      Valparin (TH);",
"     </li>",
"     <li>",
"      Valporal (IL);",
"     </li>",
"     <li>",
"      Valprax (PE);",
"     </li>",
"     <li>",
"      Valpro (AU, HK);",
"     </li>",
"     <li>",
"      Valpron (VE);",
"     </li>",
"     <li>",
"      Valsup (CO);",
"     </li>",
"     <li>",
"      Valtec-CR (IN);",
"     </li>",
"     <li>",
"      Vematina (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F232978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes increased availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, to brain neurons or may enhance the action of GABA or mimic its action at postsynaptic receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Total valproate: 11 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ; free valproate 92 L/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding (concentration dependent): 80% to 90%; free fraction: ~10% at 40 mcg/mL and ~18.5% at 130 mcg/mL; protein binding decreased in the elderly and with hepatic or renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via glucuronide conjugation (30% to 50% of administered dose) and 40% via mitochondrial beta-oxidation; other oxidative metabolic pathways occur to a lesser extent. The relationship between dose and total valproate concentration is nonlinear; concentration does not increase proportionally with the dose, but increases to a lesser extent due to saturable plasma protein binding. The kinetics of unbound drug are linear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Depakote&reg; ER: ~90% relative to I.V. dose and ~89% relative to delayed release formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination (increased in neonates, elderly and those with liver disease): Children &gt;2 months: 7-13 hours; Adults: 9-19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Depakote&reg; tablet: ~4 hours; Depakote&reg; ER: 4-17 hours; Stavzor&trade;: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal (unlabeled route): 1-3 hours (Graves, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (30% to 50% as glucuronide conjugate, &lt;3% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Breast Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65; published erratum appears in",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 77(6):603.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gaitanis JN and Drislane FW, &ldquo;Status Epilepticus: A Review of Different Syndromes, Their Current Evaluation, and Treatment,&rdquo;",
"      <i>",
"       Neurologist",
"      </i>",
"      , 2003, 9(2):61-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/12808369/pubmed\" id=\"12808369\" target=\"_blank\">",
"        12808369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graves NM and Kriel RL, &ldquo;Rectal Administration of Antiepleptic Drugs in Children,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1987, 3(6):321-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/3334021/pubmed\" id=\"3334021\" target=\"_blank\">",
"        3334021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hagg S and Spigset O, &ldquo;Anticonvulsant Use During Lactation,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2000, 22(6):425-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/10877037/pubmed\" id=\"10877037\" target=\"_blank\">",
"        10877037",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodges BM and Mazur JE, &ldquo;Intravenous Valproate in Status Epilepticus,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2001, 35(11):1465-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/11724100/pubmed\" id=\"11724100\" target=\"_blank\">",
"        11724100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes LB and Wyszynski DF, &ldquo;North American Antiepileptic Drug Pregnancy Registry,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2004, 45(11):1465.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/15509251/pubmed\" id=\"15509251\" target=\"_blank\">",
"        15509251",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leao M, &ldquo;Valproate as a Cause of Hyperammonemia in Heterozygotes With Ornithine-Transcarbamylase Deficiency,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1995, 45(3 Pt 1):593-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/7898728/pubmed\" id=\"7898728\" target=\"_blank\">",
"        7898728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Limdi NA, Shimpi AV, Faught E, et al, &ldquo;Efficacy of Rapid I.V. Administration of Valproic Acid for Status Epilepticus,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2005, 64(2):353-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/15668440/pubmed\" id=\"15668440\" target=\"_blank\">",
"        15668440",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Limdi NA, Knowlton RK, Cofield SS, et al, &ldquo;Safety of Rapid Intravenous Loading of Valproate,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(3):478-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/17319914/pubmed\" id=\"17319914\" target=\"_blank\">",
"        17319914",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meador KJ, Baker GA, Browning N, et al, &ldquo;Cognitive Function at 3 Years of Age After Fetal Exposure to Antiepileptic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(16): 1597-605.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/19369666/pubmed\" id=\"19369666\" target=\"_blank\">",
"        19369666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010,17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Misra UK, Kalita J, and Patel R, \"Sodium Valproate vs Phenytoin in Status Epilepticus: A Pilot Study,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2006; 67(2):340-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/16864836/pubmed\" id=\"16864836\" target=\"_blank\">",
"        16864836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pratt CE and Davis SM, &ldquo;Divalproex Sodium Therapy in Elderly With Dementia-Related Agitation,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(10):1625-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/12243614/pubmed\" id=\"12243614\" target=\"_blank\">",
"        12243614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramsay RE, Cantrell D, Collins SD, et al, \"Safety and Tolerance of Rapidly Infused Depacon: A Randomized Trial in Subjects With Epilepsy,\"",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 2003; 52(3):189-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/12536052/pubmed\" id=\"12536052\" target=\"_blank\">",
"        12536052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson D, Langer A, Casso D, et al, &ldquo;Pancytopenia and Valproic Acid - A Possible Association,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1995, 43(2):198.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinha S and Naritoku DK, &ldquo;Intravenous Valproate is Well Tolerated in Unstable Patients With Status Epilepticus,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2000, 55(5):722-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/10980746/pubmed\" id=\"10980746\" target=\"_blank\">",
"        10980746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sink KM, Holden KF, and Yaffe K, &ldquo;Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia. A Review of Evidence,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2005, 293(5):596-608.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/15687315/pubmed\" id=\"15687315\" target=\"_blank\">",
"        15687315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snead OC 3rd and Miles MV, &ldquo;Treatment of Status Epilepticus in Children With Rectal Sodium Valproate,\"",
"      <i>",
"       J Pediatr,",
"      </i>",
"      1985, 106(2):323-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/3918159 /pubmed\" id=\"3918159 \" target=\"_blank\">",
"        3918159",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tariot PN, Raman R, Jakimovich L, et al, &ldquo;Divalproex Sodium in Nursing Home Residents With Possible or Probable Alzheimer Disease Complicated by Agitation: A Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Am J Geriatr Psychiatry",
"      </i>",
"      , 2005, 13(11):942-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/16286437/pubmed\" id=\"16286437\" target=\"_blank\">",
"        16286437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tohen M, Castillo J, Baldessarini RJ, et al, &ldquo;Blood Dyscrasias With Carbamazepine and Valproate: A Pharmacoepidemiological Study of 2,228 Patients at Risk,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(3):413-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/7864268/pubmed\" id=\"7864268\" target=\"_blank\">",
"        7864268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Venkataraman V and Wheless JW, &ldquo;Safety of Rapid Intravenous Infusion of Valproate Loading Doses in Epilepsy Patients,&rdquo;",
"      <i>",
"       Epilepsy Res",
"      </i>",
"      , 1999, 35(2):147-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/10372567/pubmed\" id=\"10372567\" target=\"_blank\">",
"        10372567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheless JW, Vazquez BR, Kanner AM, et al, &ldquo;Rapid Infusion With Valproate Sodium is Well Tolerated in Patients With Epilepsy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 63(8):1507-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/11/25785/abstract-text/15505177/pubmed\" id=\"15505177\" target=\"_blank\">",
"        15505177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10035 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25785=[""].join("\n");
var outline_f25_11_25785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708868\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233020\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233021\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233068\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233025\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233045\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233026\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233027\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233028\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232991\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232975\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16335927\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232995\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232994\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233064\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233076\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233066\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232998\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232979\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233062\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15578418\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233015\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232987\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233002\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233033\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233003\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570489\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232989\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232992\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233005\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232978\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232997\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10035|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/35/11831?source=related_link\">",
"      Valproate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=related_link\">",
"      Valproate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_11_25786="Oral lesions";
var content_f25_11_25786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral lesions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/11/25786/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/11/25786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosing and treating dermatologic lesions of the mouth and gums is challenging for most clinicians because of the wide variety of disease processes that can present with similar appearing lesions and the fact that most clinicians receive inadequate training in mouth diseases. In a study of oral lesions in elderly patients, for example, almost all physicians surveyed felt that it was important to examine older patients' mouths, but less than one-fifth stated that they routinely performed such examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/1\">",
"     1",
"    </a>",
"    ]. Almost four-fifths did not correctly diagnose a picture of an early squamous cell carcinoma.",
"   </p>",
"   <p>",
"    One of the keys to improving accuracy in diagnosing oral lesions is forming an appropriate differential diagnosis. This review will discuss the presentation and treatment of the most common oral lesions, including tumors, infections, autoimmune and connective tissues diseases, aphthous ulcers, and other miscellaneous oral lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TUMORS (AND LESIONS THAT MIMIC)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer of the oral cavity is associated with ulcers or masses that do not heal and with dental changes or poorly fitting dentures. Tongue and lip cancers present as exophytic or ulcerative lesions often associated with pain. Up to two-thirds of patients with primary tongue lesions have nodal disease; the incidence is substantially lower in patients with hard palate and lip cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=see_link\">",
"     \"Overview of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent papules, plaques, erosions, or ulcers in the mouth should be biopsied to rule out squamous cell carcinoma, particularly in patients with appropriate risk factors (",
"    <a class=\"graphic graphic_picture graphicRef81810 graphicRef59057 graphicRef74239 \" href=\"UTD.htm?27/61/28633\">",
"     picture 1A-C",
"    </a>",
"    ). It has been estimated that the use of tobacco and alcohol account for up to 80 percent of cases of squamous cell carcinoma of the head and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/1\">",
"     1",
"    </a>",
"    ]. The combined effect of alcohol and smoking is multiplicative with the risk of developing head and neck cancer being as much as 200 times greater for heavy smokers and drinkers. A subset of oropharyngeal squamous cell carcinoma is associated with human papillomavirus (HPV) infection, particularly with high-risk type 16 (HPV-16). Oral infection with HPV-16 confers an approximately 50-fold increase in risk for HPV-positive oropharyngeal squamous cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link\">",
"     \"Epidemiology and risk factors for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link\">",
"     \"Human papillomavirus associated head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Leukoplakia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral leukoplakia is a precancerous lesion that presents as white patches or plaques of the oral mucosa (",
"    <a class=\"graphic graphic_picture graphicRef81049 graphicRef60939 graphicRef72711 \" href=\"UTD.htm?7/49/7961\">",
"     picture 2A-C",
"    </a>",
"    ). It represents hyperplasia of the squamous epithelium, which is believed to be an early step in the transformation of clonally independent premalignant lesions from hyperplasia, to dysplasia, to carcinoma in situ, to invasive malignant lesions (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=see_link\">",
"     \"Head and neck squamous cell carcinogenesis: Molecular and genetic alterations\"",
"    </a>",
"    ). Leukoplakia is also seen in purely inflammatory conditions not associated with malignancy. An association exists between leukoplakia and human papillomavirus (HPV) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leukoplakia itself is a benign reactive process. However, between 1 and 20 percent of lesions will progress to carcinoma within 10 years. The clinical significance and natural history of oral leukoplakia depends upon the presence and degree of dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. As an example, squamous hyperplasia is a common response to carcinogen exposure, mechanical irritation, or other noxious stimuli. Leukoplakic lesions that arise in trauma-prone regions of the oral cavity (cheek, dorsum of tongue) where the mucosal is normally thick show evidence of dysplasia less often than do lesions in areas where the mucosal is normally thin (ventral tongue, retromolar triangle). In these latter regions, carcinogen exposure is a proportionately greater cause than mechanical trauma.",
"   </p>",
"   <p>",
"    Risk factors for oral leukoplakia are similar to that of squamous cell carcinoma; it is particularly common in smokeless tobacco users [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/7\">",
"     7",
"    </a>",
"    ]. Any indurated areas should be biopsied to rule out carcinomatous changes. In addition, recent developments in chemoprevention, most notably the demonstration of the impact of retinoid compounds on premalignant lesions of the oral cavity and oropharynx, have triggered renewed interest in possible preventive approaches to oropharyngeal cancer in patients with precancerous lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19017?source=see_link\">",
"     \"Chemoprevention in oral dysplasia and head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate disorder, which is not premalignant, is oral hairy leukoplakia, an Epstein-Barr virus-induced lesion that occurs almost entirely in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Oral hairy leukoplakia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma should be included in the differential diagnosis of oral pigmented lesions that have any of the features of cutaneous melanoma, such as asymmetry, irregular borders, variable or changing color (ruling out the presence of an amalgam tattoo), or increasing diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/8\">",
"     8",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    ). Melanoma of the oral cavity is frequently diagnosed at more advanced stages because of the failure of patients and providers to recognize it at an early stage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These lesions must be differentiated from melanosis, which is extremely common in individuals with dark skin and generally appears in a symmetric pattern. Also in the differential are oral melanotic macules. These are darkly pigmented benign macules that occur on the lips and on the oral mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/10\">",
"     10",
"    </a>",
"    ]. These lesions are typically symmetric with sharp borders, present in adulthood, and are stable.",
"   </p>",
"   <p>",
"    Surgery is the first choice of therapy for mucosal melanomas of the head and neck. Whenever possible the lesion should be resected with negative margins. Radiation therapy may be used to achieve local control if the lesion cannot be resected with negative margins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Amalgam tattoos",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amalgam tattoos are blue-black macules seen in the adjacent gingival margin or proximal buccal mucosa near amalgam dental fillings (",
"    <a class=\"graphic graphic_picture graphicRef51720 \" href=\"UTD.htm?24/34/25120\">",
"     picture 3",
"    </a>",
"    ). They are caused by inadvertent placement of dental silver amalgam restorative material into the oral soft tissues. The most common site for amalgam tattoos is the mandibular arch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/11\">",
"     11",
"    </a>",
"    ]. Their appearance may mimic oral melanomas. Visualization of the amalgam dental filling is the key to making the correct diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fordyce spots",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fordyce spots are benign neoplasms of sebaceous gland etiology. They present as isolated to scattered, white to yellow, 1 to 2 mm discrete papules, particularly prominent on the",
"    <span class=\"nowrap\">",
"     vermilion/buccal",
"    </span>",
"    mucosal border (",
"    <a class=\"graphic graphic_picture graphicRef69406 graphicRef66778 \" href=\"UTD.htm?23/4/23622\">",
"     picture 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mucoceles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucoceles are fluid filled cavities with mucous glands lining the epithelium. They typically are seen after mild oral trauma as a result of disruption of the salivary gland duct, most frequently of the lower lip (as a result of biting of the lip), but they may also present on the labia. Seen most frequently in patients younger than age 20, mucoceles are variable in size, and may have a gelatinous fluid within that presents clinically as",
"    <span class=\"nowrap\">",
"     pinkish/blue",
"    </span>",
"    soft papules or nodules (",
"    <a class=\"graphic graphic_picture graphicRef70332 graphicRef75671 \" href=\"UTD.htm?34/21/35160\">",
"     picture 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Spontaneous rupture can result in complete resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/12\">",
"     12",
"    </a>",
"    ]. Removal with cryotherapy or excision of the entire cyst can also be performed if the lesions are symptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/13\">",
"     13",
"    </a>",
"    ]. CO2 laser vaporization has also shown good results with a low rate of recurrence, and is an option for clinicians experienced in this modality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/14\">",
"     14",
"    </a>",
"    ]. Aspiration alone may initially relieve symptoms, but is rarely indicated except to aid in diagnosis or for short-term relief of irritation, as recurrence is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Candidiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oropharyngeal candidiasis or thrush is a common local infection seen in young infants, older adults who wear dentures, diabetics, patients treated with antibiotics, chemotherapy, or radiation therapy, and those with cellular immune deficiency states, such as the acquired immunodeficiency syndrome (AIDS). Patients receiving inhaled glucocorticoids for asthma or rhinitis are also subject to this complication.",
"   </p>",
"   <p>",
"    Thrush can manifest in several ways. The pseudomembranous form is the most common and appears as white plaques on the buccal mucosa, palate, tongue, or oropharynx (",
"    <a class=\"graphic graphic_picture graphicRef82214 graphicRef61040 graphicRef75887 \" href=\"UTD.htm?2/31/2553\">",
"     picture 6A-C",
"    </a>",
"    ). The atrophic form, which is often found under dentures, is characterized by erythema without plaques (",
"    <a class=\"graphic graphic_picture graphicRef79519 \" href=\"UTD.htm?7/32/7680\">",
"     picture 6D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/15\">",
"     15",
"    </a>",
"    ]. Candidiasis may also present with a beefy red tongue and associated soreness. In addition, Candida species can cause angular cheilitis or perl&egrave;che, a painful fissuring at the corners of the mouth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=see_link\">",
"     \"Clinical manifestations of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent, recalcitrant, or extensive disease warrants immune status evaluation and HIV testing. The diagnosis is confirmed by obtaining a KOH prep, scraping the white patches or erosive areas of the mucosa; budding yeasts with or without pseudohyphae are seen.",
"   </p>",
"   <p>",
"    Most studies of therapies for oral candidiasis have been performed in patients with HIV or malignancy. Topical therapy is usually effective although relapses in immunosuppressed patients are common.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/53/32592?source=see_link\">",
"     Nystatin",
"    </a>",
"    suspension (400,000 to 600,000 units four times per day), nystatin troche (200,000 to 400,000 units four to five times per day), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    troche (10 mg troche dissolved five times per day) for 7 to 14 days can be used. Nystatin suspension is the least expensive option; clotrimazole troches are probably more palatable and possibly more effective.",
"   </p>",
"   <p>",
"    Options for patients with refractory disease or inability to tolerate topical therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=see_link\">",
"     \"Treatment of oropharyngeal and esophageal candidiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elderly patients with dentures should be reminded to clean their dentures carefully and frequently to reduce the likelihood of developing candidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Herpes simplex virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpes simplex virus type 1 (HSV-1) can infect multiple sites of the body, including the oral cavity and perioral area. Herpetic gingivostomatitis is the most common clinical manifestation of primary herpes simplex infection in childhood. The primary infection is often asymptomatic; when symptoms occur they typically include the sudden onset of multiple intraoral vesicular lesions and erosions bordered by an inflammatory, erythematous base (",
"    <a class=\"graphic graphic_picture graphicRef71764 graphicRef73975 \" href=\"UTD.htm?40/62/41959\">",
"     picture 7A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HSV is able to enter, undergo latency, and survive in neural ganglia, thereby preventing elimination of the virus by immune responses. Thus, recurrent infection is common. Most patients (&gt;85 percent) develop prodromal symptoms (eg, pain, burning, tingling) about 24 hours before the appearance of painful lesions at the lip borders [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/17\">",
"     17",
"    </a>",
"    ]. Precipitating factors include exposure to sunlight, trauma, and emotional stress [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/18\">",
"     18",
"    </a>",
"    ]. Because primary infection with HSV-1 is often asymptomatic, a recurrence may be the first manifestation of infection.",
"   </p>",
"   <p>",
"    Primary episodes of oral HSV tend to involve the buccal mucosa, while recurrent disease is usually confined to the cutaneous surface or keratinized areas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/19\">",
"     19",
"    </a>",
"    ]. Young children may have associated fever, lymphadenopathy, drooling, and decreased oral intake. In one study, 3 out of 36 children with herpes gingivostomatitis became dehydrated, requiring hospitalization for intravenous rehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/20\">",
"     20",
"    </a>",
"    ]. Immunosuppressed individuals can have extensive and persistent intraoral ulcerations due to herpetic infection.",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by identifying multinucleated giant cells on a Tzanck smear (these are also seen with varicella zoster virus infection), direct immunofluorescence smear, or by viral culture. The alcohol-wiped vesicle should be gently \"unroofed\" with a sterile needle; the vesicular fluid can be removed with a sterile cotton swab for viral culture and cells from the base of the lesion may be scraped off gently and placed onto a slide for the Tzanck prep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H12#H12\">",
"     \"Dermatologic procedures\", section on 'Tzanck smear'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard treatment regimen involves systemic antiviral therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    ), pain, and fluid management (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    ). For comfort care, consider suggesting patients use ice, popsicles, or rinse and expectorate every two hours with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    <span class=\"nowrap\">",
"     12.5/5",
"    </span>",
"    cc mixed with magnesia-alumina 1:1.",
"   </p>",
"   <p>",
"    Most immunocompetent individuals with recurrent herpes labialis do not require treatment other than the occasional use of local analgesics. Attempts to treat recurrent episodes with both topical and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    have largely been unsuccessful [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. This is mostly due to the difficulty of determining the earliest time of recurrence, since antiviral medication works only during the period of viral replication and thus has little effect if begun after the appearance of lesions. Nevertheless, some patients with an identifiable prodrome may benefit from treatment. Chronic suppression has proven helpful in preventing HSV recrudescence in individuals with frequently recurrent lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Varicella-zoster virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vesicles and erosions are commonly seen in patients with varicella (chickenpox) (",
"    <a class=\"graphic graphic_picture graphicRef83137 graphicRef83136 \" href=\"UTD.htm?2/59/2999\">",
"     picture 8A-B",
"    </a>",
"    ). In patients with herpes zoster, grouped vesicles or erosions may be seen unilaterally on the hard palate (",
"    <a class=\"graphic graphic_picture graphicRef51866 \" href=\"UTD.htm?30/44/31425\">",
"     picture 8C",
"    </a>",
"    ). Other oral areas that may be involved include the buccal mucosa, tongue, and gingiva. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Coxsackie virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections with coxsackie virus produce both intraoral and",
"    <span class=\"nowrap\">",
"     palmar/plantar",
"    </span>",
"    lesions. Coxsackie virus infections most commonly occur in children as oval shaped pale papules with a rim of erythema on the palms and soles, and small aphthae intraorally, otherwise known as hand, foot, and mouth disease (",
"    <a class=\"graphic graphic_picture graphicRef58566 graphicRef71314 graphicRef81027 graphicRef52800 graphicRef53423 \" href=\"UTD.htm?37/42/38570\">",
"     picture 9A-E",
"    </a>",
"    ). Fever is common along with sore throat and a malaise that often precedes the onset of lesions. Lesions tend to spare the lips and gingiva, in contrast to HSV. Treatment is typically supportive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=see_link\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painful mucocutaneous ulceration is one of the most distinctive manifestations of primary HIV-1 infection. Shallow, sharply demarcated ulcers may be found on the oral mucosa, anus, penis, or esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/23\">",
"     23",
"    </a>",
"    ]. These lesions may reflect mucocutaneous disease associated with primary HIV infection&nbsp;or coincident sexually transmitted infections, such as herpes simplex virus, syphilis, or chancroid [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Oral manifestations of established HIV disease are most commonly due to candidal infections, but many other opportunistic pathogens also can cause oral ulcerations. Antiretroviral treatment has decreased the frequency of HIV-associated oral lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral cryptococcosis and histoplasmosis are non-characteristic and the diagnosis must be made on biopsy.",
"     </li>",
"     <li>",
"      Mucormycosis (zygomycosis), aspergillosis, and penicilliosis are less common.",
"     </li>",
"     <li>",
"      Bacterial ulcerations are most commonly caused by bacillary epithelioid angiomatosis, and biopsy is needed to rule out Kaposi's sarcoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8182?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oral ulcerations have been reported secondary to syphilis, mycobacterium avium intracellulare, Helicobacter pylori, amoeba, and leishmaniasis.",
"     </li>",
"     <li>",
"      Viral induced ulcerations may erupt due to infection by HSV, cytomegalovirus (CMV), or herpes zoster. Patients with HIV infection tend to have more extensive HSV, while oral ulcers due to CMV are rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ulceration in oral neoplasia is seen with Kaposi's sarcoma and non-Hodgkin lymphoma. Involvement of the oral cavity occurs in approximately one-third of patients with Kaposi's sarcoma; the intraoral site most commonly affected is the palate followed by the gingiva [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"       \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug reactions (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      , interferon, dideoxycytidine) may cause oral ulcerations, agranulocytosis, and toxic epidermal necrolysis in rare cases.",
"     </li>",
"     <li>",
"      Recurrent aphthous ulcers occur in 0.6 to 13.6 percent of patients with HIV infection, the vast majority of whom will have CD4 cell counts below 100 cells per mm3 [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/28\">",
"       28",
"      </a>",
"      ]. Healing of oral ulcers has been reported with antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/29\">",
"       29",
"      </a>",
"      ]. Treatment of aphthous ulcers in HIV disease includes topical antibiotics, glucocorticoids, or analgesics, and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      . The efficacy of topical treatments for oral aphthous ulcers in patients with HIV infection has not been evaluated in randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/30\">",
"       30",
"      </a>",
"      ]. In two small randomized trials, oral thalidomide, at the dose of 200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for four to eight weeks, was more effective than placebo in inducing healing of RAS in HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucosal involvement may occur with syphilis as split, fissured papules of the oral commissures or oral erosions (",
"    <a class=\"graphic graphic_picture graphicRef66008 graphicRef72680 graphicRef52729 \" href=\"UTD.htm?20/43/21177\">",
"     picture 10A-C",
"    </a>",
"    ). Look for the more classic papulosquamous eruption involving the palms and soles and condyloma lata involving the anal region. Multiple spirochetes are found in the lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     APHTHOUS ULCERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H757722\">",
"    <span class=\"h2\">",
"     Recurrent aphthous stomatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aphthae (also called canker sores) are painful oral lesions that appear as localized, shallow, round to oval ulcers with a grayish base (",
"    <a class=\"graphic graphic_picture graphicRef63475 \" href=\"UTD.htm?13/25/13713\">",
"     picture 11",
"    </a>",
"    ). Recurrent aphthous stomatitis (RAS) is the most common cause of mouth ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Etiology and pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of aphthous ulcers is not well-defined. Alterations in local cell mediated immunity may be important in the pathogenesis of RAS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that may predispose to the development of RAS include familial tendency, trauma, hormonal factors, food or drug hypersensitivity, immunodeficiency (eg, HIV disease), and emotional stress [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. RAS may be seen in patients with celiac disease and inflammatory bowel disease. Other causes of aphthae include use of antimetabolites such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and neutropenia of any cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin and mineral deficiencies have also been implicated in the pathogenesis of recurrent oral aphthae, particularly deficiency of vitamin B12. However, in a randomized trial involving 120 patients with RAS, multivitamin supplementation did not reduce the number or duration of RAS episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Clinical presentation and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presentation of RAS is the presence of round, clearly defined, small, painful ulcers that heal within 10 to 14 days without scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/33\">",
"     33",
"    </a>",
"    ]. More severe disease, with larger lesions (&gt;5 mm) that can last for six weeks, is less common. Herpetiform ulcers, which present as multiple small clusters of pinpoint lesions that coalesce to form large irregular ulcers lasting 7 to 10 days, can also occur. Sodium lauryl sulfate, a toothpaste detergent, may prolong the ulcer healing time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some people have only two to four outbreaks per year, while others may have almost continuous eruptions. Aphthae occur more commonly in childhood and adolescence and become less frequent in adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common treatment for aphthous ulcers includes symptomatic relief with agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide in Orabase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    gel covered by Orabase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26035?source=see_link\">",
"     amlexanox",
"    </a>",
"    5 percent oral paste, and topical analgesics. These are applied to the ulcer two to four times daily until the ulcer is healed. Early initiation of treatment may result in more rapid healing; the data supporting enhanced healing are most compelling for amlexanox and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemical cautery can also be used for aphthous ulcers. Randomized trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/44\">",
"     44",
"    </a>",
"    ], or with sulfuric acid with sulfonated phenolics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/45\">",
"     45",
"    </a>",
"    ], suggest that cautery can lead to more rapid improvement in pain, although it does not appear to speed overall healing. Lesions can be numbed with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    prior to chemical cautery, and patients should rinse with water for several minutes after the procedure.",
"   </p>",
"   <p>",
"    Intralesional or oral glucocorticoids are indicated for recalcitrant lesions or severe disease.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , interferon alpha, and levamisole also may have therapeutic value in severe cases of RAS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has been studied in patients with severe RAS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/31,32,50-52\">",
"     31,32,50-52",
"    </a>",
"    ]. In a randomized trial of HIV-infected patients with RAS, treatment with thalidomide, 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four weeks, resulted in healing in 16 of 29 patients in the thalidomide group (55 percent) compared with 2 of 28 patients receiving placebo (7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/31\">",
"     31",
"    </a>",
"    ]. A retrospective study of 92 non-HIV infected patients with RAS (including 16 with Behcet's disease) reported efficacy of lower doses; at a mean initial dose of 50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    thalidomide induced complete remission in 85 percent of subjects within 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/52\">",
"     52",
"    </a>",
"    ]. Recurrence is common following cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/50\">",
"     50",
"    </a>",
"    ]; low maintenance doses of thalidomide may reduce recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    is teratogenic (pregnancy class X). In the United States, thalidomide can only be prescribed through a special distribution program designed to minimize the chance of fetal exposure to the drug (S.T.E.P.S. program; access at",
"    <span class=\"nowrap\">",
"     www.thalomid.com/steps_program.aspx).",
"    </span>",
"    (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     \"Thalidomide: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Behcet's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behcet's disease is a neutrophilic inflammatory disorder that presents with recurrent oral and genital ulcerations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most, but not all, patients initially manifest oral aphthae that are grossly and histologically similar to common oral ulcers; however, they tend to be more extensive and often multiple (",
"      <a class=\"graphic graphic_picture graphicRef76223 \" href=\"UTD.htm?9/62/10222\">",
"       picture 12",
"      </a>",
"      ). Healing of the oral ulcerations is typically spontaneous within one to three weeks; although with recurrent lesions, many patients will have ulcers present almost constantly.",
"     </li>",
"     <li>",
"      Genital lesions occur in about 75 percent of patients with Behcet's disease. They are similar in appearance to the oral aphthae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent oral ulcers (three times per year) are required for the diagnosis of Behcet's disease, in addition to two other clinical findings (recurrent genital ulcers, eye lesions, skin lesions, or a positive pathergy test [24 to 48 hours after oblique insertion of a 20 to 25 gauge needle]) (",
"    <a class=\"graphic graphic_table graphicRef54762 \" href=\"UTD.htm?25/47/26363\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mucocutaneous manifestations of Behcet's disease can be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    , topical anesthetics, topical or intralesional corticosteroids, or systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/54\">",
"     54",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    have also been shown to be effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=see_link\">",
"     \"Treatment of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Complex aphthosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex aphthosis is the term used to describe the occurrence of recurrent large oral ulcers in conjunction with genital lesions in the absence of other criteria for Behcet's disease. Other syndromes associated with both oral and genital lesions are the MAGIC syndrome (mouth and genital ulcers with inflamed cartilage), FAPA (fever, aphthosis, pharyngitis, and adenitis) syndrome, and cyclic neutropenia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    ). Infectious cases of oral and vulvar aphthae include Yersinia enterocolitis, tuberculous enterocolitis, and typhoid fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucus membrane involvement occurs in up to 50 percent of patients with systemic lupus erythematosus (SLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/55\">",
"     55",
"    </a>",
"    ]. Oral disease can involve the lips and oral mucosa. Discoid lip lesions, characterized as keratotic papules or plaques with pigment alteration, scale, photosensitivity, and atrophy, may be present in up to 25 percent of patients with discoid or subacute lupus erythematosus. Irregularly shaped raised white plaques, silvery white scarred lesions, areas of erythema, and punched out erosions or ulcers with surrounding erythema may appear on the soft or hard palate (",
"    <a class=\"graphic graphic_picture graphicRef63605 \" href=\"UTD.htm?24/32/25103\">",
"     picture 13",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast with the discoid lesions that tend to be painful, the oral ulcers are usually painless. There is no apparent association between the presence of such ulcers and systemic activity.",
"   </p>",
"   <p>",
"    The diagnosis is made with a skin biopsy, or if the lesions are found in conjunction with other features of SLE. Treatment of lip lesions includes topical or intralesional glucocorticoids; antimalarials are used for oral ulcerations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/56\">",
"     56",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"    </a>",
"    ). New oral lesions that develop on the buccal mucosa in a patient with SLE who is being treated with an antimalarial drug may represent a lichenoid drug eruption secondary to the antimalarial agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bullous pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous pemphigoid is an autoimmune blistering disorder. Lesions commonly occur in the flexural areas, groin, and axillae. Oral involvement consisting of intact bullae or erosions occurs in about one-third of cases but is rarely the presenting feature. Skin lesions may consist of bullae or urticarial plaques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290498#H53290498\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is made on routine and direct immunofluorescence testing of lesional and perilesional skin, respectively. Standard therapy remains oral glucocorticoids, although many other agents are also effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Mucous membrane pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucous membrane pemphigoid includes a heterogeneous group of chronic inflammatory blistering diseases that affect oral, ocular, pharyngeal, laryngeal, genital, or anal mucosa. Oropharyngeal involvement predominates. Oral lesions include desquamative gingivitis and bullae with a tendency to scar (",
"    <a class=\"graphic graphic_picture graphicRef77654 \" href=\"UTD.htm?15/51/16178\">",
"     picture 14",
"    </a>",
"    ). Significant ocular and upper airway involvement also can occur.",
"   </p>",
"   <p>",
"    The diagnosis is made on routine and direct immunofluorescence testing of lesional and perilesional skin, respectively, along with the appropriate clinical findings. Potent immunosuppressants are often necessary to control this disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290512#H53290512\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338636\">",
"    <span class=\"h2\">",
"     Epidermolysis bullosa acquisita",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa acquisita is a rare autoimmune bullous disease presenting with blisters that are localized predominantly at sites of trauma and heal with scarring and milia. Erosions and blisters may occur in the mouth, larynx, and esophagus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"     \"Epidermolysis bullosa acquisita\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pemphigus vulgaris",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigus vulgaris is characterized by flaccid bullae that typically begin in the oropharynx and then may spread to involve the skin, with a predilection for the scalp, face, chest, axillae, and groin (",
"    <a class=\"graphic graphic_picture graphicRef57924 \" href=\"UTD.htm?0/48/769\">",
"     picture 15",
"    </a>",
"    ). The bullae rupture easily, so that the patient often presents with only painful erosions and no intact bullae. One variant, paraneoplastic pemphigus, tends to markedly involve the oral and ocular mucosa.",
"   </p>",
"   <p>",
"    The diagnosis of pemphigus vulgaris is made on routine and direct immunofluorescence testing of lesional and perilesional skin, respectively. Serum levels of antibodies may also be used to make the diagnosis. Standard therapy remains oral glucocorticoids, but recalcitrant disease can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , intravenous gamma globulin, and in severe cases, plasmapheresis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ERYTHEMA MULTIFORME AND STEVENS-JOHNSON SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythema multiforme and Stevens-Johnson syndrome are hypersensitivity reactions that often present with both skin lesions and mucosal involvement (",
"    <a class=\"graphic graphic_picture graphicRef68153 graphicRef62370 graphicRef68682 graphicRef76141 graphicRef73805 \" href=\"UTD.htm?42/3/43066\">",
"     picture 16A-E",
"    </a>",
"    ). Erythema multiforme is frequently related to herpes simplex infections, but also may be caused by other infections (eg, Mycoplasma pneumoniae) or medications, or may be idiopathic. Stevens-Johnson syndrome is most commonly induced by drugs. Target skin lesions are a characteristic feature of erythema multiforme; erythematous, purpuric macules and skin detachment may occur in Stevens-Johnson syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mucosal involvement is seen in more than 90 percent of patients with erythema multiforme and Stevens-Johnson syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/57\">",
"     57",
"    </a>",
"    ]. When oral lesions are the primary feature, erythema and edema of the lips along with intraoral bullae may occur. The bullae often rupture, leaving painful friable raw surfaces and even hemorrhagic crusts. Pain is a prominent feature when oral lesions are present.",
"   </p>",
"   <p>",
"    The management of these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41334?source=see_link\">",
"     \"Treatment of erythema multiforme\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1840503\">",
"    <span class=\"h2\">",
"     Lichen planus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral mucosal involvement may occur with lichen planus as an isolated event or in conjunction with cutaneous or genital disease. The presentation of oral lichen planus may vary from lace-like white patches (Wickham striae) on the buccal mucosa to erosions on the gingival margin (",
"    <a class=\"graphic graphic_picture graphicRef76338 graphicRef54143 graphicRef62826 \" href=\"UTD.htm?3/54/3945\">",
"     picture 17A-C",
"    </a>",
"    ). Lesions are often painful and interfere with oral intake. Oral lichen planus tends to be chronic, and may increase the risk for oral cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=see_link\">",
"     \"Oral lichen planus: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59929804\">",
"    <span class=\"h2\">",
"     Atrophic glossitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophic glossitis is an inflammatory disorder of the tongue that leads to the atrophy of the filiform papillae. The tongue appears smooth, glossy, and erythematous (",
"    <a class=\"graphic graphic_picture graphicRef85872 graphicRef54472 \" href=\"UTD.htm?4/43/4791\">",
"     picture 18A-B",
"    </a>",
"    ). Causes of atrophic glossitis include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nutritional deficiencies (iron, vitamin B12,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=see_link\">",
"       \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dry mouth (sicca symptoms) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H720851756#H720851756\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Dry eye in older adults'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H720851742#H720851742\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Epidemiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sj&ouml;gren syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"       \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oral Candida infection (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Candidiasis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Protein-calorie malnutrition in older adults (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=see_link\">",
"       \"Geriatric nutrition: Nutritional issues in older adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Celiac disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"       \"Diagnosis of celiac disease\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with atrophic glossitis often complain of a burning sensation and increased sensitivity when eating acidic or salty foods. Treatment is directed at the underlying condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59929819\">",
"    <span class=\"h2\">",
"     Fissured tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fissured tongue is a benign condition of unknown etiology usually seen in adults. Deep grooves are located on the midline or evenly distributed on the tongue surface (",
"    <a class=\"graphic graphic_picture graphicRef85871 \" href=\"UTD.htm?26/59/27573\">",
"     picture 19",
"    </a>",
"    ). Fissured tongue is also seen in patients with Down syndrome or Melkersson-Rosenthal syndrome (a rare syndrome characterized by the triad of fissured tongue, facial palsy, and granulomatous cheilitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link&amp;anchor=H2688998#H2688998\">",
"     \"Clinical features and diagnosis of Down syndrome\", section on 'Skin disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=see_link&amp;anchor=H14#H14\">",
"     \"Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults\", section on 'Melkersson-Rosenthal syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with fissured tongue are generally asymptomatic. The condition is permanent and does not require treatment unless the patient gets irritation from entrapped debris in the fissures. In such cases, brushing the affected area or using an oral irrigator may provide benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Black tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperpigmentation of the tongue and oral mucosa is commonly seen in dark-skinned individuals. Less common causes of tongue hyperpigmentation include drugs (eg, tetracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , bismuth subsalicylate, antidepressants, proton pump inhibitors, interferon), Addison disease (",
"    <a class=\"graphic graphic_picture graphicRef67179 \" href=\"UTD.htm?6/39/6771\">",
"     picture 20",
"    </a>",
"    ), Laugier-Hunziker disease, or pellagra [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H338200\">",
"    <span class=\"h2\">",
"     Black hairy tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Black hairy tongue (lingua villosa nigra) is a benign condition associated with antibiotic use, candida albicans infection, or poor oral hygiene. Patients have elongated filiform papillae or, in pseudohairy tongue, a yellowish white to brown dorsal tongue surface (",
"    <a class=\"graphic graphic_picture graphicRef76664 \" href=\"UTD.htm?26/24/27012\">",
"     picture 21",
"    </a>",
"    ). Therapy consists of brushing that area of the tongue with a soft-bristle toothbrush and toothpaste two to three times per day [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Geographic tongue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geographic tongue (benign migratory glossitis) is a disorder of unknown etiology that affects the epithelium of the tongue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/67\">",
"     67",
"    </a>",
"    ]. Local loss of filiform papillae leads to ulcer-like lesions that appear as erythematous patches on the dorsal tongue with circumferential white polycyclic borders (",
"    <a class=\"graphic graphic_picture graphicRef74654 graphicRef79512 \" href=\"UTD.htm?19/31/19959\">",
"     picture 22A-B",
"    </a>",
"    ). Lesions can change location, pattern, and size within minutes to hours, and patients may have numerous exacerbations and remissions over time. Exacerbations are usually asymptomatic, although some patients complain of oral discomfort, burning, or foreign body sensations.",
"   </p>",
"   <p>",
"    The differential diagnosis includes candidiasis, psoriasis, Reiter syndrome, lichen planus, leukoplakia, systemic lupus erythematosus, herpes simplex virus, and drug reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/67\">",
"     67",
"    </a>",
"    ]. The diagnosis is typically based on the clinical presentation and biopsy is not necessary. However, biopsy may be reassuring in unclear cases. The histology of involved areas is similar to pustular psoriasis.",
"   </p>",
"   <p>",
"    No therapy is needed since patients are usually asymptomatic or have only mild symptoms. Symptomatic treatments that have been reported but are unproven include fluids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , mouth rinsing with a topical anesthetic agent, antihistamines, anxiolytics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Cheilitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cheilitis is characterized by erythema and scaling of the lips. Factors that may precipitate or aggravate the condition include retinoids, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    (Soriatane), wind-burns, and allergies. Chronic lip licking is a common cause in young children as the saliva causes a repeated irritant dermatitis. Secondary infection resulting in impetigo is common in young children. Treatment involves the use of bland lubricants such as petrolatum and addressing any secondary infection or irritation from foods or spices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337632\">",
"    <span class=\"h3\">",
"     Actinic cheilitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Actinic cheilitis is a common condition that may develop into invasive squamous cell carcinoma if left untreated (",
"    <a class=\"graphic graphic_picture graphicRef68057 \" href=\"UTD.htm?42/49/43794\">",
"     picture 23",
"    </a>",
"    ). Multiple methods of treatment have been reported, including cryosurgery, electrocautery, 5-fluorouracil, carbon dioxide laser, erbium:yttrium-aluminum garnet (Er:YAG) laser, scalpel vermilionectomy, and topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"     diclofenac",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/25,71-73\">",
"     25,71-73",
"    </a>",
"    ]. Most therapies have a low clinical failure rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H337639\">",
"    <span class=\"h3\">",
"     Angular cheilitis (perl&egrave;che)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angular cheilitis or perl&egrave;che is an acute or chronic inflammation of the angles of the lips caused in most cases by mechanical trauma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fungal or bacterial infection. In adults, it is usually associated with ill-fitting dentures, change in bony",
"    <span class=\"nowrap\">",
"     structure/bite,",
"    </span>",
"    sicca symptoms (dry mouth), poor oral hygiene, and secondary",
"    <em>",
"     Candida",
"    </em>",
"    <em>",
"     albicans",
"    </em>",
"    or, less commonly,",
"    <em>",
"     S. aureus",
"    </em>",
"    infection (",
"    <a class=\"graphic graphic_picture graphicRef55357 \" href=\"UTD.htm?26/36/27201\">",
"     picture 24",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Less common causes include nutritional deficiencies, immune deficiency, or irritant or allergic reactions to oral hygiene products or denture materials. The diagnosis of angular cheilitis is usually straightforward. A potassium hydroxide (KOH) preparation from lesions and oral mucosa beneath the dentures is needed to confirm or rule out Candida infection. In patients with recalcitrant cheilitis, a lesions swab for bacterial and fungal culture should be obtained. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Treatment of angular cheilitis involves general measures such as improving denture fit and cleaning, proper oral hygiene, and the use of salivary substitutes (sialogogues) when needed. For patients with negative KOH preparation, barrier creams (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    paste) or petrolatum applied two times a day may be helpful. For",
"    <em>",
"     Candida",
"    </em>",
"    infection, topical antifungal therapy with azole (eg, miconazole, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    ) ointment is used. Azole ointment is applied two times per day for one to three weeks. In patients with associated",
"    <em>",
"     Candida",
"    </em>",
"    stomatitis, clotrimazole&nbsp;troches (one 10-mg troche dissolved slowly five times daily for two weeks) or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (100 mg per day for one to two weeks) may be required. Staphylococcal infection may be treated with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    ointment. Topical mupirocin is applied two times a day for 7 to 14 days. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Candidiasis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Contact and irritant stomatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contact or irritant stomatitis is a less common cause of oral lesions, but may present with a wide variety of manifestations, including erosions, ulcerations, lichenoid-like reactions, leukoplakic lesions, or only erythema (",
"    <a class=\"graphic graphic_picture graphicRef58869 \" href=\"UTD.htm?38/4/38976\">",
"     picture 25",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/77\">",
"     77",
"    </a>",
"    ]. Allergic reactions are primarily due to metallic mercury, cinnamon aldehyde, and gold salts, among others (",
"    <a class=\"graphic graphic_table graphicRef54139 \" href=\"UTD.htm?5/13/5339\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lip and perioral involvement is seen when the offending agent is chewed or applied topically. Repetitive friction, particularly in relationship to dental appliances, may result in traumatic ulcers. Leukoplakic-like lesions can occur due to repeated friction from poorly fitting prostheses, cheek sucking, or with the use of oral tobacco. Lichenoid, lace-like, localized, buccal mucosal patches may occur secondary to amalgam. Symptoms usually outweigh clinical disease.",
"   </p>",
"   <p>",
"    Burning mouth syndrome is most commonly seen in middle aged women and is not necessarily related to any allergies. Contact urticaria is seen most commonly due to allergies to dental materials or natural rubber latex, and anaphylaxis can occur. Food related inflammation may present with prominent lip swelling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     \"Overview of dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Dental erosions/gingival hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to perform a thorough dental examination even in the absence of oral complaints. Patients on chronic antiepileptic medications may develop gingival hyperplasia, particularly those on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , as can patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef82641 \" href=\"UTD.htm?29/35/30257\">",
"     picture 26",
"    </a>",
"    ). Dental erosions can occur from even mild systemic illness, such as chronic gastroesophageal reflux, and once established erosions can predispose to aspiration syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/11/25786/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Inherited epidermolysis bullosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermolysis bullosa describes a group of rare inherited diseases with the common finding of epithelial fragility. Affected sites occur most commonly in areas of trauma and friction. Milder forms do not typically involve the mucosae, while more severe manifestations involve the oral, pharyngeal, and esophageal mucosa and tooth formation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H13#H13\">",
"     \"The genodermatoses\", section on 'Epidermolysis bullosa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=see_link\">",
"       \"Patient information: Mouth sores (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/34/16929?source=see_link\">",
"       \"Patient information: Leukoplakia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7432083\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dermatologic lesions of the mouth and gums include a wide variety of disease processes that can present with similar appearing lesions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tumors and precancerous lesions include squamous cell carcinoma (",
"      <a class=\"graphic graphic_picture graphicRef81810 graphicRef59057 graphicRef74239 \" href=\"UTD.htm?27/61/28633\">",
"       picture 1A-C",
"      </a>",
"      ), leukoplakia (",
"      <a class=\"graphic graphic_picture graphicRef81049 graphicRef60939 graphicRef72711 \" href=\"UTD.htm?7/49/7961\">",
"       picture 2A-C",
"      </a>",
"      ), and melanoma. Lesions that can mimic tumors of the oral mucosa include amalgam tattoos (",
"      <a class=\"graphic graphic_picture graphicRef51720 \" href=\"UTD.htm?24/34/25120\">",
"       picture 3",
"      </a>",
"      ), Fordyce spots (",
"      <a class=\"graphic graphic_picture graphicRef69406 graphicRef66778 \" href=\"UTD.htm?23/4/23622\">",
"       picture 4A-B",
"      </a>",
"      ), and mucocele (",
"      <a class=\"graphic graphic_picture graphicRef70332 graphicRef75671 \" href=\"UTD.htm?34/21/35160\">",
"       picture 5A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Tumors (and lesions that mimic)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections of the oral mucosa include candidiasis (",
"      <a class=\"graphic graphic_picture graphicRef82214 graphicRef61040 graphicRef75887 graphicRef79519 \" href=\"UTD.htm?6/53/7002\">",
"       picture 6A-D",
"      </a>",
"      ), herpes simplex virus infection (",
"      <a class=\"graphic graphic_picture graphicRef71764 graphicRef73975 \" href=\"UTD.htm?40/62/41959\">",
"       picture 7A-B",
"      </a>",
"      ), varicella-zoster infection (",
"      <a class=\"graphic graphic_picture graphicRef83137 graphicRef83136 graphicRef51866 \" href=\"UTD.htm?19/24/19849\">",
"       picture 8A-C",
"      </a>",
"      ), coxsackie virus infection (hand, foot, and mouth disease) (",
"      <a class=\"graphic graphic_picture graphicRef58566 graphicRef71314 graphicRef81027 graphicRef52800 graphicRef53423 \" href=\"UTD.htm?37/42/38570\">",
"       picture 9A-E",
"      </a>",
"      ), HIV infection, and primary (",
"      <a class=\"graphic graphic_picture graphicRef82771 \" href=\"UTD.htm?23/49/24338\">",
"       picture 27",
"      </a>",
"      ) or secondary syphilis (",
"      <a class=\"graphic graphic_picture graphicRef66008 graphicRef72680 graphicRef52729 \" href=\"UTD.htm?20/43/21177\">",
"       picture 10A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aphthous ulcerations include recurrent aphthous stomatitis, the most common cause of oral ulcers (",
"      <a class=\"graphic graphic_picture graphicRef63475 \" href=\"UTD.htm?13/25/13713\">",
"       picture 11",
"      </a>",
"      ), Beh&ccedil;et disease (",
"      <a class=\"graphic graphic_picture graphicRef76223 \" href=\"UTD.htm?9/62/10222\">",
"       picture 12",
"      </a>",
"      ), and complex aphthosis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Aphthous ulcerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoimmune diseases with involvement of the oral mucosa include systemic lupus erythematosus (",
"      <a class=\"graphic graphic_picture graphicRef63605 \" href=\"UTD.htm?24/32/25103\">",
"       picture 13",
"      </a>",
"      ), bullous pemphigoid (",
"      <a class=\"graphic graphic_picture graphicRef66179 \" href=\"UTD.htm?31/58/32675\">",
"       picture 28",
"      </a>",
"      ), mucous membrane pemphigoid (",
"      <a class=\"graphic graphic_picture graphicRef77654 \" href=\"UTD.htm?15/51/16178\">",
"       picture 14",
"      </a>",
"      ), epidermolysis bullosa acquisita, and pemphigus vulgaris (",
"      <a class=\"graphic graphic_picture graphicRef57924 \" href=\"UTD.htm?0/48/769\">",
"       picture 15",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Autoimmune diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral involvement occurs in more than 90 percent of patients with erythema multiforme and Stevens-Johnson syndrome with erythema, edema, bullae, and erosions of the lips and oral mucosa (",
"      <a class=\"graphic graphic_picture graphicRef68153 graphicRef62370 graphicRef68682 graphicRef76141 graphicRef73805 \" href=\"UTD.htm?42/3/43066\">",
"       picture 16A-E",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Erythema multiforme and Stevens-Johnson syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other disorders of the lips and mouth include oral lichen planus (",
"      <a class=\"graphic graphic_picture graphicRef76338 graphicRef54143 graphicRef62826 \" href=\"UTD.htm?3/54/3945\">",
"       picture 17A-C",
"      </a>",
"      ), tongue hyperpigmentation (",
"      <a class=\"graphic graphic_picture graphicRef67179 \" href=\"UTD.htm?6/39/6771\">",
"       picture 20",
"      </a>",
"      ), atrophic glossitis (",
"      <a class=\"graphic graphic_picture graphicRef54472 \" href=\"UTD.htm?8/39/8821\">",
"       picture 18B",
"      </a>",
"      ), fissured tongue (see",
"      <a class=\"local\" href=\"#H59929819\">",
"       'Fissured tongue'",
"      </a>",
"      above), geographic tongue (",
"      <a class=\"graphic graphic_picture graphicRef74654 graphicRef79512 \" href=\"UTD.htm?19/31/19959\">",
"       picture 22A-B",
"      </a>",
"      ), actinic cheilitis (",
"      <a class=\"graphic graphic_picture graphicRef68057 \" href=\"UTD.htm?42/49/43794\">",
"       picture 23",
"      </a>",
"      ), angular cheilitis (perl&egrave;che) (",
"      <a class=\"graphic graphic_picture graphicRef55357 \" href=\"UTD.htm?26/36/27201\">",
"       picture 24",
"      </a>",
"      ), contact and irritant stomatitis (",
"      <a class=\"graphic graphic_picture graphicRef58869 \" href=\"UTD.htm?38/4/38976\">",
"       picture 25",
"      </a>",
"      ), dental erosions and gingival hypertrophy (",
"      <a class=\"graphic graphic_picture graphicRef82641 \" href=\"UTD.htm?29/35/30257\">",
"       picture 26",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Miscellaneous'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe forms of epidermolysis bullosa, a group of rare inherited diseases characterized by skin fragility, may be associated with blistering and scarring of the oral mucosa and teeth abnormalities. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Inherited epidermolysis bullosa'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/1\">",
"      Morgan R, Tsang J, Harrington N, Fook L. Survey of hospital doctors' attitudes and knowledge of oral conditions in older patients. Postgrad Med J 2001; 77:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/2\">",
"      Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/3\">",
"      Cianfriglia F, Di Gregorio DA, Cianfriglia C, et al. Incidence of human papillomavirus infection in oral leukoplakia. Indications for a viral aetiology. J Exp Clin Cancer Res 2006; 25:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/4\">",
"      Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000; 6:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/5\">",
"      Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br J Cancer 2000; 82:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/6\">",
"      van der Waal I, Schepman KP, van der Meij EH. A modified classification and staging system for oral leukoplakia. Oral Oncol 2000; 36:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/7\">",
"      Grady D, Greene J, Daniels TE, et al. Oral mucosal lesions found in smokeless tobacco users. J Am Dent Assoc 1990; 121:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/8\">",
"      DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 1998; 5:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/9\">",
"      Eisen D, Voorhees JJ. Oral melanoma and other pigmented lesions of the oral cavity. J Am Acad Dermatol 1991; 24:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/10\">",
"      Kaugars GE, Heise AP, Riley WT, et al. Oral melanotic macules. A review of 353 cases. Oral Surg Oral Med Oral Pathol 1993; 76:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/11\">",
"      Owens BM, Johnson WW, Schuman NJ. Oral amalgam pigmentations (tattoos): a retrospective study. Quintessence Int 1992; 23:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/12\">",
"      Chi AC, Lambert PR 3rd, Richardson MS, Neville BW. Oral mucoceles: a clinicopathologic review of 1,824 cases, including unusual variants. J Oral Maxillofac Surg 2011; 69:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/13\">",
"      B&ouml;hler-Sommeregger K, Kutschera-Hienert G. Cryosurgical management of myxoid cysts. J Dermatol Surg Oncol 1988; 14:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/14\">",
"      Huang IY, Chen CM, Kao YH, Worthington P. Treatment of mucocele of the lower lip with carbon dioxide laser. J Oral Maxillofac Surg 2007; 65:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/15\">",
"      Budtz-J&oslash;rgensen E. Oral mucosal lesions associated with the wearing of removable dentures. J Oral Pathol 1981; 10:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/16\">",
"      Kanli A, Demirel F, Sezgin Y. Oral candidosis, denture cleanliness and hygiene habits in an elderly population. Aging Clin Exp Res 2005; 17:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/17\">",
"      Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med 1986; 314:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/18\">",
"      Young SK, Rowe NH, Buchanan RA. A clinical study for the control of facial mucocutaneous herpes virus infections. I. Characterization of natural history in a professional school population. Oral Surg Oral Med Oral Pathol 1976; 41:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/19\">",
"      Hebert AA, Lopez MD. Oral lesions in pediatric patients. Adv Dermatol 1997; 12:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/20\">",
"      Amir J, Harel L, Smetana Z, Varsano I. The natural history of primary herpes simplex type 1 gingivostomatitis in children. Pediatr Dermatol 1999; 16:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/21\">",
"      Spruance SL, Crumpacker CS, Schnipper LE, et al. Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir. Antimicrob Agents Chemother 1984; 25:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/22\">",
"      Raborn GW, Martel AY, Grace MG, McGaw WT. Oral acyclovir in prevention of herpes labialis. A randomized, double-blind, multi-centered clinical trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/23\">",
"      Lapins J, Gaines H, Lindb&auml;ck S, et al. Skin and mucosal characteristics of symptomatic primary HIV-1 infection. AIDS Patient Care STDS 1997; 11:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/24\">",
"      Sarti GM, Haddy RI, Schaffer D, Kihm J. Black hairy tongue. Am Fam Physician 1990; 41:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/25\">",
"      Lima Gda S, Silva GF, Gomes AP, et al. Diclofenac in hyaluronic acid gel: an alternative treatment for actinic cheilitis. J Appl Oral Sci 2010; 18:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/26\">",
"      Ram&iacute;rez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, et al. The Changing Clinical Spectrum of Human Immunodeficiency Virus (HIV)-Related Oral Lesions in 1,000 Consecutive Patients: A 12-Year Study in a Referral Center in Mexico. Medicine (Baltimore) 2003; 82:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/27\">",
"      Nichols CM, Flaitz CM, Hicks MJ. Treating Kaposi's lesions in the HIV-infected patient. J Am Dent Assoc 1993; 124:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/28\">",
"      Reichart PA. Oral ulcerations in HIV infection. Oral Dis 1997; 3 Suppl 1:S180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/29\">",
"      Alegre M, Dalmau J, Domingo P, et al. Successful treatment of major oral aphthous ulcers in HIV-1 infection after highly active antiretroviral therapy. Int J Infect Dis 2007; 11:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/30\">",
"      Kuteyi T, Okwundu CI. Topical treatments for HIV-related oral ulcers. Cochrane Database Syst Rev 2012; 1:CD007975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/31\">",
"      Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/32\">",
"      Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis 1999; 28:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/33\">",
"      Ship JA. Recurrent aphthous stomatitis. An update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/34\">",
"      Savage NW, Mahanonda R, Seymour GJ, et al. The proportion of suppressor-inducer T-lymphocytes is reduced in recurrent aphthous stomatitis. J Oral Pathol 1988; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/35\">",
"      Landesberg R, Fallon M, Insel R. Alterations of T helper/inducer and T suppressor/inducer cells in patients with recurrent aphthous ulcers. Oral Surg Oral Med Oral Pathol 1990; 69:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/36\">",
"      McBride DR. Management of aphthous ulcers. Am Fam Physician 2000; 62:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/37\">",
"      Rogers RS 3rd. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cutan Med Surg 1997; 16:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/38\">",
"      Lalla RV, Choquette LE, Feinn RS, et al. Multivitamin therapy for recurrent aphthous stomatitis: a randomized, double-masked, placebo-controlled trial. J Am Dent Assoc 2012; 143:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/39\">",
"      Shim YJ, Choi JH, Ahn HJ, Kwon JS. Effect of sodium lauryl sulfate on recurrent aphthous stomatitis: a randomized controlled clinical trial. Oral Dis 2012; 18:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/40\">",
"      Greer RO Jr, Lindenmuth JE, Juarez T, Khandwala A. A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg 1993; 51:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/41\">",
"      Binnie WH, Curro FA, Khandwala A, Van Inwegan RG. Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent 1997; 18:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/42\">",
"      Murray B, Biagioni PA, Lamey PJ. The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration. J Oral Pathol Med 2006; 35:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/43\">",
"      Liu C, Zhou Z, Liu G, et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med 2012; 125:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/44\">",
"      Alidaee MR, Taheri A, Mansoori P, Ghodsi SZ. Silver nitrate cautery in aphthous stomatitis: a randomized controlled trial. Br J Dermatol 2005; 153:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/45\">",
"      Rhodus NL, Bereuter J. An evaluation of a chemical cautery agent and an anti-inflammatory ointment for the treatment of recurrent aphthous stomatitis: a pilot study. Quintessence Int 1998; 29:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/46\">",
"      Ruah CB, Stram JR, Chasin WD. Treatment of severe recurrent aphthous stomatitis with colchicine. Arch Otolaryngol Head Neck Surg 1988; 114:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/47\">",
"      Thornhill MH, Baccaglini L, Theaker E, Pemberton MN. A randomized, double-blind, placebo-controlled trial of pentoxifylline for the treatment of recurrent aphthous stomatitis. Arch Dermatol 2007; 143:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/48\">",
"      Lynde CB, Bruce AJ, Rogers RS 3rd. Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 2009; 145:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/49\">",
"      Altenburg A, Abdel-Naser MB, Seeber H, et al. Practical aspects of management of recurrent aphthous stomatitis. J Eur Acad Dermatol Venereol 2007; 21:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/50\">",
"      Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/51\">",
"      Bonnetblanc JM, Royer C, Bedane C. Thalidomide and recurrent aphthous stomatitis: a follow-up study. Dermatology 1996; 193:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/52\">",
"      Hello M, Barbarot S, Bastuji-Garin S, et al. Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. Medicine (Baltimore) 2010; 89:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/53\">",
"      Criteria for diagnosis of Beh&ccedil;et's disease. International Study Group for Beh&ccedil;et's Disease. Lancet 1990; 335:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/54\">",
"      Sakane T, Takeno M, Suzuki N, Inaba G. Beh&ccedil;et's disease. N Engl J Med 1999; 341:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/55\">",
"      Sultan SM, Ioannou Y, Isenberg DA. A review of gastrointestinal manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 1999; 38:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/56\">",
"      Callen JP. Oral manifestations of collagen vascular disease. Semin Cutan Med Surg 1997; 16:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/57\">",
"      Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/58\">",
"      Reamy BV, Derby R, Bunt CW. Common tongue conditions in primary care. Am Fam Physician 2010; 81:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/59\">",
"      Pastore L, Carroccio A, Compilato D, et al. Oral manifestations of celiac disease. J Clin Gastroenterol 2008; 42:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/60\">",
"      B&oslash;hmer T, Mow&eacute; M. The association between atrophic glossitis and protein-calorie malnutrition in old age. Age Ageing 2000; 29:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/61\">",
"      Daneshpazhooh M, Nazemi TM, Bigdeloo L, Yoosefi M. Mucocutaneous findings in 100 children with Down syndrome. Pediatr Dermatol 2007; 24:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/62\">",
"      Rose AE, Leger M, Chu J, Meehan S. Cheilitis granulomatosa. Dermatol Online J 2011; 17:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/63\">",
"      Jover-Diaz F, Cuadrado-Pastor JM, Talents-Bolos A, Martin-Gonzalez C. Black tongue associated with linezolid. Am J Ther 2010; 17:e115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/64\">",
"      Guinovart RM, Carrascosa JM, Bielsa I, et al. A black tongue in a young woman. Clin Exp Dermatol 2011; 36:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/65\">",
"      Cohen PR. Black tongue secondary to bismuth subsalicylate: case report and review of exogenous causes of macular lingual pigmentation. J Drugs Dermatol 2009; 8:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/66\">",
"      Ma DL, Vano-Galvan S. Hyperpigmentation in Laugier-Hunziker syndrome. CMAJ 2011; 183:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/67\">",
"      Assimakopoulos D, Patrikakos G, Fotika C, Elisaf M. Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med 2002; 113:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/68\">",
"      Sigal MJ, Mock D. Symptomatic benign migratory glossitis: report of two cases and literature review. Pediatr Dent 1992; 14:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/69\">",
"      Brooks JK, Balciunas BA. Geographic stomatitis: review of the literature and report of five cases. J Am Dent Assoc 1987; 115:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/70\">",
"      Ishibashi M, Tojo G, Watanabe M, et al. Geographic tongue treated with topical tacrolimus. J Dermatol Case Rep 2010; 4:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/71\">",
"      Dufresne RG Jr, Curlin MU. Actinic cheilitis. A treatment review. Dermatol Surg 1997; 23:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/72\">",
"      Armenores P, James CL, Walker PC, Huilgol SC. Treatment of actinic cheilitis with the Er:YAG laser. J Am Acad Dermatol 2010; 63:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/73\">",
"      Ulrich C, Forschner T, Ulrich M, et al. Management of actinic cheilitis using diclofenac 3% gel: a report of six cases. Br J Dermatol 2007; 156 Suppl 3:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/74\">",
"      Terai H, Shimahara M. Cheilitis as a variation of Candida-associated lesions. Oral Dis 2006; 12:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/75\">",
"      Park KK, Brodell RT, Helms SE. Angular cheilitis, part 2: nutritional, systemic, and drug-related causes and treatment. Cutis 2011; 88:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/76\">",
"      Park KK, Brodell RT, Helms SE. Angular cheilitis, part 1: local etiologies. Cutis 2011; 87:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/77\">",
"      Tosti A, Piraccini BM, Peluso AM. Contact and irritant stomatitis. Semin Cutan Med Surg 1997; 16:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/11/25786/abstract/78\">",
"      Lazarchik DA, Filler SJ. Effects of gastroesophageal reflux on the oral cavity. Am J Med 1997; 103:107S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5572 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25786=[""].join("\n");
var outline_f25_11_25786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7432083\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TUMORS (AND LESIONS THAT MIMIC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Leukoplakia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Amalgam tattoos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fordyce spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mucoceles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Herpes simplex virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Varicella-zoster virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Coxsackie virus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      APHTHOUS ULCERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H757722\">",
"      Recurrent aphthous stomatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Etiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Clinical presentation and course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Behcet's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Complex aphthosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      AUTOIMMUNE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H338636\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pemphigus vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ERYTHEMA MULTIFORME AND STEVENS-JOHNSON SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      MISCELLANEOUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1840503\">",
"      Lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59929804\">",
"      Atrophic glossitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59929819\">",
"      Fissured tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Black tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H338200\">",
"      Black hairy tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Geographic tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Cheilitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H337632\">",
"      - Actinic cheilitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H337639\">",
"      - Angular cheilitis (perl&egrave;che)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Contact and irritant stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Dental erosions/gingival hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Inherited epidermolysis bullosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7432083\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5572\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5572|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/47/44784\" title=\"picture 1A\">",
"      Squamous cell carcinoma - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/59/36786\" title=\"picture 1B\">",
"      Squamous cell carcinoma - lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/38/8802\" title=\"picture 1C\">",
"      Squamous cell carcinoma - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/2/18464\" title=\"picture 2A\">",
"      Leukoplakia - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/48/36608\" title=\"picture 2B\">",
"      Leukoplakia - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/39/2675\" title=\"picture 2C\">",
"      Leukoplakia - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/34/25120\" title=\"picture 3\">",
"      Amalgam tattoo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/19/9521\" title=\"picture 4A\">",
"      Fordyce spots - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/0/13313\" title=\"picture 4B\">",
"      Fordyce spots - lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/2/38944\" title=\"picture 5A\">",
"      Mucocele - lower lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/31/12790\" title=\"picture 5B\">",
"      Mucoceles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/42/12963\" title=\"picture 6A\">",
"      Oral candidiasis - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/30/28128\" title=\"picture 6B\">",
"      Oral candidiasis - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/12/5312\" title=\"picture 6C\">",
"      Oropharyngeal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/32/7680\" title=\"picture 6D\">",
"      Candida denture stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/48/5891\" title=\"picture 7A\">",
"      Herpes simplex - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/0/17410\" title=\"picture 7B\">",
"      Herpes simplex labialis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/39/18034\" title=\"picture 8A\">",
"      Chickenpox oral 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/12/3265\" title=\"picture 8B\">",
"      Chickenpox oral 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/44/31425\" title=\"picture 8C\">",
"      Herpes zoster - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/2/13344\" title=\"picture 9A\">",
"      Hand-foot-and-mouth disease - buccal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/27/20912\" title=\"picture 9B\">",
"      Hand-foot-and-mouth disease - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/61/16339\" title=\"picture 9C\">",
"      Enanthem in Coxsackie infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/12/4293\" title=\"picture 9D\">",
"      Hand-foot-and-mouth disease - lip and hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/22/14689\" title=\"picture 9E\">",
"      Hand-foot-and-mouth disease - foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/17/14610\" title=\"picture 10A\">",
"      Secondary syphilis - oral fissure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/21/3409\" title=\"picture 10B\">",
"      Secondary syphilis - oral mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/10/39073\" title=\"picture 10C\">",
"      Secondary syphilis - tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/25/13713\" title=\"picture 11\">",
"      Aphthous ulcers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/62/10222\" title=\"picture 12\">",
"      Oral aphthae in Behcets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/32/25103\" title=\"picture 13\">",
"      Mucous membrane lesions in SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/51/16178\" title=\"picture 14\">",
"      Cicatricial pemphigoid - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/48/769\" title=\"picture 15\">",
"      Pemphigus vulgaris - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/62/21474\" title=\"picture 16A\">",
"      Erythema multiforme lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/14/13540\" title=\"picture 16B\">",
"      Erythema multiforme acral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/55/42866\" title=\"picture 16C\">",
"      Stevens-Johnson syndrome - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/25/27030\" title=\"picture 16D\">",
"      Cutaneous findings of Stevens Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/7/30836\" title=\"picture 16E\">",
"      Mucosal changes in Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/30/20961\" title=\"picture 17A\">",
"      Lichen planus - oral Wickham striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/10/27808\" title=\"picture 17B\">",
"      Oral lichen planus - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/20/38209\" title=\"picture 17C\">",
"      Oral lichen planus - erosive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/29/38366\" title=\"picture 18A\">",
"      Atrophic glossitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/39/8821\" title=\"picture 18B\">",
"      Atrophic glossitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/59/27573\" title=\"picture 19\">",
"      Fissured tongue adult 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/39/6771\" title=\"picture 20\">",
"      Black tongue Addison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/24/27012\" title=\"picture 21\">",
"      Hairy tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/1/4113\" title=\"picture 22A\">",
"      Geographic tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/62/10211\" title=\"picture 22B\">",
"      Geographic tongue - distal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/49/43794\" title=\"picture 23\">",
"      Actinic cheilitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/36/27201\" title=\"picture 24\">",
"      Angular cheilitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/4/38976\" title=\"picture 25\">",
"      Contact stomatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/35/30257\" title=\"picture 26\">",
"      Gingival hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/49/24338\" title=\"picture 27\">",
"      Primary syphilis oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/58/32675\" title=\"picture 28\">",
"      Bullous pemphigoid oral mucosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5572|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/47/26363\" title=\"table 1\">",
"      Diagnosis of Behcets disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/13/5339\" title=\"table 2\">",
"      Sources contact stomatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36216?source=related_link\">",
"      Bell's palsy: Pathogenesis, clinical features, and diagnosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/36/19017?source=related_link\">",
"      Chemoprevention in oral dysplasia and head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29972?source=related_link\">",
"      Clinical manifestations of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/63/8182?source=related_link\">",
"      Epidemiology and clinical manifestations of Bartonella infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/12/31946?source=related_link\">",
"      Geriatric nutrition: Nutritional issues in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34825?source=related_link\">",
"      Head and neck squamous cell carcinogenesis: Molecular and genetic alterations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=related_link\">",
"      Oral lichen planus: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=related_link\">",
"      Overview of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/34/16929?source=related_link\">",
"      Patient information: Leukoplakia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=related_link\">",
"      Patient information: Mouth sores (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=related_link\">",
"      Thalidomide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33498?source=related_link\">",
"      Treatment of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41334?source=related_link\">",
"      Treatment of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20793?source=related_link\">",
"      Treatment of oropharyngeal and esophageal candidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_11_25787="Etiology of urethral stricture";
var content_f25_11_25787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of urethral stricture",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Etiology of stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Anterior urethra",
"       </td>",
"       <td>",
"        Meatus",
"       </td>",
"       <td>",
"        Instrumentation, iatrogenic, hypospadius, skin disorders (lichen sclerosus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pendulous urethra",
"       </td>",
"       <td>",
"        Instrumentation, iatrogenic, hypospadius, skin disorders (lichen sclerosus), sexually transmitted infections, crush injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bulbar urethra",
"       </td>",
"       <td>",
"        Instrumentation, iatrogenic, skin disorders (lichen sclerosus), sexually transmitted infections, crush injury, straddle type injury",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Posterior urethra",
"       </td>",
"       <td>",
"        Membranous urethra",
"       </td>",
"       <td>",
"        Instrumentation, pelvic fracture with urethral distraction defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatic urethra",
"       </td>",
"       <td>",
"        Instrumentation, radiation therapy for prostate cancer (external beam radiation therapy, brachytherapy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder neck",
"       </td>",
"       <td>",
"        Instrumentation, radiation therapy for prostate cancer (external beam radiation therapy, brachytherapy)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25787=[""].join("\n");
var outline_f25_11_25787=null;
var title_f25_11_25788="High vs low voltage injury";
var content_f25_11_25788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison among lightning, high-voltage, and low-voltage electrical injuries",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lightning",
"       </td>",
"       <td class=\"subtitle1\">",
"        High voltage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low voltage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Voltage, V",
"       </td>",
"       <td>",
"        &gt;30 x 10 6",
"       </td>",
"       <td>",
"        &gt;1,000",
"       </td>",
"       <td>",
"        &lt;600",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current,",
"A",
"       </td>",
"       <td>",
"        &gt;200,000",
"       </td>",
"       <td>",
"        &lt;1,000",
"       </td>",
"       <td>",
"        &lt;240",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration",
"       </td>",
"       <td>",
"        Instantaneous",
"       </td>",
"       <td>",
"        Brief",
"       </td>",
"       <td>",
"        Prolonged",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type of current",
"       </td>",
"       <td>",
"        DC",
"       </td>",
"       <td>",
"        DC or AC",
"       </td>",
"       <td>",
"        Mostly AC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac arrest",
"       </td>",
"       <td>",
"        Asystole",
"       </td>",
"       <td>",
"        Ventricular fibrillation",
"       </td>",
"       <td>",
"        Ventricular fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory arrest",
"       </td>",
"       <td>",
"        Direct CNS injury",
"       </td>",
"       <td>",
"        Indirect trauma or tetanic contraction of respiratory",
"muscles",
"       </td>",
"       <td>",
"        Tetanic contractions of respiratory muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscles",
"contraction",
"       </td>",
"       <td>",
"        Single",
"       </td>",
"       <td>",
"        Single (DC); Tetanic (AC)",
"       </td>",
"       <td>",
"        Tetanic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burns",
"       </td>",
"       <td>",
"        Rare, superficial",
"       </td>",
"       <td>",
"        Common, deep",
"       </td>",
"       <td>",
"        Usually superficial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rhabdomyolysis",
"       </td>",
"       <td>",
"        Uncommon",
"       </td>",
"       <td>",
"        Very common",
"       </td>",
"       <td>",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blunt injury (cause)",
"       </td>",
"       <td>",
"        Blast effect (shock wave)",
"       </td>",
"       <td>",
"        Fall (muscle contraction)",
"       </td>",
"       <td>",
"        Fall (uncommon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute mortality",
"       </td>",
"       <td>",
"        Very high",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DC: direct current; AC: alternating current; CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koumbourlis, AC. Electrical injuries. Crit Care Med 2002; 30:S425. Copyright &copy; 2002 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25788=[""].join("\n");
var outline_f25_11_25788=null;
var title_f25_11_25789="Recommendations for tilt testing";
var content_f25_11_25789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for tilt testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Methodology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supine pre-tilt phase of at least 5 min, when no venous cannulation, and of at least 20 min, when cannulation is undertaken, is recommended",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt angle between 60 and 70&deg; is recommended",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Passive phase of a minimum of 20 min and a maximum of 45 min is recommended",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For nitroglycerine, a fixed dose of 300 to 400 &micro;g sublingually administered in the upright position is recommended",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        For isoproterenol, an incremental infusion rate from 1 up to 3 &micro;g/min in order to increase average heart rate by ~20 to 25 percent over baseline is recommended",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Indications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt testing is indicated in the case of an unexplained single syncopal episode in high risk settings (eg, occurrence of, or potential risk of physical injury or with occupational implications), or recurrent episodes in the absence of organic heart disease, or in the presence of organic heart disease, after cardiac causes of syncope have been excluded",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt testing is indicated when it is of clinical value to demonstrate susceptibility to reflex syncope to the patient",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt testing should be considered to discriminate between relfex and OH syncope",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt testing may be considered for differentiating syncope with jerking movements from epilepsy",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt testing may be indicated for evaluating patients with recurrent unexplained falls",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt testing may be indicated for evaluating patients with frequent syncope and psychiatric disease",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilt testing is not recommended for assessment of treatment",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Isoproterenol tilt testing is contraindicated in patients with ischaemic heart disease",
"       </td>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Diagnostic criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients without structural heart disease the induction of relfex hypotension/bradycardia with reproduction of syncope or progressive OH (with or without symptoms) are diagnostic of reflex syncope and OH, respectively",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients without structural heart disease the induction of reflex hypotension/bradycardia without reproduction of syncope may be diagnostic of reflex syncope",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In patients with structural heart disease, arrhythmia, or other cardiovascular cause of syncope should be excluded prior to considering positive tilt test results as diagnostic",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Induction of LOC in absence of hypotension and/or bradycardia should be considered diagnostic of psychogenic pseudosyncope",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BP: blood pressure; CSM: carotid sinus massage; HR: heart rate; LOC: loss of consciousness; OH: orthostatic hypotension; TIA: transient ischaemic attack; &micro;g: micrograms.",
"     <br>",
"      * Class of recommendation.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Level of evidence.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25789=[""].join("\n");
var outline_f25_11_25789=null;
var title_f25_11_25790="GFR and plasma creatinine";
var content_f25_11_25790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F74963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F74963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    True relation between the plasma creatinine and GFR",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between the Pcr and the true GFR (as measured by the inulin clearance) in 171 patients with glomerular disease. Each closed circle represents one patient; the continuous line reflects the idealized relationship between these parameters if creatinine were excreted solely by glomerular filtration; and the dashed line represents the upper limit of \"normal\" for the Pcr of 1.4 mg/dL. With the GFR varying between 120 and 60 mL/min in different patients, there is often little elevation in the Pcr due primarily to enhanced tubular secretion. Once the Pcr is above 1.5 to 2 mg/dL, tubular secretion becomes saturated and the Pcr rises as expected with further reductions in GFR. (From Shemesh, O, Golbetz, H, Kriss, JP, Myers, BD, Kidney Int 1985; 28:830. Reprinted by permission from Kidney International.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25790=[""].join("\n");
var outline_f25_11_25790=null;
var title_f25_11_25791="Right mainstem intubation";
var content_f25_11_25791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left lung atelectasis caused by endotracheal tube in the right mainstem bronchus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Portable supine radiograph of a neonate with respiratory distress. This radiograph demonstrates complete opacification of the left hemithorax with associated ipsilateral mediastinal shift. The tip of the endotracheal tube is within the orifice of the right mainstem bronchus, causing complete left lung atelectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_11_25791=[""].join("\n");
var outline_f25_11_25791=null;
